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„Our greatest weakness lies in giving up. The most certain way 
to succeed is always to try just one more time.“ 
Thomas A. Edison 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
 
Ionotropic receptors mediate cell-cell communication 
Communication between cells is generally achieved via signal molecules or 
ions. Nerve cells are specialized cells that contact other cells through so-called 
‚synapses’. A synapse is formed by a presynaptic terminal where signal molecules, 
i.e. neurotransmitters, are released and a post-synaptic terminal where the 
neurotransmitters bind to specialized, membrane-bound proteins. These proteins are 
classified according to their respective biochemical reaction, i) metabotropic 
receptors, which induce secondary signal mechanisms that trigger a range of 
intracellular events, and ii) ionotropic receptors, which, upon ligand binding, open a 
channel that allows ions such as Na+, K+ or Cl- to flow along their electrochemical 
gradient. In contrast, so-called ion channels are proteins that are activated e.g. by 
voltage changes, pH changes or mechanical stretch. Ion channels and ionotropic 
receptors are membrane-associated, oligomeric proteins and the ion channel pore is 
located in the membrane-domain. But only ionotropic receptors have an extracellular 
domain (ECD) where ligands can bind. Binding of a ligand to the ECD induces 
rearrangements in the protein that lead to the opening of the inherent ion channel 
(Mayer, 2006). Such receptors are involved in fast signal transmission as their 
operating time scale is in the range of a few milliseconds compared to seconds or 
minutes in metabotropic receptors (Kandel, 2000). Ionotropic receptors or their 
evolutionary ancestor proteins can be found throughout all life forms, e.g. bacteria, 
plants, insects, fish, birds, amphibians, reptiles and mammals. Their significance for 
cell-cell communication becomes apparent when mutations in the respective genes 
cause so-called channelopathies. Channelopathies are disorders or 
pathophysiological conditions that are caused by a mutation in an ion channel or 
ionotropic receptor. Examples for channelopathies caused by mutations in ionotropic 
receptors are, hyperekplexia or startle disease (Shiang et al., 1993), different forms 
of epilepsy (Steinlein et al., 1995, De Fusco et al., 2000, Baulac et al., 2001, Wallace 
et al., 2001, Endele et al., 2010), congenital myasthenic syndrome (Engel et al., 
1993) or mental retardation (Endele et al., 2010). Additionally, ionotropic receptors 
are implicated in numerous neurological diseases such as, Alzheimer’s, Parkinson’s 
or Huntington’s (Dingledine et al., 1999, Wu et al., 2006). In order to develop 
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treatment for such disorders it is essential to gain insight into the structure and 
function of these proteins. 
 
Ligand-gated ion channels (LGICs), a subtype of ionotropic receptors 
LGICs belong to the class of ionotropic receptors and are comprised of three 
superfamilies, the pentameric Cys-loop receptors, the tetrameric ionotropic glutamate 
receptors (iGluRs) and the trimeric ATP-gated channels (P2X receptors). Receptors 
are generally classified according to a specific ligand that activates the respective 
receptor type. However, all these receptors have a common basic structure of an 
extracellular domain (ECD), a transmembrane domain (TMD) and an intra-
/extracellular C-terminal domain (CTD). Families within the Cys-loop receptor 
superfamily are nicotinic acetylcholine receptors (nAchRs), glycine receptors (GlyRs), 
γ-amino butyric acid type A receptors (GABAARs) and serotonin type 3 receptors (5-
HT3 receptors). These receptors form pentameric complexes, the binding pocket for 
ligands is located in the interface between the ECDs of two neighboring subunits, the 
transmembrane domain of each subunit is formed by four transmembrane helices 
(TM1-TM4) and the TM2s in the pentamer are lining the ion channel pore and the 
CTD lies extracellular. Interestingly, nAChRs and 5-HT3 receptors are cationic 
channels and lead to depolarization of the post-synaptic potential, whereas GlyRs 
and GABAARs are anionic channels and lead to hyperpolarization. Cys-loop 
receptors represent an interesting pharmacological target as anesthetics, steroids 
and benzodiazepines act via modulation of GABAA or glycine receptor function 
(Thurmon et al., 1996a, Maksay et al., 2001, Thio et al., 2003, Garcia et al., 2010). 
The N-methyl-D-aspartate receptors (NMDARs), (RS)-2-amino-3-(3-hydroxy-5-
methyl-4-isoxazolyl)propionic acid receptors (AMPARs) and kainate receptors 
(KARs) form three distinct subfamilies in the family of iGluRs. Commonly, iGluRs can 
be activated by glutamate, however, the efficiency of activation depends on the 
subunit composition of the receptor (Dingledine et al., 1999). In contrast to Cys-loop 
receptors, the respective subunits assemble to form tetrameric complexes 
(Sobolevsky et al., 2009). Ligand-binding occurs in the ECD but not between, but 
within subunits. The TMD is organized by three transmembrane domains (TM1, TM3 
and TM4), the M2 domain is a re-rentrant loop that is not spanning the membrane. 
The CTD is located on the intracellular side of the membrane (Madden, 2002). 
IGluRs convey the majority of excitatory neurotransmission in the mammalian central 
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nervous system and as such they are also implicated in the glutamate-induced 
excitotoxicity (Dingledine et al., 1999). Excessive activation of iGluRs by glutamate 
leads to overexcitation of the cell, which drives the cell into apoptosis. This basic 
principle underlies many neurodegenerative disorders, e.g. Alzheimer’s, Parkinson’s, 
Huntington’s and multiple sclerosis (Dingledine et al., 1999). 
 
Fig. 1. Overview of the three superfamilies in LGICs. Cartoon representation of examples 
for Cys-loop receptors, iGluRs and P2X receptors. Each subunit is colored differently for a 
better overview. (A-B) Side/Top view of the pentameric GluCl crystal structure (PDB ID: 
3RHW, Hibbs et al., 2011), which is an invertebrate Cys-loop receptor and is depicted here 
as a model for vertebrate Cys-loop receptors, (C-D) Crystal structure of the tetrameric 
GluA2-type AMPA receptor (PDB ID: 3KG2, Sobolevsky et al., 2009), (E-F) Crystal structure 
of the trimeric ATP-gated P2X4 receptor (PDB ID: 3I5D, Kawate et al., 2009). 
LBD ligand-binding domain, NTD N-terminal domain, TMD transmembrane domain. 
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ATP-gated P2X receptors are cationic channels and have only two 
transmembrane domains (TM1, TM2), the N- and C-termini are intracellular located 
and the extracellular loop between TM1 and TM2 of two subunits form the ATP-
binding site (Kawate et al., 2009). In contrast to Cys-loop and iGluRs, the P2X 
receptors form trimeric complexes. P2X receptors are implicated in a variety of 
physiological processes, such as synaptic transmission, inflammation, sensing of 
taste and pain (Kawate et al., 2009). 
Although, all the ligand-gated ion channels serve the function of ligand-
inducible ion channels that conduct ions along their respective electrochemical 
gradient, the molecular structure and overall organization of the receptors differ 
greatly. In the future it will be interesting to compare the structure and function 
relationship between the superfamilies in order to identify basic principles of receptor 
function. However, first the structure and function relationship within the superfamilies 
need to be analyzed. The work presented here is focused on the research of 
structure and function relationship in NMDARs and iGluRs in general. 
 
Ionotropic glutamate receptors (iGluRs) 
Based on distinct functional properties iGluRs are further discriminated into 
non-NMDA receptors, i.e. AMPA and kainate receptors, and NMDA receptors 
(Dingledine et al., 1999). Four AMPA receptor subunits exist, which are GluA1-4 and 
each subunit has two isoforms, i.e. flip or flop (Hollmann and Heinemann, 1994). For 
kainate receptors five subunits are known, i.e. GluK1-5 (Hollmann and Heinemann, 
1994). Non-NMDA receptors are non-selective cationic channels. Thus, Na+ and K+ 
permeate through the ion channel pore, however, Ca2+ permeability depends on the 
subunit composition (Traynelis et al., 2010). AMPARs lacking the GluA2 subunit will 
be permeable for Ca2+, but if a GluA2 subunit is incorporated it depends on post-
transcriptional RNA editing at the so-called Q/R editing site, if the receptor is Ca2+ 
permeable or not (Traynelis et al., 2010). Non-NMDA receptors are mainly 
responsible for the fast depolarization of the post-synaptic membrane. 
Subunits of the NMDA receptors are, GluN1 subunits with 8 isoforms, the 
GluN2A-D and GluN3A-B subunits (Monyer et al., 1994, Dingledine et al., 1999, Cull-
Candy et al., 2001). NMDA receptors are obligate heteromeric complexes, the 
‘conventional’ NMDA receptor is composed of two glycine-binding GluN1 subunits 
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and two glutamate-binding GluN2 subunits (Laube et al., 1998, Rosenmund et al., 
1998, Dingledine et al., 1999, Furukawa et al., 2005). In comparison to AMPA and 
kainate receptors, the conventional NMDA receptors do not only conduct Na+ and K+ 
but are highly Ca2+ permeable (Mayer and Westbrook, 1987, Burnashev et al., 1995). 
Also, at resting potential conventional NMDA receptors are blocked by extracellular 
Mg2+, which functions as a channel blocker (Dingledine et al., 1999). When the post-
synaptic membrane is depolarized by non-NMDA receptors, Mg2+ ions are repelled 
from the NMDAR channel pore and NMDA receptors can be activated. Thus, 
conventional NMDA receptors become only active upon ligand-binding and 
membrane depolarization, therefore they are also referred to as coincidence 
detectors (Dingledine et al., 1999). The high Ca2+ permeability is important as Ca2+ 
triggers second messenger signal cascades inside the cell, which are required for 
learning and memory formation (Collingridge and Bliss, 1995, Yashiro and Philpot, 
2008). 
NMDA receptors composed of glycine binding GluN1 and GluN3 subunits are 
referred to as ‘excitatory glycine receptors’ and exhibit very small currents 
(Chatterton et al., 2002, Madry et al., 2007a, Awobuluyi et al., 2007). Although these 
receptors have not been identified in vivo yet, they pose a very interesting target for 
the study of structure and function relationship as receptor currents can be 
potentiated up to ~125-fold by the co-application of glycine, Zn2+ and a GluN1 
antagonist (Madry et al., 2008, Madry et al., 2010). 
NMDARs stand out in the iGluR family because of their obligate heteromeric 
assembly, ligand- and voltage-dependency, implication in neurological disorders and 
the high degree of receptor modulation (Dingledine et al., 1999, Madry et al., 2008, 
Traynelis et al., 2010). Thus, understanding structure and function relationship in 
NMDA receptors is a great and exciting challenge. 
 
Modular composition of iGluRs 
It is currently believed that iGluRs have evolved from bacterial ancestor 
proteins (Lampinen et al., 1998, Masuko et al., 1999, Chen et al., 1999, Wollmuth et 
al., 2004, Matsuda et al., 2005). This hypothesis was supported by the identification 
of a missing link, the glutamate-binding GluR0 subtype receptors, which show 
homologies to prokaryotic potassium channels and eukaryotic iGluRs. (Chen et al., 
1999, Kuner et al., 2003). This evolutionary connection was further supported by the 
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identification of amino acid binding proteins, which show homologies to different 
domains in the modular composition of iGluRs. 
 
Fig. 2. Modular composition of iGluRs. Shown is a model of an iGluR dimer. 
Transmembrane region is grey, S1 and S2 subdomains of the LBD are colored blue and 
orange, respectively, NTDs are colored in green. 
Mayer, 2006 
 
The most distal part of an iGluR subunit from the membrane is the N-terminal 
domain (NTD). This domain shows sequence homology to the bacterial periplasmic 
Leucine-Isoleucine-Valine binding protein (LIVBP) and consists of ~400 amino acids 
(Masuko et al., 1999, Matsuda et al., 2005). The NTD has a bilobed structure, which 
means that the NTD is subdivided into the R1 and R2 domains. At the interface 
between these two subdomains a cavity is formed that is also a binding-site for 
allosteric modulators, e.g. Zn2, which has been shown to inhibit GluN1/GluN2A 
receptor currents (Paoletti et al., 1997, Herin and Aizenman, 2004). The R1 and R2 
subdomains are in constant movement in vivo opening and closing the binding-site 
periodically. This movement has been termed ‘oscillation’ and the frequencies of 
these oscillations are subunit specific and largely affect desensitization and channel 
open probability (P0) of GluN1/GluN2 receptors (Yuan et al., 2009, Gielen et al., 
2009). Structure and function studies with AMPA receptors have implicated that the 
NTDs determine the subunit specific assembly. In detail, GluA1 and GluA3 subunits 
as well as GluA2 and GluA4 dimerize readily whereas GluA1 and GluA2 or GluA2 
and GluA3 subunits do not (Ayalon and Stern-Bach, 2001, Ayalon and Stern-Bach, 
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2005, Rossmann et al., 2011). However, if the NTDs are removed the subunits 
dimerize with no favored combination (Ayalon and Stern-Bach, 2001, Pasternack et 
al., 2002). Taken together, NTDs are implicated in the assembly of iGluRs and the 
modulation of iGluR function. However, little is known about the functional roles of the 
GluN3 NTDs. 
The ligand-binding domain (LBD) lies between the NTD and the 
transmembrane domain (TMD). The LBD is homologous to the Lysine-Arginine-
Ornithine binding protein (LAOBP) and is also bilobed and as such subdivided into 
the S1 and S2 subdomains (Lampinen et al., 1998, Matsuda et al., 2005). Similar to 
the NTDs, the ligand-binding site is located at the interface between the S1 and S2 
subdomains (Furukawa et al., 2003). They form a clamshell-like structure and the 
subdomains close in a ‘venus-flytrap’ like fashion upon agonist recognition (Furukawa 
et al., 2003). This conformational change is transduced to the TMD and leads to the 
opening of the ion channel pore (Armstrong and Gouaux, 2000, Furukawa et al., 
2003). It has been suggested that the degree of clamshell-closure is directly 
correlated to the extent of receptor activation (Armstrong and Gouaux, 2000, 
Furukawa et al., 2003). According to this hypothesis antagonists would prevent 
clamshell-closure, partial agonists, which induce submaximal activation would allow 
for partial clamshell-closure and only agonists would allow for full clamshell-closure. 
However, crystallization studies have shown that also partial agonists are capable of 
inducing full clamshell-closure (Inanobe et al., 2005). Thus, the exact molecular 
mechanism of partial agonism is unclear.  
The TMD is homologous to the KcsA-type potassium channel, which has two 
transmembrane domains (TM1, TM3) and one re-entrant loop (M2)(Doyle et al., 
1998, Wollmuth et al, 2004, Sobolevsky et al., 2009). The TMDs of iGluRs share the 
same organization but resemble the situation of an inverted KcsA channel and 
additionally a fourth membrane domain, the TM4, is present (Wollmuth et al., 2004, 
Sobolevsky et al., 2009). Crystallization studies have shown that the TM3 lines the 
ion channel pore but the M2 domain determines the ion selectivity (Doyle et al., 1998, 
Sobolevsky et al., 2009). The role of the TM4 is currently not well understood as this 
domain is absent in KcsA channels it doesn’t seem to be required for proper channel 
function. A study by Horak et al. (2008) identified endoplasmatic reticulum (ER) 
retention signals in the TM3s of GluN1 and GluN2B and it was shown that the TM4 is 
required to mask those ER retention signals. If not, the subunits remain ER localized 
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and are subsequently degraded. However, if this also applies to GluN1/GluN3 
receptors and the non-NMDA receptors is not known. Also it is not known if the TM4 
is further involved in receptor function as studies found that mutations in the TM4 
affect channel gating (Beck et al., 1999, Ren et al., 2003). Therefore, it was 
suggested that the TM4 might directly contribute to the ion channel pore (Beck et al., 
1999, Ren et al., 2003). 
The C-terminal domain (CTD) of NMDA and non-NMDA receptors is localized 
intracellular and may interact with intracellular scaffolding proteins that determine 
their accumulation at post-synaptic membranes (Bolton et al., 2000). 
As aforementioned, iGluR subunits show homologies to prokaryotic amino 
acid binding proteins (NTD and LBD) and to prokaryotic ion channels (TMD). One 
focus of structure and function relationship studies is to understand the role of each 
domain for receptor function. But another very interesting focus is to gain insight into 
the role of interfaces between subdomains in one subunit e.g. R1-R2 for the NTD and 
S1-S2 for the LBD or between domains of two neighboring subunits, such as NTD-
NTD, LBD-LBD or TMD-TMD. Therefore, structural data is necessary, either by 
crystallizing the respective proteins or by using bioinformatic protocols, such as 
homology modelling. However, homology modelling always requires crystal 
structures of homologous proteins as templates. Several crystal structures have 
emerged throughout the years, which gave important insights into the overall 
organization of iGluRs. 
 
Overall organization of iGluR structure 
Due to the modular structure of iGluR subunits, it was possible to express the 
NTDs and LBDs as soluble proteins and subsequently crystallize them (Armstrong et 
al., 1998, Armstrong and Gouaux, 2000, Furukawa et al., 2003, Furukawa et al., 
2005, Yao and Mayer, 2006, Yao et al., 2008, Jin et al., 2003, Kumar et al., 2009, 
Karakas et al., 2009, Karakas et al., 2011). Some of these crystal structures did not 
only show one domain but dimeric assemblies such as the heteromeric GluN1-
GluN2A LBD dimer (Armstrong and Gouaux, 2000, Furukawa et al., 2005, Karakas et 
al., 2011). According to this crystal structure the LBDs are arranged in a ‘back-to-
back’ conformation (Fig. 3A) and the interface between the subunits is subdivided 
into three distinct interaction sites (sites I-III, Fig. 2B)(Furukawa et al., 2005). The first 
interaction site is formed by the GluN1 D-helix and the J-helix of GluN2A (Fig. 3B,C). 
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The second interaction site is located between sites I and III and here the ß-sheets 
ß10 and ß14 of each subunit are mediating the contact (Fig. 3D). Lastly, the third 
interaction site is analogous to site I, here the GluN1 J-helix is forming a contact with 
the GluN2 J-helix (Fig. 3E).  
 
 
Fig. 3. Crystal structure of the GluN1-GluN2A-LBD (PDB ID: 2A5T, Furukawa et al., 
2005). Shown are the LBDs of the GluN1 subunit (green) and the GluN2A subunit (blue). 
Residues implicated in intersubunit contacts are depicted as sticks. (A) Side view of the 
‘back-to-back’ conformation. (B) Top view on the interface between the GluN1 and GluN2A 
subunits. The three distinct interaction sites are depicted in red ovals. (C) Close view of the 
interaction site I, D-helix of GluN1 and J-helix of GluN2A are forming this contact. (D) Close 
view of the interaction site II, ß-sheets 10 and 14 of each subunit are involved. (E) Close 
view of the interaction site III, J-helix of GluN1 and D-helix of GluN2A are forming this 
contact. 
Adadpted from Furukawa et al., 2005 
 
The strength of these interface interactions has been shown to critically determine 
the activation and desensitization properties of iGluRs (see ‘Activation mechanism of 
iGluRs’)(Stern-Bach et al., 1998, Armstrong et al., 2006, Traynelis et al., 2010). 
Until recently the organization of the NTDs was suspected to be in a similar 
‘back-to-back’ fashion as it was described for the LBD dimers (Paoletti et al., 2007, 
Gielen et al., 2009). However, in the most significant crystal structure for the past 
years, the tetrameric GluA2-type AMPA receptor structure (PDB ID: 3KG2), it was 
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shown that the NTDs are arranged in a side-by-side orientation (Fig. 
4A,B)(Sobolevsky et al., 2009). 
 
Fig. 4. Crystal structure of the tetrameric GluA2-type AMPA receptor (PDB ID: 3KG2, 
Sobolevsky et al., 2009). Colors indicate the tetrameric composition. (A) Side view on the 
homomeric GluA2-type AMPA receptor. (B) 90° degree rotated side view of the AMPA 
receptor structure. 
Sobolevsky et al., 2009 
 
According to this crystal structure, the NTDs can adopt two different 
orientations. First, the NTD of a subunit lines up with the subjacent LBD, which itself 
is lined up with the TMD (Fig. 5A) and Sobolevsky et al. (2009) suggest that in 
NMDARs GluN1 subunits adopt this conformation. Second, the NTD can adopt a 
conformation where it is not lined up with the respective LBD but orients itself to the 
diagonal subunit and it is thought that GluN2 NTDs adopt this conformation in 
NMDARs (Sobolevsky et al., 2009) and this idea is further supported by the 
introduction of cysteine residues and the formation of disulfide bridges and 
subsequent affinity purification in a study by Lee et al. (2011). According to these 
findings the GluN1-NTDs and GluN2-NTDs form local heterodimers but the GluN2-
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NTDs additionally form a homodimeric contacts. The heterodimeric interface has 
been shown to govern the binding site for ifenprodil in GluN1/GluN2B receptors. 
Ifenprodil is a high affinity allosteric inhibitor of Glun1/GluN2B receptor function 
(Madry et al., 2007b). It was thought that ifenprodil binds in the binding pocket of the 
GluN2B-NTD (Madry et al., 2007b) but the crystal structure of the GluN1/GluN2B 
NTD with ifenprodil bound to the heterodimeric interface falsified this hypothesis 
(Karakas et al., 2011). Furthermore it was shown by Karakas et al. (2011) that 
ifenprodil binding to the interface reduces flexibility and thus increases the rigidity of 
the NTDs, which inhibits GluN1/GluN2B receptor function. However, we have no 
information about this interface in GluN1/GluN2A and GluN1/GluN3 receptors. As 
well, we do not know in which way the homodimeric contacts of the GluN2-NTDs are 
implicated in NMDAR function. 
 
 
Fig. 5. Crystal structures of the single GluA2-subunits from the tetrameric GluA2-type 
AMPA receptor structure (PDB ID: 3KG2, Sobolevsky et al., 2009). Although this is a 
homomeric receptor crystal structure the subunits can adopt two different conformations. (A) 
Subunits A and C adopt the same conformation with the NTDs, LBDs and TMDs lined up. (B) 
The subunits B and D adopt a twisted conformation where the NTDs are rotated 161° and 
the TMDs are rotated by 104° with respect to the LBDs. The NTDs of subunits B and D are in 
close contact with each other. 
Sobolevsky et al., 2009 
 
The TMDs of iGluRs are homologous to prokaryotic potassium-conducting KcsA 
channels (Doyle et al., 1998, Sobolevsky et al., 2009). Despite the homology there 
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are also few differences. The first one is that the TMDs of iGluRs are inversely 
embedded into the membrane compared to the KcsA structure (Doyle et al., 1998, 
Sobolevsky et al., 2009). Second, iGluR TMDs possess a fourth membrane domain, 
the TM4, which is not present in the KcsA channel (Doyle et al., 1998). According to 
the AMPAR crystal structure, this TM4 domain is remotely located to the TMs of the 
same subunit, however, it is close to the TM1 and TM3 of the neighboring subunit 
(Fig. 6)(Sobolevsky et al., 2009). Based on this crystal structure it is possible to 
conduct structure and function relationship studies on the intersubunit interface that 
is formed by the TM4 of one subunit and the TM1 and TM3 of the neighboring 
subunit. It was suggested that the TM4 is an evolutionary addition to the iGluR TMDs 
but it is not known why this additional membrane domain was necessary. 
 
 
Fig. 6. Homology model of the GluN1-GluN2A TMDs. GluN1 subunits (green) and GluN2A 
subunits (cyan) are arranged highly symmetrical. The TM3 domains are lining the ion 
channel pore whereas the M2 domains are forming the selectivity filter (loop region). The 
TM4 domains of each subunit are engaged in intersubunit contacts with the neighboring 
subunits’ TM1 and TM3 domain. 
 
 18 
Activation mechanism of iGluRs 
Functional and crystallization studies have focused on understanding the 
activation mechanism of iGluRs (Sun et al., 2002, Furukawa et al., 2003, Inanobe et 
al., 2005, Armstrong et al., 2006, Mayer, 2006). It was found that during receptor 
activation first the S2 subdomain approaches the S1 subdomain and thus the ligand-
binding pocket is closed, this conformational rearrangement conveys enough strain 
to open the ion channel pore (Furukawa et al., 2003, Inanobe et al., 2005, Armstrong 
et al., 2006, Mayer, 2006). These initial LBD conformational changes also cause 
strain onto the LBD dimer interface and cause a rupture of the interface (Fig. 4), 
which in turn causes the ion channel to close (Mayer, 2006, Traynelis et al., 2010). In 
this situation the ligands are still bound to the LBDs but the ion channel is closed, this 
conformational state is termed the ‘desensitized’ state (Fig. 7A)(Sun et al., 2002, 
Armstrong et al., 2006, Mayer, 2006). This principle is thought to be valid for 
conventional NMDA receptors and non-NMDA receptors. But the activation 
mechanism depends not only LBD rearrangements, NTD truncations and NTD 
substitution experiments have shown that the NTDs play an important role in 
determining apparent agonist affinities, extent of desensitization, desensitization 
kinetics and channel open probability (P0)(Madry et al., 2007b, Yuan et al., 2009, 
Gielen et al., 2009). In this respect ‘oscillations’ of the NTDs have been implicated, 
which are thought to be periodic movements that open and close the binding pocket 
of the respective NTDs. A high frequency of these oscillations leads to a reduced P0 
whereas lower frequencies increase the P0 (Gielen et al., 2009). But it is still unclear 
how these oscillations are conveyed to the ion channel pore. In the aforementioned 
studies it was also found that the NTD-LBD linkers play an important role as for the 
NTD substitution experiments with GluN2 subunits it was necessary to not only 
substitute the NTD between subunits but also the linker region, in order to transfer 
GluN2 subunit specific properties from one GluN2 subunit to another GluN2 subunit 
(Yuan et al., 2009, Gielen et al., 2009). 
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Fig. 7. Model for the activation mechanism in GluN1/GluN2A and GluN1/GluN3A 
receptors. Subdomains of the NTDs and LBDs are colored in different shades. Glycine 
molecules are depicted as red circles, glutamate is green. (A) GluN1/GluN2 receptors 
require ligand binding to GluN1 and GluN2 subunits to be activated. Upon agonist binding 
the S2 subdomains are rearranging to open the ion channel. This weakens the interface 
interactions, the receptor desensitizes depending on the strength of intersubunit interactions. 
(B) In GluN1/GluN3A receptors the GluN3A is the principal activating subunit. Agonist 
binding to the GluN3A subunit activates the receptor, whereas ligand binding to the GluN1 
subunit is thought to induce receptor desensitization (Madry et al., 2007a). 
Adapted from Madry et al., 2007a 
 
The activation mechanism for GluN1/Glun3 receptors is thought to be different 
than the rest of the iGluRs (Madry et al., 2007a, Awobuluyi et al., 2007, Madry et al., 
2008). In detail, ligand-binding to the GluN3 subunit alone induces sufficient 
conformational strain to induce channel opening, whereas ligand-binding to the 
GluN1 subunit immediately leads the receptor to desensitize (Madry et al., 2007a). 
This hypothesis is further supported by the ~25-fold potentiation of GluN1/GluN3A 
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receptor currents, if the GluN1 subunit is antagonized, e.g. by MDL-29951, or when 
the ligand-binding pocket is mutated (Madry et al., 2007a, Madry et al., 2008). Thus it 
is concluded that ligand-binding to the GluN1 and GluN3 subunits have distinct 
effects, ligand-binding to the GluN3 subunit activates the receptor and ligand-binding 
to the GluN1 subunit has an inhibitory effect. GluN1/GluN3 receptors exhibit very 
small currents upon glycine-application and it is thought that the underlying 
mechanism are the differential roles of the subunits for receptor activation. However, 
it is unclear why the GluN1 subunit is required for full activation in GluN1/GluN2 but 
in GluN1/GluN3 receptors it inhibits receptor function. Structure and function 
relationship studies should address the question in which way the NTDs or LBDs of 
GluN3 subunits are involved in the inhibitory role of the GluN1 subunit in 
GluN1/GluN3 receptors. 
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Aim of this work 
As aforementioned, iGluRs have a modular structure and the NTDs, LBDs as 
well as the TMDs have prokaryotic homologs. Depending on the type of iGluR and its 
subunit composition the pharmacological and functional properties differ greatly. The 
aim of the work presented here was to investigate which functional properties, such 
as the activation mechanism, apparent agonist affinities, extent of desensitization 
and maximal inducible currents, of NMDARs are determined by intra- and 
intersubunit interfaces. For this purpose bioinformatics protocols, i.e. ligand docking 
studies, homology modelling and mutual information analysis (MI) were combined 
with electrophysiological as well as molecular biology methods, i.e. two-electrode 
voltage-clamp (TEVC) on Xenopus laevis oocytes and site-directed mutagenesis. 
First, using molecular docking and homology modelling, the ligand-protein 
interactions were analyzed to disclose in which way the S1 and S2 subdomains 
interact with each other and what determines the efficacy of a ligand. Thus, we 
intended to gain insight into the molecular activation mechanism. Next, the role of the 
GluN1-GluN2 LBD heterodimer interface was analyzed using the MI analysis and by 
introducing amino acid mutations in the GluN1 subunit and characterizing these 
mutations using TEVC with regards to apparent agonist affinities, extent of 
desensitization an maximal inducible currents. These experiments were carried out 
on a reduced receptor model, i.e. NTD-lacking GluN1/GluN2 receptors. In 
comparison to GluN1/GluN2 receptors, GluN1/GluN3 receptors were found to have a 
very low efficacy. In order to understand which structural properties account for this 
difference, GluN1/GluN3 LBD heterodimer interface mutations and mutations in the 
GluN3A-NTDs were analyzed with respect to apparent agonist affinities, extent of 
desensitization and maximal inducible currents. For this, TEVC was combined with 
homology modelling. In addition to the analysis of NTD and LBD interactions, 
interactions in the TMDs were analyzed by MI analysis and by means of homology 
modelling and TEVC. Specifically, the question for the role of the TM4 domain in 
receptor function was addressed. 
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ABSTRACT 
Ionotropic glutamate receptors (iGluRs) are ligand-gated ion channels that 
mediate the majority of excitatory neurotransmission in the mammalian central 
nervous system. A unique feature of the respective subunits is the clamshell 
like closure of the ligand-binding domains (LBD) upon agonist recognition. To 
date, a lot of effort went into analyzing whether the extent of clamshell closure 
of the LBD is correlated to the extent of receptor activation. In order to 
understand how conformational states induced by full and partial agonists 
modulate the activity of the receptor we conducted docking experiments with 
crystal structures and homology models. First, we used GluN1 LBD crystal 
structures to determine if agonists, partial agonists and antagonists 
energetically prefer distinct conformations, i.e. closed-cleft, partially closed-
cleft or open-cleft, respectively. Indeed, we found that agonists have their 
lowest binding energy in the closed-cleft conformation whereas partial 
agonists and antagonists dock best into partially closed-cleft and open-cleft 
conformations, respectively. Subsequently, we constructed homology models 
for GluN2A and GluN3A LBDs using GluN1 LBD crystal structures with 
different extents of clamshell closure and used these models for docking 
experiments. We did not find a strong correlation between the action of the 
ligand and the extent of clamshell closure for agonists and partial agonists. 
This finding might indicate that GluN1 and GluN2A/GluN3A subunits do not use 
the same molecular mechanism to distinguish between agonists and partial 
agonists, notwithstanding the loss of accuracy between docking experiments 
with crystal structures and homology models. Also it is possible that the LBDs 
behave differently when expressed as isolated, soluble proteins as it is 
required for X-ray crystallography. Thus, it would not be possible to disclose 
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the molecular mechanism that defines the action of a ligand by analyzing 
crystal structures or homology models of iGluR subunits. 
 
INTRODUCTION 
Ionotropic glutamate receptors (iGluRs) are tetrameric complexes of homologous 
subunits, such as GluA1-4 for AMPA receptors, GluK1-4 for kainate receptors and 
GluN1, GluN2A-D as well as GluN3A-B for NMDA receptors. All of these subunits 
share a common modular structure composed of i) a bilobed, extracellular N-terminal 
domain (NTD), ii) a bilobed, extracellular ligand-binding domain (LBD), iii) a 
membrane-bound domain consisting of 3 transmembrane helices (TM1, TM3 and 
TM4) and one pore-forming re-entrant loop (M2) and lastly iv) an intracellular C-
terminal domain (CTD)(overview in Madden, 2002). The bilobed LBD is formed by 
the two subdomains S1 and S2, the S1 subdomain consists of the ~150 AAs before 
the TM1 and the S2 consists of a ~150 amino acids (AAs) extracellular loop between 
TM3 and TM4. The LBD shows similarity to the bacterial, periplasmic Lysine-
Arginine-Ornithine binding protein (LAOBP)(Lampinen et al., 1998). It is known that 
the two subdomains are arranged in a clamshell-like architecture and upon ligand 
binding the two subdomains approach each other, i.e. the binding pocket closes, in a 
clamshell like mechanism. It is suggested that this conformational movement is 
required for the opening of the ion channel pore (Armstrong and Mayer, 2000, 
Furukawa et al., 2003, Inanobe et al., 2005). In this respect, especially partial 
agonists are useful molecules with which to probe the relationship between agonist 
binding, conformational changes and ion channel activation. According to del Castillo 
and Katz (1957) a partial agonist is a ligand that produces a channel open probability 
(P0) of less than 1 upon occupancy of all binding sites. Later, the Monod-Wyman-
Changeux model (Monod et al., 1965) claimed that ligand-gated ion channels are in 
an equilibrium between two distinct states: closed/inactive and open. An agonist 
would then be a molecule that is maximally effective in shifting the equilibrium from 
closed/inactive to open. Li et al. (1997) extended this model by saying that partial 
agonists are less effective than full agonists in shifting the equilibrium to the open 
state. Although this hypothesis might appear logical, crystallization studies suggest 
that the LBDs are present in several distinct conformational states (Armstrong and 
Mayer, 2000) 
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GluA2 LBD crystallization studies with agonists, partial agonists and antagonists 
suggested that the degree to which the LBD clamshell closes is correlated to the 
extent of receptor activation. Accordingly, a full agonist would induce a complete 
closure of the LBD clamshell, whereas a partial agonist would stabilize a partially 
closed-cleft conformation and an antagonist would prevent the conformational 
change and stabilize an apo-state like conformation, the conformation before a ligand 
is bound. As NMDARs and non-NMDARs share the same modular composition it 
was expected that NMDAR subunits would behave like their AMPAR counterparts. 
But crystallization of the GluN1 LBD with partial agonists, such as D-cycloserine 
(DCS), 1-aminocyclopropane-1-carboxylic acid (ACPC) and 1-aminocyclobutane-1-
carboxylic acid (ACBC), revealed that partial agonists can induce a full closure of the 
LBD similar to full agonists (i.e. glycine and D-serine)(Furukawa et al., 2003, Inanobe 
et al., 2005). However, agonist efficacies seem to be correlated to the size of the 
ligand as, compared to glycine, the larger ligand ACPC resulted in only 80% 
activation, ACBC with one carbon atom more induced 42% activation and 
cycloleucine with one more carbon atom did not elicit currents in concentrations up to 
50mM. The respective crystal structures show that while the ACPC- and ACBC-
bound structures (PDB IDs: 1Y1Z, 1Y20) show a fully closed clamshell, the 
cycloleucine-bound structure (PDB ID: 1Y1M) has a partially open-cleft. The size of a 
ligand is reasonably correlated to its function but for the small ligands, additional 
discrimination mechanisms might be present (Inanobe et al., 2005). In this respect 
Inanobe et al. (2005) reported that the glycine- and ACPC- or ACBC-bound 
structures differ in 8 residues, which are located in the so-called hinge region (GluN1 
T749-S756). It has been observed that the L538 residue in the GluN1-LBD made a 
hydrogen-bonded interaction with F754 in the glycine-bound structure, whereas in 
the ACPC- and ACBC-bound structure the interaction was with F753. It was 
suggested that this switch from F754 to F753 might be responsible for the 
discrimination between agonists and partial agonists. It was also reported that W731 
and V689 are sensitive to the size of the ligand and thus large ligands cannot induce 
a full closure of the LBD due to steric effects. 
Based on the previous findings we hypothesized that the action of a ligand is 
mainly determined by its size. Although ligands such as ACPC and ACBC can induce 
a full closure of the GluN1 LBD (in the crystal structure), we believe that in vivo partial 
agonists would energetically prefer a partially closed- cleft conformation. Thus, we 
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docked 21 ligands (agonists, partial agonists and antagonists, Fig. 1) to the crystal 
structures of the glycine- (1PB7, closed-cleft conformation), cycloleucine- (1Y1M, 
partially closed-cleft conformation) and 5,7-dichlorokynurenic acid (DCKA)-bound 
LBD structures (1PBQ chain A and B, open-cleft conformations). For each ligand we 
compared how well it docks into each conformer. We expect that the conformer with 
the lowest energy for each ligand will be its favored state in vivo. 
 
Fig. 1 Agonists, partial agonists and antagonists of NMDAR-subunits. 
 
GlycineD-Serine
L-Alanine
D-Alanine
HA-966
ACBC ACPC
CycloleucineCNQX D-Cycloserine
5,7-DCKA 5-CKA 7-CKA
Kynurenic acid
MDL-29951L-687414 L-689560 L-701324
NMDA
Glutamate
D-AP5
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In order to assess the feasibility of docking experiments on homology models, we 
compared docking results from crystal structures and homology models. For this, 
homology models for the GluN1 LBD were computed based on GluA2 crystal 
structures: closed-cleft AMPA-bound structure, partially closed-cleft kainate-bound 
structure, open-cleft UBP277-bound structure and maximally open-cleft UBP282-
bound structure (PDB IDs respectively: 1FTM, 1FTK, 3H03, 3H06). To further 
analyze whether GluN1, GluN2 and GluN3 LBDs share the same molecular 
mechanisms to discriminate between agonists and partial agonists, i.e. extent of 
clamshell closure, we constructed homology models for the GluN2A and GluN3A 
LBDs based on the different conformers of the GluN1 LBD. Using this approach we 
intended to overcome the problem that no crystal structures for partial agonist or 
antagonist bound GluN2 or GluN3 LBDs are available. By these means we simulated 
different degrees of clamshell closure, from the apparent apo-state to the fully closed 
state. These models were then used for docking experiments using the same 21 
ligands that were used for the GluN1 LBDs (Fig. 1). An overview of the known actions 
of these ligands on the respective LBDs is summarized in Table 1. 
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Table 1. Ligands of NMDAR-subunits and their respective published activity. 
n/a means that no activity was measurable. 
 
Our approach is based on several assumptions, one of these assumptions is that 
the LBD crystal structures reflect the in vivo behavior of the LBDs. Also we assumed 
that all of the ligands bind in the same binding pocket, as indicated by previous 
crystal structures (Furukawa et al., 2003, Inanobe et al., 2005), and that the 5,7-
DCKA-bound GluN1 structure (PDB ID: 1PBQ) reflects the apo-state of the LBD as 
suggested by Furukawa et al. (2003). 
 
EXPERIMENTAL PROCEDURES 
Molecular modeling of the NMDAR LBDs - Sequence alignment of the NMDA 
receptor subunits was taken from Sobolevsky et al. (2009). GluN1 LBD homology 
models are based on GluA2 crystal structures from: 1FTM (closed-cleft), 1FTK 
(partially closed-cleft), 3H03 (open-cleft) and 3H06 (maximally open-cleft). The 
GluN2A and GluN3A models are based on the GluN1 crystal structures of: 1Y1M 
Compound GluN1 Reference GluN2A Reference GluN3A Reference
5,7$DCKA Antagonist Leeson2et2al.,21991
Foster2et2al.,21992
5$CKA Antagonist Leeson2et2al.,21991
Foster2et2al.,21992
7$CKA Antagonist Leeson2et2al.,21991
Foster2et2al.,21992
ACBC part.2Agonist Inanobe2et2al.,22005
ACPC part.2Agonist Inanobe2et2al.,22005
CNQX Antagonist Ramakers2et2al.,21991 Antagonist Yao2et2al.,22006
Madry2et2al.,22007a
Cycloleucine Antagonist Inanobe2et2al.,22005
D$Alanine Agonist McBain2et2al.,21989
D$AP5 Antagonist Collingridge2et2al.,21983
D$Cycloserine part.2Agonist Furukawa2et2al.,22003
D$Serine Agonist Furukawa2et2al.,22003 Agonist Chatterton2et2al.,22002
Glutamate Agonist Furukawa2et2al.,22005 n/a Chatterton2et2al.,22002
Glycine Agonist Furukawa2et2al.,22003 Agonist Madry2et2al.,22007a
Furukawa2et2al.,22005 Yao2et2al.,22008
HA$966 part.2Agonist Priestley2et2al.,21995
Kynurenic2acid Antagonist Elmslie2et2al.,21985
L$Alanine part.2Agonist McBain2et2al.,21989
L$687414 part.2Agonist Priestley2et2al.,21995
L$689560 Antagonist Ivanovic2et2al.,21998
L$701324 Antagonist Kulagowski2et2al.,21994
Konieczny2et2al.,21999
MDL$29951 Antagonist Ivanovic2et2al.,21998
NMDA Agonist Erreger2et2al.,22007 n/a Chatterton2et2al.,22002
Activity8on8ligand;binding8domain
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(partially closed-cleft), 1PBQ chain B (open-cleft), 1PBQ chain A (maximally open-
cleft). We compared docking results from energy-minimized structures and non-
minimized structures and we found that energy minimization led to an inaccessible 
binding pocket and therefore non-minimized structures were used in the docking 
experiments. 
The models for the LBDs were generated using the Modeller program 9v7 (Fiser and 
Sali, 2003) and energy-minimized using Chimera build 2577 (Pettersen et al., 2004).  
 
Docking experiments - The docking experiments with crystal structures and 
homology models were conducted using Autodock Vina (Trott et al., 2010). Autodock 
Vina has improved accuracy and speed compared to the commonly used Autodock 
4. The scoring function in Autodock Vina assesses hydrophobic (i.e. van der Waals) 
interactions, hydrogen-bonded interactions as well as torsional penalties. Based on 
these parameters Autodock Vina calculates a gradient while seeking a local optimum. 
The final docked energy represents the binding energy of the ligand to the receptor. 
Thus, the binding energy largely depends on the ligand, consequently it is not 
advisable to compare binding energies between ligands. However, it is feasible to 
compare the binding energies of one ligand to different conformers. For each docking 
run the following residues were selected to have flexible side chains, their selection is 
based on direct involvement in binding modes observed in crystal structures 
(Furukawa et al., 2003, Inanobe et al., 2005, Furukawa et al., 2005, Yao et al., 2008): 
- GluN1: F408, F484, T518, R523, S688, W731, D732 
- GluN2A: H485, S511, T513, R518, S689, T690, D731 
- GluN3A: Y605, S631, S633, R638, S801, D845 
Note: Glycine and proline residues cannot have flexible side chains because glycine 
only has one hydrogen atom as its side chain and proline has no rotatable bonds. 
A boundary box, also called the grid box, restricts the 3-dimensional docking space 
for the ligand. The grid box’ size was adjusted to engulf the binding pocket and all the 
residues with flexible side chains. Autodock Vina then calculates grid maps for each 
atom type present in the protein and the ligand. Based on these grid maps the 
docking is being performed with the selected ligands (Fig. 1). 
 
Pymol 1.3 (Schrödinger Inc., New York, NY, USA) was used for illustration. 
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RESULTS 
Assessing the feasibility of docking experiments with crystal structures 
and homology models - According to the available crystal structures of the GluN1 
LBD with glycine, cycloleucine and 5,7-DCKA (PDB IDs: 1PB7, 1Y1M, 1PBQ, 
respectively) the LBD can adopt conformations with differing clamshell-closure 
degrees. The S1 and S2 domains behave as relatively rigid bodies apart from the 
hinge region (Furukawa et al., 2003). In order to compare the ‘openness’ of the 
binding pocket we selected residues in each subdomain and measured the distance 
between their Cα-atoms. For GluN1 these are M501 (C-helix) with S688 (F-helix) and 
F458 (B-helix) with A714 (H-helix). The distances increase from 11.8/16.9 Å (closed-
cleft) up to 14.6/19.9 Å (open-cleft)(Fig. 2A-D). 
In a first set of experiments we tested whether Autodock Vina is able to predict 
the correct ligand bound conformations known from the crystal structures. For this, 
we used the following crystal structures and measured the root mean squared 
deviation (RMSD) in Angstrom (Å) from the crystallized position of the ligand: 
- GluN1:  1PB7 (glycine)  0.624 Å 
1Y1M (cycloleucine) 0.034 Å 
1PBQ_B (5,7-DCKA) 0.045 Å 
1PBQ_A (5,7-DCKA) 0.056 Å 
 - GluN2A: 2A5S (glutamate)  1.395 Å 
 - GluN3A: 2RC7 (glycine)  0.578 Å 
 - GluA2: 1FTM (AMPA)  0.739 Å 
1FTK (kainate)  0 Å 
3H03 (UBP277)  0.793 Å 
3H06 (UBP282)  0.344 Å 
Note: None of the docking results showed a greater RMSD than 1.395 Å, thus we 
conclude that the predicted binding modes by Autodock Vina are reliable. 
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Fig. 2. Crystal structures and homology models of the GluN1 LBD. (A-D) GluN1 LBD 
crystal structures, PDB IDs 1PB7, 1Y1M, 1PBQ chain B and 1PBQ chain A, respectively, (E-
H) GluN1 LBD homology models based on GluA2 LBD crystal structures, PDB IDs 1FTM, 
1FTK, 3H03 and 3H06, respectively. 
Yellow dotted lines indicate Cα-atom distances between residues M501 and S688 (left) and 
F458 and A714 (right). 
 
In order to assess the feasibility of docking experiments with homology models 
we constructed models of the GluN1 LBD based on crystal structures of GluA2 LBDs. 
These were AMPA-bound (closed-cleft), kainate-bound (partially closed-cleft), 
UBP277-bound (open-cleft) and UBP282-bound structures (maximally open-
cleft)(PDB IDs: 1FTM, 1FTK, 3H03 and 3H06, respectively). The GluA2 and GluN1 
LBDs share a sequence identity of 30%. Again, measuring the distances between 
M501 and S688, as well as F458 and A714 of GluN1 shows an increase from 
12.7/16.4 Å up to 17.7/20.1 Å (Fig. 2E-H). Comparing these distances to the GluA2 
crystal structures that we used as templates we see deviations of not more than 1 Å. 
On the other hand, when we compare the distances from the GluN1 homology 
models to their respective crystal structures (PDB IDs: 1PB7, 1Y1M, 1PBQ chain B 
and 1PBQ chain A), we see deviations of up to ~3 Å. These deviations most probably 
arise because the different GluA2 conformers do not represent the exact degree of 
clamshell closure of the GluN1 LBD crystal structures. 
Subsequently, we used the GluN1 LBD crystal structures and homology models 
for docking experiments. Each of the 21 ligands was docked into the four conformers 
of the crystal structures and the four conformers of the homology models and the 
binding energies were evaluated (Table 2). According to our hypothesis, each ligand 
will favor one conformer where the binding energy will be the lowest, this would be 
A
11.8Å
GluN1cryst GluN1cryst GluN1cryst GluN1cryst
GluN1mod GluN1mod GluN1mod GluN1mod
12.7Å 16.4Å 13.0Å 17.1Å 17.1Å
19.1Å
17.7Å
20.1Å
16.9Å
13.0Å
19.2Å 14.5Å 19.2Å 14.6Å 19.9Å
B C D
E F G H
I J K L
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reflected in the activity of the ligand in vivo (agonist, partial agonist, antagonist). In 
line with our hypothesis, large ligands docked best into the open-cleft conformers, i.e. 
1PBQ chain B and 1PBQ chain A, whereas smaller ligands preferred the partially 
closed-cleft or closed-cleft conformations, i.e. 1Y1M and 1PB7, respectively. Looking 
at the docking energies with the GluN1 homology models we were surprised to see 
that 18 out of 21 ligands dock best into the partially closed-cleft conformation, i.e. 
N1_1FTK. This discrepancy with our hypothesis might be due to the fact that the 
GluA2 template structure possesses a larger binding pocket, as the respective 
agonist is glutamate, which is significantly larger than the GluN1 agonist glycine, i.e. 
the homology models might not recognize small changes in ligand size. 
 
Table 2. Docked energies of each ligand to GluN1 LBD crystal structures and 
homology models. 
Lowest docked energies for each ligand are depicted in yellow. 
 
Comparing the docking energies from GluN1 crystal structures and from 
homology models we found that out of 21 ligands, 13 ligands (~62%) are classified 
into the same group/activity (Table 2). The remaining 8 ligands (38%) differ in the 
conformer that results in the lowest binding energy. This indicates that our homology 
models lead to differing results in 8 of the 21 ligands compared to results obtained 
from crystal structures. Nevertheless, with 62% accuracy it should still be possible to 
estimate whether ligand size is the main determinant of ligand action or not. Next, we 
compared these docking results with the published functional activity of each ligand 
(Table 4). We consider a ligand as an agonist if the binding energy is lowest for the 
Compound 1PB7 1Y1M 1PBQ_B 1PBQ_A N1_1FTM N1_1FTK N1_3H03 N1_3H06
5,7$DCKA $ $7.9 98.8 $8.6 $ $8.7 $6.4 $6.0
5$CKA $ $8.1 98.2 $7.9 $ $8.4 $6.4 $6.3
7$CKA $ $7.8 98.6 $8.5 $ $8.2 $6.1 $6.0
ACBC $ 95.9 $4.9 $4.4 $ $4.8 $3.7 $3.4
ACPC $2.5 95.3 $4.4 $4.3 $3.7 $4.6 $3.3 $3.3
CNQX $ $8.0 98.5 $8.3 $6.5 $7.8 $6.7 $6.2
Cycloleucine $ 96.6 $5.2 $5.0 $4.0 $5.3 $4.1 $4.3
D$Alanine $3.5 94.7 $3.9 $3.8 $3.6 $4.1 $3 $3.2
D$AP5 $ 95.7 $5.2 $4.8 $5.2 $5.6 $7.2 $4.0
D$Cycloserine $3.2 95.0 $4.0 $4.0 $ $4.1 $2.8 $3.7
D$Serine $3.9 94.8 $4.2 $4.1 $3.4 $4.2 $2.6 $2.9
Glutamate $ 95.8 $5.0 $5.0 $5.2 $5.6 $4.8 $3.9
Glycine 94.1 $3.9 $3.5 $3.4 $3.4 $4.1 $2.7 $2.4
HA$966 $1.5 95.8 $4.4 $4.4 $ $4.9 $3.5 $3.5
KynurenicGacid $ $7.3 98.0 $7.8 $6.8 $8.1 $6.2 $6.3
L$Alanine $3.5 94.7 $3.8 $3.9 $3.7 $4.0 $2.7 $3.2
L$687414 $ 95.8 $4.9 $4.7 $ $5.3 $4 $3.8
L$689560 $ $5.5 910.1 $10.0 $ $ $8.9 $7.9
L$701324 $ $9.6 $10.3 910.9 $ $ $9.7 $8.6
MDL$29951 $ $7.5 98.3 $7.9 $4.4 $8.3 $6.5 $6.6
NMDA $ 95.4 $4.7 $4.6 $ $5.7 $3.8 $3.3
GluN1Bstructures GluN1Bmodels
bindingGenergyG[kcal/mol] bindingGenergyG[kcal/mol]
  37 
closed-cleft conformation (Fig. 2A/E), a partial agonist if the energy is lowest for the 
partially closed-cleft conformation (Fig. 2B/F) and an antagonist if the energy is 
lowest for one of the two open-cleft conformations (Fig. 2C/D and G/H). According to 
this discrimination, the docking with the GluN1 crystal structures (Fig. 2A-D) leads to 
a ~90% correct prediction of the ligand activity whereas with the GluN1 homology 
models (Fig. 2E-H) we only get 50% correct predictions. 
In summary, Autodock Vina correctly identifies ligand-binding modes verified with 
crystal structures. Furthermore, our hypothesis that the size of the ligand mainly 
determines its activity on the GluN1 LBD, by stabilizing different degrees of 
clamshell-closure, seems to be valid. Lastly, homology models that are used for 
docking experiments have a reduced, approx. 62%, accuracy compared to results 
obtained from crystal structures. Furthermore, the prediction of ligand activity based 
on our docking results with the GluN1 homology models is 50% accurate, i.e. in line 
with published functional activity. 
 
Molecular mechanism of ligand activity at GluN2A and GluN3A LBDs - To 
date GluN2A and GluN3A LBDs have been crystallized only in the agonist bound 
closed-cleft conformation. Accordingly, we have no partial agonist or antagonist 
bound structure, which would help to disclose the conformational changes induced 
by agonist binding. In order to circumvent this problem we built homology models of 
the GluN2A and GluN3A LBDs using partial agonist and antagonist bound GluN1 
LBD crystal structures (PDB IDs: 1Y1M, 1PBQ chain B and 1PBQ chain A)(Fig. 3B-D 
and 3F-H). Using this approach, we were able to generate different conformers with 
different degrees of clamshell-closure of the respective LBDs. In order to assess the 
degree of closure we measured the distances between the Cα-atoms of M462 and 
S655, as well as F425 and V679 of the GluN2A subunit. The homologous residues in 
the GluN3A subunit are L616 and S801, as well as Y579 and T825 (Fig. 3). Note that 
the distances closely resemble the distances measured in the GluN1 LBD (Fig. 2A-
D). 
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Fig. 3. Crystal structures and homology models of GluN2A and GluN3A LBDs. (A) 
GluN2A LBD crystal structure (PDB ID: 2A5S), (B-D) GluN2A LBD homology models based 
on GluN1 LBD crystal structures (PDB IDs: 1Y1M, 1PBQ chain B and 1PBQ chain A, 
respectively), (E) GluN3A LBD crystal structure (PDB ID: 2RC7), (F-H) GluN3A LBD 
homology models based on GluN1 LBD crystal structures (PDB IDs: 1Y1M, 1PBQ chain B 
and 1PBQ chain A, respectively). 
Yellow dotted lines indicate Cα-atom distances between residues M462 (L616) and S655 
(S801) (left) and F425 (Y579) and V679 (T825) of GluN2A (GluN3A) (right). 
 
The fact that we have used GluN1 LBD crystal structures for modeling the 
GluN2A and GluN3A LBDs also means that we assume that these NMDAR LBDs 
perform the same conformational changes upon ligand binding. Whether this 
assumption holds true will only be uncovered when partial agonist- and antagonist-
bound structures become available. Furthermore, based on our previous docking 
experiments with GluN1 homology models we can expect a 62% accuracy for 
docking to our homology models compared to results obtained from docking to 
crystal structures. Thus, we may not be able to correctly assign the conformation that 
is best stabilized by each ligand but a general tendency should become evident. 
We docked the same 21 ligands which we used for the GluN1 LBD docking 
experiments and evaluated which conformer is favored by each ligand (Table 3). 
A
GluN2Acryst GluN2Amod GluN2Amod GluN2Amod
GluN3Acryst GluN3Amod GluN3Amod GluN3Amod
11.3Å
11.9Å
16.9Å
13.0Å
19.2Å
14.4Å
19.2Å
14.6Å
19.9Å
17.9Å 13.0Å 19.1Å 14.6Å 19.9Å 14.6Å 19.9Å
B C D
E F G H
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Table 3. Docked energies of each ligand to GluN2A and GluN3A LBD homology 
models. 
Lowest docked energies for each ligand are depicted in yellow. 
 
The homology models were built using the same templates, thus, one might 
expect that the results are very similar. Out of the 21 ligands that were docked only 
10 ligands (48%) display the same docking results, i.e. have their lowest energies at 
the same conformers. This is a good indication that the results are not dominated by 
the template structure that has been used to build these models. It is noteworthy that 
large ligands such as MDL-29951 can also be docked into the closed-cleft 
conformation of GluN2A and GluN3A. But there is still a tendency that larger ligands 
dock best into the partially closed-cleft or open-cleft conformers (compare 5,7-DCKA, 
5-CKA, 7-CKA, CNQX, D-AP5, Kynurenic acid and L-687414). Comparing the activity 
of each ligand, proposed by the docking results with the published activity, we find 
that for GluN2A only NMDA is correctly identified as an agonist (Table 4). L-
Glutamate and D-AP5 have their lowest binding energy in the partially closed-cleft 
conformation rendering them falsely partial agonists in our model. The dockings 
correctly identified D-serine and CNQX as agonist and antagonist, respectively, of the 
GluN3A LBD (Table 4). Despite this, the agonist glycine docked best into the partially 
closed-cleft conformation. 
 
Compound 2A5S N2A_1Y1M N2A_1PBQ_B N2A_1PBQ_A 2RC7 N3A_1Y1M N3A_1PBQ_B N3A_1PBQ_A
5,7$DCKA $ 78.1 $7.5 $7.5 $ 78.0 $7.3 $8.0
5$CKA $4.7 77.9 $6.9 $7.1 $ 77.1 $7.0 $7.0
7$CKA $4.7 77.8 $7.4 $7.3 $ $7.1 $7.0 77.3
ACBC 75.6 $5.0 $4.4 $4.8 $4.2 75.6 $4.5 $4.2
ACPC 75.0 $4.7 $3.4 $4.5 $4.5 74.8 $3.6 $3.9
CNQX $ $7.8 78.1 $7.7 $ $7.3 78.6 $8.4
Cycloleucine 76.0 $5.4 $4.1 $5.2 $3.3 75.6 $4.2 $4.6
D$Alanine $3.8 74.5 $3.6 $4.0 74.7 $4.3 $2.5 $3.4
D$AP5 $5.2 75.4 $4.5 $4.7 $ 74.9 $3.3 $4.1
D$Cycloserine 75.1 $4.8 $4.2 $4.3 75.1 $4.8 $3.4 $3.6
D$Serine 74.1 $3.6 $4.0 $4.1 74.6 $3.6 $3.4 $3.3
Glutamate $5.3 75.6 $4.9 $4.9 $ 75.5 $3.7 $4.0
Glycine $ 77.6 $7.5 $7.4 $ 77.8 $7.0 $6.9
HA$966 74.7 $4.5 $4.1 $4.1 74.7 $3.9 $3.0 $3.7
KynurenicGacid $5.3 $5.2 $5.5 75.6 $ 75.0 $4.7 $4.7
L$Alanine $4.1 $8.4 78.6 $8.6 $ $7.4 $9.0 79.4
L$687414 $7.0 $9.2 $9.2 79.8 $ 710.5 $9.9 $9.9
L$689560 $4.5 $6.7 $6.8 77.0 $ 77.9 $6.5 $7.6
L$701324 75.8 $5.6 $5.8 $5.8 $4.2 $4.8 75.2 $5.2
MDL$29951 76.7 $5.6 $5.0 $5.0 75.4 $5.4 $4.9 $4.9
NMDA 76.3 $5.4 $4.9 $4.8 $4.6 75.3 $5.0 $4.1
GluN2A@models GluN3A@models
bindingGenergyG[kcal/mol] bindingGenergyG[kcal/mol]
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Table 4. Comparison of docking results with proposed activities. Based on which LBD 
conformer each ligand docked to with the lowest energy we classified the ligands as agonist 
(docked best to closed-cleft conformation), partial agonist (docked best to partially closed-
cleft conformation) or antagonist (docked best to open-cleft conformations). We used green 
color to highlight results that are in agreement with published results and red if they were not. 
No color means that no published results are available. 
 
Out of 9 large ligands (5,7-DCKA, 5-CKA, 7-CKA, CNQX, D-AP5, Kynurenic 
acid, L-689560, L701324 and MDL-29951) 3 were found to dock best into the open-
cleft conformation of GluN2A and GluN3A (N2A_1PBQ and N3A_1PBQ). For the 
partially closed-cleft conformations (N2A_1Y1M and N3A_1Y1M) 4 of the 9 large 
ligands for GluN2A and 5 ligands for GluN3A were found to have their lowest binding 
energy. The closed-cleft structure was preferred by 2 ligands for GluN2A and 1 ligand 
Compound GluN1,cryst GluN1,models GluN2A,models GluN3A,models
5,7$DCKA Antagonist part.3Agonist part.3Agonist part.3Agonist
5$CKA Antagonist part.3Agonist part.3Agonist part.3Agonist
7$CKA Antagonist part.3Agonist part.3Agonist Antagonist
ACBC part.3Agonist part.3Agonist Agonist part.3Agonist
ACPC part.3Agonist part.3Agonist Agonist part.3Agonist
CNQX Antagonist part.3Agonist Antagonist Antagonist
Cycloleucine part.3Agonist part.3Agonist Agonist part.3Agonist
D$Alanine part.3Agonist part.3Agonist part.3Agonist Agonist
D$AP5 part.3Agonist Antagonist part.3Agonist part.3Agonist
D$Cycloserine part.3Agonist part.3Agonist Agonist Agonist
D$Serine part.3Agonist part.3Agonist Agonist Agonist
Glutamate part.3Agonist part.3Agonist part.3Agonist part.3Agonist
Glycine Agonist part.3Agonist part.3Agonist part.3Agonist
HA$966 part.3Agonist part.3Agonist Agonist Agonist
Kynurenic3acid Antagonist part.3Agonist Antagonist part.3Agonist
L$Alanine part.3Agonist part.3Agonist Antagonist Antagonist
L$687414 part.3Agonist part.3Agonist Antagonist part.3Agonist
L$689560 Antagonist Antagonist Antagonist part.3Agonist
L$701324 Antagonist Antagonist Agonist Antagonist
MDL$29951 Antagonist part.3Agonist Agonist Agonist
NMDA part.3Agonist part.3Agonist Agonist part.3Agonist
Comparison,of,known,and,proposed,activity,of,ligands,on,NMDAR,LBDs
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for GluN3A, respectively. Taken together we found a general tendency that large 
ligands seem to stabilize conformations where the clamshell is at least partially open. 
 
DISCUSSION 
A unique feature of ionotropic glutamate receptors is the bilobed, clamshell-like 
structure of the LBDs and the clamshell closure upon ligand recognition. Crystal 
structures of various subunits of the different iGluR families have indicated that 
agonists and partial agonists induce the same degree of clamshell-closure. Here, we 
used an in silico approach to verify our hypothesis that partial agonists can induce full 
closure of the bilobed LBDs but the equilibrium is shifted towards a partially closed 
clamshell.  
Our results show a tendency that more than other properties, the size of the 
ligand determines its activity (agonist, partial agonist or antagonist). However, using 
homology models for docking experiments reduces the significance and the accuracy 
of the results but this approach can give a rough estimate of a ligands action when 
no structural information is present. 
 
GluN1, GluN2A and GluN3A LBDs might share similar ligand recognition 
mechanisms - According to our working hypothesis, i.e. ligand activity is determined 
by the degree of clamshell-closure and stabilization of this conformation, we were 
able to correctly identify the activity of a ligand with an accuracy of 83% using GluN1 
LBD crystal structures. Using GluN1 LBD homology models this high degree of 
accuracy dropped to ~50%. For example with our docking approach, using GluN1 
LBD crystal structures, we were able to correctly predict 8 out of 9 antagonists 
correctly, one wrongly identified as a partial agonist. In contrast, using the GluN1 
LBD homology models, only 3 antagonists were correctly identified, the remaining 6 
antagonists were classified as partial agonists. We obtained similar results from 
GluN2A and GluN3A docking experiments. For each subunit, 3 large ligands were 
identified as antagonists, 4 ligands for GluN2A and 5 ligands for GluN3A were 
classified as partial agonists, lastly 2 ligands for GluN2A and 1 ligand for GluN3A 
were classified as agonists. We take this as an indication that the mechanism of 
antagonism is similar or conserved between the NMDAR- as well as other iGluR-
subunits. Despite these similarities the mechanism of partial agonism is more 
delicate. The GluN2 subunits are activated by glutamate and NMDA, molecules that 
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are larger in size than glycine, thus the binding pocket in the GluN2 subunits must be 
larger to accomodate the ligand. It is conceivable that partial agonists for the GluN2 
subunits might be recognized by other mechanisms than their size. 
 
Crystal structures and homology models are not ideal to analyze partial 
agonism - As aforementioned we cannot exclude the possibility that partial agonism 
relies on different molecular mechanisms in the different iGluR subunits. In order to 
find possible explanations other than the size of the ligand we closely investigated 
the crystal structures of GluA2 and GluN1 LBDs in agonist-bound and partial agonist-
bound conformations. In a study by Furukawa et al. (2003) it was reported that a 
hydrogen-bonded interaction of L538 with F754 in the glycine-bound structure 
switches to F753 in the partial agonist-bound structures, which might be the cause for 
the low efficacy of partial agonists. However, the same has not been observed for 
AMPAR-subunits (Armstrong and Mayer, 2000). Thus, it is questionable if this 
interaction is the key to partial agonism. In our evaluations of the crystal structures 
we did not find possible explanations for the differences between agonism and partial 
agonism. This led us to rethink our assumptions. One of our assumptions was that 
the crystal structures resemble the in vivo behavior of the LBDs. But the LBDs are 
expressed as soluble proteins lacking other parts of the receptor. Thus, it might be 
the case that the molecular mechanism of partial agonism cannot be explained by 
analyzing the crystal structures of the isolated LBDs.  
 
Using locked LBDs as a tool to identify partial agonists - Our data indicate that 
partial agonism might not be solely controlled by the (isolated) LBDs. While 
determining the action of a ligand is feasible in homodimeric receptors, such as 
GluA2-type AMPA receptors, it is more complicated in heterodimeric receptors such 
as NMDA-receptors. In order to use in silico approaches it is necessary to validate 
the models that are being used. Therefore, ligands must be unambiguously 
characterized and identified as partial agonists. Because of the complex structure of 
NMDA-receptors this is rather difficult. Previous studies have employed NMDAR 
subunits where the S1 and S2 subdomains are locked in the closed-cleft 
conformation using disulfide bridges by introducing cysteine mutations (Blanke and 
VanDongen, 2008, Kussius et al., 2010). It was found that locking the GluN1 LBD in 
its closed-cleft conformation leads to solely glutamate-gated GluN1/GluN2A 
  43 
receptors. On the contrary, locking the GluN2A LBD leads to an overall agonist-
independent increase in channel activity. This indicates that GluN1 and GluN2 
subunits unequally participate in receptor activation with the GluN2 subunits being 
more important. We propose that such LBD locked subunits might prove useful tools 
to determine the activity of different ligands in detail. It is also advisable to combine 
docking experiments with molecular dynamics simulations. In detail, a LBD would be 
simulated for a fixed period and different conformations would then be used for 
docking experiments. This approach would provide many more conformers, thus a 
more complete understanding might be gained instead of using only 4 different 
conformers. 
 
Conclusions - Using docking experiments with different crystal structures and 
homology models we put forward a model where the size of the ligand mainly 
determines its activity (agonist, partial agonist or antagonist) at iGluR LBDs. We did 
find good indications that this holds true for agonists and antagonists at GluN1, 
GluN2A and GluN3A LBDs. We have also good indications that partial agonists at 
the GluN1 LBD are not efficient at stabilizing the closed-cleft conformation. Docking 
experiments with homology models are not accurate enough to disclose whether 
GluN2A and GluN3A LBDs behave similar to the GluN1 LBD in this respect. 
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 N-Methyl-D-Aspartic acid (NMDA) receptors belong to the family of 
ionotropic glutamate receptors (iGluRs) that mediate the majority of the 
excitatory neurotransmission in the mammalian central nervous system. 
Conventional NMDA receptors composed of two glycine-binding GluN1 and 
two glutamate-binding GluN2 subunits require simultaneous binding of both 
ligands within their ligand-binding domains (LBD) for channel opening. Based 
on structural and functional studies, a mechanistic model for the activation and 
desensitization of the NMDA receptor has emerged. Accordingly, agonist 
occupation of both, the GluN1 and GluN2 LBDs, which are arranged as hetero-
dimers in a ´back-to-back´ fashion, leads to closures of the LBDs that 
generates sufficient conformational strains resulting in channel opening. 
Subsequent weakening of the heteromeric GluN1/GluN2-LBD dimer interface is 
assumed to lead to receptor desensitization which is influenced by the N-
terminal domains (NTD) of the respective subunits. Thus, to investigate the 
impact of residues within the GluN1/GluN2 LBD heterodimer interface for 
NMDAR function we generated single-point mutations in the interface of the 
GluN1/GluN2 LBDs in NTD-deleted NMDA receptor subunits (GluN1Δ, GluN2Δ) 
and analyzed their functional properties by TEVC upon heterologous 
expression in Xenopus oocytes. Residues implicated in interface interactions 
were identified by the GluN1/GluN2A LBD crystal structure and mutual 
information and mutated to alanine. The mutations we introduced caused 
changes in apparent glycine and glutamate affinities and also desensitization 
properties as well as maximal inducible currents were affected. However, the 
effects were moderate and unspecific. Thus, it was not possible to infer 
specific roles for the interface interactions. Nevertheless, the GluN1-E781A 
mutation consistently led to a decrease in apparent glutamate affinity and IMax 
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in GluN1Δ/GluN2AΔ and GluN1Δ/GluN2BΔ receptors. This effect  
 was rescued by the GluN1-NTD but not the NTD of GluN2A. Our data show that 
reduced stability of GluN1/GluN2 LBD interactions upon mutation of single 
interface residues can be compensated selectively by the GluN1 NTD 
implicating a prominent role of the GluN1 NTD on LBD interface stability. 
 
Introduction 
N-Methyl-D-aspartic acid (NMDA) receptors are heterotetrameric complexes 
that are involved in excitatory neurotransmission in the CNS (Johnson and Ascher, 
1987, Laube et al., 1998). Together with the (RS)-2-amino-3-(3-hydroxy-5-methyl-4-
isoxazolyl)propionic acid (AMPA) and kainate (KA) receptors they form three distinct 
subfamilies in the family of ionotropic glutamate receptors (iGluRs). The respective 
subunits of the iGluRs share a common modular composition of (i) a large 
extracellular N-terminal domain (NTD) which was implicated in oligomerization of 
subunits and modulation of receptor function, (ii) a bilobed extracellular ligand-
binding domain (LBD), (iii) the channel forming membrane associated domain (TMD) 
consisting of three membrane spanning domains and one re-entry loop, and (iv) an 
intracellular C-terminal domain (CTD) involved in interactions with scaffolding and 
signal transduction proteins (reviewed in Madden, 2002). NMDA-receptors are 
unique within the family of iGluRs with respect to their pharmacological properties 
and their pivotal role during brain development and neurological disorders (Nakanishi 
et al., 1992, Collingridge et al., 1995, Dingledine et al., 1999, Endele et al., 2010). In 
the heterotetrameric complex two obligate GluN1-subunits are associated with two 
GluN2-subunits in the case of the conventional NMDA-receptor (Sucher et al., 1995, 
Laube et al., 1997, Nishi et al., 2001, Yao and Mayer, 2006). The GluN1- and GluN2-
LBDs form heterodimers in a back-to-back conformation similar to AMPA- (GluA) and 
kainate-LBDs (GluK) (Armstrong and Gouaux 2000, Furukawa et al., 2005, Mayer et 
al., 2006). Although previous studies examined the role of LBD interface contacts it is 
still a matter of debate if and in which way these contacts determine functional 
properties such as ligand affinities, desensitization and maximal inducible currents 
(IMax) (Swanson et al., 1997, Stern-Bach et al., 2000, Sun et al., 2002, Furukawa et 
al., 2005, Borschel et al., 2011). 
Studies on AMPA- and kainate-receptors demonstrated that during receptor 
activation the ligand-binding domain closes in a clamshell-like fashion, i.e. the S2-
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subdomain converges towards the S1-subdomain, which results in opening of the ion 
channel. This conformation however strains the LBD dimer interface and, depending 
on the stability of the LBD dimer interface interactions, these contacts are disrupted 
and the receptor adopts a desensitized state (see Fig. 1A). Thus it is thought that the 
strength of the dimer interface contacts is directly correlated to the desensitization 
properties and even a single mutation (e.g. L483Y in GluA2) is capable of rendering 
the receptor non-desensitizing (Stern-Bach et al., 1998, Sun et al., 2002, Mayer 
2006, Armstrong et al., 2006, Chaudhry et al., 2009). 
The crystallization of the heterodimeric GluN1-GluN2A LBD crystal structure 
allows further analysis with respect to structure-function relationship of NMDA-
receptors (Furukawa et al., 2005). Three distinct interface contacts (sites I-III, see 
Fig. 1B) between the GluN1- and GluN2A-LBDs were identified and the GluN1 
residues N521, K531, Q696, R755 and E781A were reported to make polar contacts 
with the GluN2A-LBD. Due to similarities with the GluA2 dimer interface it is 
concluded that the D- and J-Helices (sites I and III, see Fig 1B,C and E) determine 
receptor desensitization properties (e.g. GluN1-N521 and GluN1-E781)(Fig. 1). It was 
also reported that the site I residue GluN1-N521 is involved in the heterodimerization 
process, whereas site II contacts, especially GluN1-Y535, are thought to be involved 
in receptor deactivation. Site II is also known as a binding site for allosteric 
modulators in AMPA-receptors and thus it is hypothesized that the large GluN1-Y535 
side chain is an inherent modulator of NMDA-receptor deactivation. 
However, there is no study to date that characterizes the sites I-III extensively 
in NMDA-receptors. In spite of the homology between AMPA-, kainate- and NMDA-
receptors there are also large differences with regard to the extent of receptor 
desensitization (i.e. NMDA-receptors desensitize much slower), the unique 
requirement in conventional NMDA-receptors for two agonists (i.e. glycine and 
glutamate), the Mg2+-block at NMDARs at resting membrane potential and the 
obligate heteromeric stoichiometry. The heterodimerization of NMDA-receptor 
subunits poses an important step in the assembly process (Schuler et al., 2008). As 
NTD-lacking NMDA-receptors are able to form functional receptors (Madry et al., 
2007b) we hypothesized that the heterodimeric LBD contacts might play an essential 
role in the assembly process. Thus, we reasoned that subtype-specific heterodimer 
association is organized by certain contacts in the LBDs. 
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In order to identify residues that are important for receptor function and 
assembly, we analyzed the GluN1-GluN2A LBD crystal structure by Furukawa et al. 
(2005). We also applied a bioinformatics approach called mutual information (MI). 
This approach can be used to identify residues in the NMDA-receptor heterodimer 
interface that are evolutionary interdependent (Weil et al., 2009). The MI analysis 
quantifies the amount of information about one specific position in the alignment 
inferred from knowing the amino acid at another specific position (MacKay, 2003). 
Such information about another position might be present because such two 
positions require mutating simultaneously in order to keep the receptor functional for 
example. Also such two positions might be interdependent because they are in close 
proximity, and thus interact with each other, in the tertiary structure despite the fact 
that MI calculation only uses 1-dimensional (i.e. sequence) information. Using the MI 
approach we identified residues in the D- and J-Helices that gave highly significant 
interdependency signals. 
We chose to assess the effect of single amino acid substitutions in NTD-
lacking receptors as it was reported that the NTDs of NMDA-receptors are able to 
determine receptor properties such as agonist affinities, open probability, 
deactivation and desensitization (Madry et al., 2007b, Gielen et al., 2009, Yuan et al., 
2009). Working on such a reduced receptor model (i.e. NTD-lacking receptor) should 
allow for unambiguous interpretation of the effects caused by the mutations. Also we 
tested the effect of interface mutations with partially NTD-deleted receptors. 
 
EXPERIMENTAL PROCEDURES 
cDNA constructs, heterologous expression and electrophysiology - The 
cDNA constructs of GluN1-1a, GluN1∆, GluN2A, GluN2A∆ and GluN2B∆ have been 
described previously (Madry et al., 2007b). Single point mutations were introduced 
via site-directed mutagenesis (QuikChange XL Site-Directed Mutagenesis Kit, 
Stratagene) and confirmed by DNA sequencing (Eurofins MWG Operon). All 
constructs were linearized and transcribed into cRNA (mCAP mRNA Capping Kit, 
Ambion) as described (Madry et al., 2010). For electrophysiological analysis, 
Xenopus laevis oocytes were injected with 40 ng of the respective wt or mutant 
GluN1 and GluN2 cRNAs at a ratio of 1:2. Oocytes were isolated enzymatically or 
manually and maintained as described previously (Laube et al., 1997). 2-4 days after 
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injection, two-electrode voltage-clamp (TEVC) recordings of whole-cell currents was 
performed according to (Laube et al., 1997).  
 
Mutual Information analysis - Sequence alignment of the iGluR-receptor 
subunits was taken from (Sobolevsky et al., 2009) and supplemented with the 
sequences of GluA1-4, GluK1-4, GluN1, GluN2A-D and GluN3A-B from different 
species which gave a total of 257 sequences that were downloaded from NCBI. The 
alignments were computed using Geneious Software (v.4.8.3, Biomatters Ltd., 
Auckland, New Zealand) and then the alignment was optimized by hand and trimmed 
to the D- and J-Helices only. The data set consisting of all 257 sequences is referred 
to as ‘iGluR alignment’, whereas a second data set consisting of all the iGluR-
subunits without the GluN2- and GluN3-subunits is referred to as ‘iGluR w/o GluN2/3 
alignment’ (210 sequences) and should resemble the LBDs that are capable of 
forming homodimers. Last, a third data set consisting of only the GluN2/3-subunits 
was composed and is referred to as ‘GluN2/3 alignment’ (47 sequences), which 
should resemble the LBDs that strictly require heterodimerization. These different 
data sets have been used to identify residues that are especially important for the 
heterodimeric NMDA-receptors. In the MI analysis interdependencies between pairs 
of positions in a multiple sequence alignment are calculated. If it is possible to infer 
the amino acid at a certain position by knowing the amino acid at another position, 
these two positions will have a high MI value, thus they are interdependent. If it is not 
possible to infer the amino acid at another position, such a pair will have a low MI 
value and thus they are not interdependent. The MI is calculated according to the 
following equation: !" !;! = ! !,! log! ! !,!! ! ! !!!  
p(x) and p(y) represent the frequencies of each amino acid type at position X or Y, 
respectively. The probability to observe the combination of these two amino acids is 
given by p(x,y). Apart from the 20 standard amino acids, x and y can have a gap “-“ 
or “X” for non-standard amino acids as their values. The MI calculation results in a N 
x N matrix with N being the sequence length of the multiple sequence alignment. 
Thus the symmetrical MI matrix holds !(!!!)!  values, one for each pair of positions in 
the alignment. The calculation was performed using the statistical software package 
R (v.2.10, R Development Core Team 2011) and the BioPhysConnectoR library 
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(Hoffgaard et al., 2010). Based on the sequence alignment the MI matrix was 
computed and standardized to a null model with 10,000 randomization steps (White 
et al., 2007, Weil et al., 2009). The null model consists of the same alignment but the 
amino acids in each column are shuffled vertically in their position as to remove the 
sequence correlation. In each randomization step a new null model MI matrix is 
computed. The expectation value from the null model mij is the average of the 10,000 
(i,j) entries and together with the corresponding variances the Z-scores can be 
calculated. For this, the null model was subtracted from the MI matrix and the 
resulting matrix was divided by the standard deviation (square root of the variance). 
The entries in the resulting matrix represent Z-scores, which are normalized onto the 
standard deviation. Thus each Z-score has the standard deviation as its unit e.g. a 
value of 10 means that the Z-Score is 10 standard deviations away from the 
expectation value mij. Because of its symmetry the diagonal and the lower triangle of 
the Z-score matrix were set to 0. For subsequent data analyses Microsoft Excel 
(v.2011) and for visualization purposes PyMOL v.1.3 (Schrödinger Inc., New York, 
NY, USA) were used. 
For statistical data analysis Graphpad Prism v.5.0a (GraphPad Software Inc., San 
Diego, CA, USA) has been used. 
For all analyses, values are given as means ± SEM if not stated otherwise. 
Statistical significance was tested with one-way ANOVA and the Dunnett Post-Hoc-
Test. For all p-values applies (*) p<0.01, (**) p<0.001 if not stated otherwise. 
 
RESULTS 
Our aim was to identify crucial LBD interface interactions that determine 
functional properties such as apparent agonist affinities, extent of receptor 
desensitization and the maximal inducible currents. Also we would like to understand 
how obligatory heterodimerization of the NMDA-receptor subunits is accomplished on 
a molecular level. 
 
Selection of amino acids for mutagenesis studies - First the GluN1-
GluN2A LBD crystal structure by Furukawa et al. (2005)(Fig. 1A, 1B) was analyzed 
and we focused on the interaction site I which involves the D-Helix of the GluN1 and 
the J-Helix of the GluN2-subunits. In this site, the GluN1-N521 residue forms a polar 
interaction with the backbone carbonyl oxygen of L777 in GluN2A (L778 in GluN2B) 
  53 
(Fig. 1C). This interaction has been implicated in desensitization and assembly of 
AMPA- and NMDA-receptors (Stern-Bach et al., 1998, Furukawa et al., 2005). 
The site II interactions include a hydrogen-bond between K531 in the GluN1 with the 
backbone carbonyl oxygen of a phenylalanine residue (Fig. 1D) (F524 in GluN2A, 
F525 in GluN2B). Notably, this interaction is conserved between all AMPA- and 
NMDA-receptor subunits. The role of this interaction is presently unclear. 
Another residue at site II is GluN1-Y535. Previously it was found that mutations of the 
GluN1-Y535 residue modulate deactivation (Furukawa et al., 2005) and it was 
concluded that the large side chain of the tyrosine residue mimics the action of 
allosteric modulators (e.g. Aniracetam) known to bind in the LBD dimer interface in 
AMPA-receptors (Jin et al., 2005). 
In a similar vein to site I, the site III interaction involves the J-Helix of GluN1 
and the D-Helix of GluN2. Here the GluN1-E781 residue in the GluN1 subunit makes 
a hydrogen-bonded interaction with the backbone nitrogen of E516 in the GluN2A 
(Fig. 1E) (E517 in GluN2B). Interestingly, this residue (GluN1-E781) is conserved in 
more than 97% of “iGluR w/o GluN2/3 alignment” subunits. The GluN2- and GluN3-
subunits, however, have strictly aliphatic non-polar residues at this position. 
 
Fig. 1. GluN1-GluN2A LBD heterodimer interface interactions. (A) Side view of the 
GluN1-GluN2A heterodimer in the back-to-back conformation in complex with glycine and 
glutamate, respectively. The GluN1 subunit is colored in green whereas GluN2A is cyan. D- 
and J-helices of the respective subunits are highlighted for a better orientation. (B) Top view 
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of the GluN1-GluN2A heterodimer, the interface is classified into three distinct interaction 
sites (site I-III) depicted in the rectangles. This classification is according to Furukawa et al., 
2005. (C-E) Magnification of the three interaction sites (I-III). Dashed lines indicate polar 
interactions. The residues participating in intersubunit contacts are shown as sticks and are 
colored in white (GluN1) and cyan (GluN2A). 
 
Second MI analysis was applied to identify evolutionary interdependencies 
between residues in the D- and J-Helices (site I and III). First, we made a histogram 
of the Z-scores to get an idea how the values are distributed. The histogram indicates 
a bimodal distribution with the two centers of each distribution closely together (see 
Fig. 2A). This might be due to distinct signals, i.e. distributions, which are partially 
overlapping. Based on this observation we propose to discard the first culmination of 
Z-scores (Z-scores < 30) because supposedly these values may be distorted by a 
false random signal. We made the calculations for three data sets: iGluR alignment, 
iGluR alignment w/o GluN2/3 alignment and GluN2/3 alignment (see Experimental 
procedures). Out of the respective results we filtered correlations that were present in 
the iGluR alignment and the GluN2/3 alignment but not in the iGluR w/o GluN2/3 
alignment. Thus, we intended to identify residues that are specifically important for 
the unique features of the heteromeric NMDA-receptors but not the iGluRs in 
general. The resulting correlations are shown in Fig. 2B for GluN1, GluN2A and 
GluN3A as examples as we focused on the analysis of NMDARs in this study. We did 
not observe motifs where every 3rdor 4th residue is correlated. Thus, we conclude that 
the residues that are correlated fulfill certain functions based on the nature of their 
interactions (e.g. polar interactions). In the following we will mainly concentrate on the 
GluN1-subunit as this subunit is incorporated into every NMDA-receptor and thus it is 
possible to analyze different subunit compositions (i.e. GluN1/GluN2A and 
GluN1/GluN2B). Interestingly the correlation that received the highest Z-score is 
between GluN1-N521 and GluN1-E781 (see Fig. 2C #1). These residues had been 
implicated in the dimerization and desensitization properties of AMPA- and NMDA-
receptors (Stern-Bach et al., 1998, Furukawa et al., 2005). Both of these residues 
directly point and make hydrogen-bonds with the opposing subunit. For the 
correlations #2 and #8 (see Fig. 2C #2 and #8) a hydrophobic amino acid is 
correlated with a hydrophilic residue of which both point into the LBD dimer interface. 
These correlations might not be important for the GluN1-subunit but eventually for the 
GluN2- or GluN3-subunits. For example instead of the A524 residue in GluN1 the 
homologous position in the GluN3A-subunit is occupied by a hydrophilic serine (i.e. 
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S639). The remaining correlations #3-7 and #9-10 have either hydrophilic amino 
acids that do not point into the LBD dimer interface or they are pointing to the 
opposing subunit but are hydrophobic (see Fig. 2C #3-7 and #9-10). To test for a 
functional role we decided to introduce neutral alanine mutations at the positions 
GluN1-N521 and GluN1-E781. Also to assess the role of site II residues, we 
introduced alanine mutations at the positions GluN1-K531 and GluN1-Y535. (see Fig. 
1D). 
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Fig. 2. Results of Mutual Information analysis. (A) Example of Z-score distribution for 
iGluR alignment. High values represent higher significance of the results. (B) Correlations 
that were found by MI analysis in the D- and J-Helices of GluN1-, GluN2A- and GluN3A-
subunits. These results represent correlations that were found in the iGluR and GluN2-GluN3 
LBD data set but not the homomeric iGluR LBD data set. (C) Visualization of the 10 most 
significant MI correlated residues (white sticks) in the GluN1 subunit (green) together with the 
GluN2A subunit (cyan). 
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We used the MI analysis as a tool to identify critical residues in the GluN1-
GluN2A LBD crystal structure and we intend to identify molecular mechanisms that 
determine functional properties of the iGluR-subunits. 
 
Electrophysiological characterization of GluN1 LBD mutations - We 
introduced mutations in the GluN1-LBD to disrupt the GluN1-GluN2 heterodimer 
interface. These mutations are GluN1-N521A, -K531A, -Y535A and –E781A. These 
mutants were expressed in the heterologous Xenopus oocyte system and 
characterized using TEVC. The GluN1 mutations were tested in NTD-lacking 
GluN1Δ/GluN2AΔ- and GluN1Δ/GluN2BΔ-receptors (Fig. 3A and 3B respectively). We 
assessed the effects of the mutations on apparent agonist affinities, extent of 
desensitization and maximal inducible currents (IMax)(Fig. 3). 
 
 Fig. 3. Agonist-induced traces of N-terminal deleted GluN1Δ/GluN(2AΔ/2BΔ) NMDA 
receptors. (A and B) Here are shown agonist-induced traces of wt and mutant 
GluN1Δ/GluN2AΔ- and GluN1Δ/GluN2BΔ-receptors. 
 
The analysis of glycine EC50 values shows that the GluN1-Y535A mutation 
decreases the apparent affinity in GluN1Δ/GluN2AΔ-receptors (wt 4.87±0.72µM, 
GluN1Δ-Y535A/GluN2AΔ 16.29±1.73µM, p<0.001) whereas in GluN1Δ/GluN2BΔ-
receptors it is the GluN1-E781A mutation that causes a decrease (wt 1.70±0.40µM, 
GluN1Δ-E781A/GluN2BΔ 11.11±1.76µM, p<0.001)(Table 1 and Fig. 4A). A similar 
result was found for the glutamate EC50 values as the GluN1 mutant K531A caused a 
significant reduction in the apparent affinity when expressed with GluN2AΔ (Table 1 
and Fig. 4B). In combination with the GluN2BΔ subunit this mutation had no effect. 
Instead the GluN1-N521A mutant reduced the glutamate EC50. However, the GluN1-
  58 
Y535A and –E781A mutations decreased the glutamate EC50 significantly in both 
receptor combinations (Table 1 and Fig. 4B). Notably, the GluN1-Y535A and –E781A 
mutations each led to a reduction in EC50 in 4 of 5 cases. However the reduction was 
at best a highly significant but modest 14.5-fold (Glu EC50 GluN1Δ/GluN2BΔ 
0.62±0.05µM vs GluN1Δ-E781A/GluN2BΔ 9.05±1.24µM, p<0.001). 
Next we analyzed the extent of desensitization by comparing the agonist-
induced peak currents and steady-state currents. The quotient of these two values 
gives an estimate of the extent of desensitization. According to our MI analysis we 
expected the GluN1-N521A and GluN1-E781A mutations to result in the strongest 
effects. Looking at the GluN1Δ/GluN2AΔ receptor combination our hypotheses was 
validated; the extent of desensitization was increased from 48±9% to 78±3% 
(p<0.001) and 83±6% (p<0.001), respectively (Table 1 and Fig. 4C). However, we 
also observed an increase in the extent of desensitization with the GluN1-K531A 
mutation, which was 77±2%. In comparison with the GluN1Δ/GluN2BΔ receptor 
combination we observed an increase in the extent of desensitization only with the 
GluN1-N521A mutation (wt 56±4%, GluN1Δ-N521A/GluN2BΔ 87±1%, p<0.001)(Table 
1 and Fig. 4C). 
The last parameter we intended to determine is the IMax. This parameter is 
very variable and largely depends on the variability of protein expression in Xenopus 
oocytes. Nonetheless, the GluN1Δ-K531A/GluN2AΔ mutant receptor showed an 
increased IMax (wt 4.00±0.44µA, GluN1Δ-K531A/GluN2A 7.97±1.15µA, p<0.001) 
whereas the GluN1-Y535A and –E781A mutations decreased the IMax (GluN1Δ-
Y535A/GluN2AΔ 0.32±0.08µA, GluN1Δ-E781A/GluN2AΔ 0.29±0.07µA, p<0.001)(Fig. 
4D). In the GluN1Δ/GluN2BΔ receptor combinations only the GluN1-E781A mutation 
led to a significant decrease in the IMax (Fig. 4D). 
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Table 1. Pharmacology of NTD-lacking wt and mutated GluN1Δ/GluN2AΔ and 
GluN1Δ/GluN2BΔ NMDA-receptors. Glycine and glutamate EC50 values as well as IMax 
values were determined in the presence of 100 µM glycine or glutamate. 
 
Gly Glu
μM μA
GluN1Δ / GluN2AΔ 4.87 ± 0.72 1.15 ± 0.15 4.00 ± 0.44 0.52 ± 0.09
GluN1Δ-N521A / GluN2AΔ 3.67 ± 0.61 4.39 ± 0.78 3.86 ± 0.81 0.78 ± 0.03**
GluN1Δ-K531A / GluN2AΔ 3.12 ± 1.66 6.04 ± 0.81**     7.97 ± 1.15** 0.77 ± 0.02*
GluN1Δ-Y535A / GluN2AΔ 16.29 ± 1.73** 5.15 ± 0.80** 0.32 ± 0.08** 0.49 ± 0.04
GluN1Δ-E781A / GluN2AΔ 5.60 ± 0.65 7.98 ± 1.43**     0.29 ± 0.07** 0.83 ± 0.06**
GluN1Δ / GluN2BΔ 1.70 ± 0.40 0.62 ± 0.05 5.48 ± 0.48 0.56 ± 0.04
GluN1Δ-N521A / GluN2BΔ 4.52 ± 1.20     5.59 ± 1.02** 4.20 ± 0.49 0.87 ± 0.01**
GluN1Δ-K531A / GluN2BΔ 0.70 ± 0.10 1.90 ± 0.64 4.54 ± 1.27 0.69 ± 0.03
GluN1Δ-Y535A / GluN2BΔ 1.90 ± 0.54 4.58 ± 1.32* 4.04 ± 0.95 0.48 ± 0.09
GluN1Δ-E781A / GluN2BΔ   11.11 ± 1.76**     9.05 ± 1.24**     0.54 ± 0.13** 0.66 ± 0.06
* P < 0.01
** P < 0.001
n = 4-18
IMax/ISSIMaxEC50Subunit Composition
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Fig. 4. Functional properties of wt and mutated GluN1Δ/GluN2(AΔ/BΔ) receptors. (A) 
Scatter plot with mean and SEM of the apparent glycine affinity for GluN1Δ/GluN2AΔ- (left) 
and GluN1Δ/GluN2BΔ-receptors (right). (B) Scatter plot with mean and SEM of the apparent 
glutamate affinity for GluN1Δ/GluN2AΔ- (left) and GluN1Δ/GluN2BΔ-receptors (right). (C) 
Scatter plot with mean and SEM of the IMax/ISS ratio (in percent) as a measure for the 
desensitization of GluN1Δ/GluN2AΔ- (left) and GluN1Δ/GluN2BΔ-receptors (right). (D) Scatter 
plot with mean and SEM of the maximal inducible current (IMax) for GluN1Δ/GluN2AΔ- (left) 
and GluN1Δ/GluN2BΔ-receptors (right). (*) p < 0.01, (**) p < 0.001 
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In summary, the mutations in the LBD dimer interface appear to affect not only 
one parameter but always a combination of different parameters. It is therefore not 
possible to relate one effect to a specific interaction. Nevertheless, the GluN1-E781A 
mutation consistently led to a decrease in apparent glutamate affinity and IMax in 
GluN1Δ/GluN2AΔ and GluN1Δ/GluN2BΔ receptors. 
 
The GluN1-NTD compensates the reduced IMax caused by the GluN1-
E781A mutation in NTD-lacking GluN1/GluN2-receptors - In a last set of 
experiments we addressed the question if either the GluN1- or GluN2-NTDs are able 
to compensate the reduced IMax of receptors carrying the GluN1-E781A mutation. 
Therefore we injected NTD-lacking subunits together with their full-length 
counterparts. Namely these receptor combinations were GluN1/GluN2AΔ, 
GluN1/GluN2BΔ and GluN1Δ/GluN2A, GluN1Δ/GluN2B as well as the respective 
GluN1-E781A mutant receptor combinations. We determined the IMax in these 
receptors (Fig. 5A) and it became evident that the GluN1-NTD recovers wt-like IMax 
whereas the GluN2A-NTD does not (Fig. 5A and 5C). Obviously the GluN1-NTD has 
a pivotal role that is connected to the GluN1-E781 LBD dimer interface interaction. 
We asked ourselves which role this might be and hypothesized, relying on a study by 
Farina et al. (2011), that the GluN1-NTD homodimerization might be responsible for 
the recovery effect. Farina et al. identified the homodimer interface of the GluN1-
NTDs and described two mutations that disturb/promote the homodimerization. The 
GluN1-Y109C mutation leads to a stabilization of the NTD homodimer interface 
leading to a reduction of surface expressed receptors. Vice versa, the GluN1-T110A 
mutation disturbs the NTD homodimerization leading to an increase in cell surface 
receptors. But it is also concluded that the GluN1-NTDs are required for efficient cell-
surface expression. To analyze if the homodimerization feature of the GluN1-NTDs is 
related to the IMax reduction caused by the GluN1-E781A mutation we introduced the 
Y109C and T110A mutations in the full-length GluN1-E781A subunits. Then we 
expressed these double mutants with GluN2A-subunits and determined the apparent 
agonist affinities as well as the IMax. The double mutant receptors showed wt-like 
agonist-induced currents and we didn’t find significant changes in the parameters 
analyzed (Fig. 5B-C). 
  62 
 
 
Fig. 5. Functional properties of partially NTD-deleted GluN1/GluN2A-receptors and 
double mutant GluN1/GluN2A-receptors. (A) Scatter plot with mean and SEM of the IMax 
for wt and mutant GluN1Δ/GluN2A-receptors as well as wt and mutant GluN1/GluN2AΔ-
receptors. (B) Scatter plot with mean and SEM of the IMax for wt and double mutated 
GluN1/GluN2A-receptors. 
(*) p < 0.01, (**) p < 0.001 
 
 
Table 2. Pharmacology of partially NTD-deleted wt and mutant GluN1/GluN2A- as well 
as double mutant GluN1/GluN2A-receptors. Glycine and glutamate EC50 values as well as 
IMax values were determined in the presence of 100 µM glycine or glutamate. 
 
 
Gly Glu
μA
GluN1Δ / GluN2A 0.80 ± 0.38 1.76 ± 0.13 2.14 ± 0.54
GluN1Δ-E781A / GluN2A 1.26 ± 0.31 2.55 ± 0.68 0.07 ± 0.01
GluN1 / GluN2AΔ 2.30 ± 0.53 1.89 ± 0.35 5.63 ± 0.50
GluN1-E781A / GluN2AΔ 2.80 ± 0.71 2.91 ± 0.43 4.55 ± 0.52
GluN1 / GluN2A 0.97 ± 0.40 1.3 ± 0.32 5.47 ± 0.17
GluN1-Y109C-E781A / GluN2A 0.86 ± 0.18 1.60 ± 0.35 4.47 ± 0.20
GluN1-T110A-E781A / GluN2A 1.04 ± 0.03 2.23 ± 0.21 3.62 ± 0.30
* P < 0.01
** P < 0.001
n = 3-7
 Gly IMaxEC50
μM
Subunit Composition
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This leads to the conclusion that the GluN1-NTD homodimerization does not 
interfere with the GluN1-E781A mutation. Thus the molecular mechanism of the 
GluN1-NTD induced recovery effect is yet to be determined. 
 
DISCUSSION 
In our studies we applied mutual information analysis and measured current 
responses to agonists to characterize the functional role of the ligand-binding domain 
heterodimer interface in NMDA-receptors. In our experiments we found mutations in 
the heterodimer interface that decrease the apparent agonist affinities but also 
increase the extent of desensitization and two out of four mutations led to a 
significant decrease in the IMax. 
The mutations we introduced resulted in pleiotropic effects on receptor function. 
Therefore we cannot ascribe single, specific roles to each of the three interaction 
sites. This observation suggests that the LBD dimer interface unspecifically 
participates in the conformational changes that occur during receptor activation. 
Hence, numerous interface residues might have an indirect effect on receptor 
function. Nonetheless, specific roles have been suggested for the homologous 
position to GluN1-N521 in AMPA- and kainate-receptors based on experimental data 
(Stern-Bach et al., 1998, Sun et al., 2002, Mayer, 2006, Armstrong et al., 2006, 
Chaudhry et al., 2009). Interestingly, glutamate-gated currents in AMPARs/KARs 
were not only non-desensitizing but also smaller than wt (Stern-Bach et al., 1998), 
consistent with the suggestion that the site I interaction of GluN1-N521 facilitates the 
heterodimerization which was shown by analytical ultracentrifugation of isolated 
GluN1 and GluN2A LBDs (Furukawa et al., 2005). We do not exclude the possibility 
that site I - and possibly site II - interactions contribute to the formation of 
heterodimers in NMDARs, however, our data indicate that the site III interaction of 
GluN1-E781 has a much more profound effect as it significantly reduces the IMax. 
Whether this reduction is due to disturbed function, trafficking or assembly is yet to 
be determined. Remarkably, the homologous residue in GluN2A-B subunits is a 
glycine and in GluN3A-B a serine, meaning that this interaction is not symmetrical 
and the GluN1 subunit presumably contributes to a larger extent to the 
heterodimerization than the GluN2- or GluN3-subunits. Interestingly, our multiple 
sequence alignment shows that although the GluN1-E781 residue is not conserved 
among the NMDAR-subunits, it is very well conserved in the AMPAR- and KAR-
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subunits. This also means that in an intact non-NMDA LBD dimer this interaction is 
symmetrical and from an evolutionary perspective the GluN2 and GluN3 subunits 
presumably have lost the negative charge at this position. It seems that the GluN2 
and GluN3 subunits could homodimerize if a glutamate was introduced at the 
homologous position. It would be interesting to conduct affinity purification 
experiments with GluN2- and GluN3-subunits carrying asparagine and glutamate 
residues at the homologous positions to GluN1-N521 and GluN1-E781. Also relying 
on these observations and the GluN1-GluN2A LBD crystal structure as well as our MI 
analysis we suggest to introduce double mutations (based on the MI analysis see 
Fig. 2B), especially GluN1-N521A-E781A to see if their effects are additive with 
respect to receptor function according to our hypothesis. 
 
As stated earlier we conducted our experiments on a reduced receptor model 
(NTD-lacking NMDA-receptors). By this means we were able to observe effects 
caused by the LBD dimer interface mutations that are else concealed by the NTDs. 
The GluN1-E781A mutation led to a significant decrease in IMax in combination with 
NTD-lacking GluN2A or GluN2B receptors. The GluN1-NTD but not the GluN2-NTD 
is capable of compensating this effect (Fig. 6A). To date it has been reported that the 
NTDs are critically involved in the oligomerization of the iGluRs (Kuusinen et al., 
1999, Leuschner and Hoch, 1999, Ayalon and Stern-Bach, 2001, Meddows et al., 
2001, Greger et al., 2007). It was also reported that the GluN1-subunit 
homodimerizes in the ER, presumably through its NTD, but whether this observation 
is important for proper receptor assembly is still under debate (Schuler et al., 2008, 
Farina et al., 2011, Lee et al., 2011). Despite this, NTD-lacking receptors have been 
successfully expressed in other as well as our experiments indicating that the NTDs 
of iGluRs are not obligatory to form functional receptors (Pasternack et al., 2002, 
Armstrong et al., 2006, Madry et al., 2007b, Madry et al., 2008)(Fig. 6B). Thus an 
overarching functional role of the GluN1-NTD is currently unknown. Our finding, that 
the GluN1-NTD compensates a mutation based decrease in IMax is to our knowledge 
the first time of a functional role of the GluN1-NTD. In order to understand the 
molecular mechanism of the GluN1-NTD-induced recovery we would suggest 
analyzing double mutations of the LBD dimer interface in full-length GluN1-subunits. 
Also it might be interesting to analyze the interface between the GluN1-NTD and the 
subjacent –LBD. Certain interactions in this interface might lead to a stabilization of 
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the LBD dimer contacts. However, as no full-length crystal structure is available, one 
has to rely on homology modeling based on the full-length GluA2 tetrameric structure 
(Sobolevsky et al., 2009). 
 
 
Fig. 6. Schematic representation of the influence of NTD-deletion and LBD mutation on 
the maximal inducible current. (A) Shown is a model of the tetrameric GluN1/GluN2A 
receptor in green and red, respectively. The partial or full deletion of the NTDs does not have 
a substantial effect on the IMax. (B) Introducing a mutation (GluN1-E781A) in the heterodimer 
interface leads to a significant reduction in the IMax of GluN1-NTD lacking receptors. 
Receptors where the GluN1-NTD is present are able to compensate the detrimental effect of 
the mutation. 
 
Our aim was to gain insight into the heterodimer interface of the LBDs in NMDA-
receptors. It is conceivable that interfaces between protomers require strong 
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interactions for the oligomers to remain stable. In spite of this, the interface 
interactions also need to allow for conformational changes that are necessary for the 
respective biological activity. Thus, such interfaces are likely to have conserved 
interactions that promote the oligomerization and secure the normal function of the 
oligomer. However, we reasoned that the LBD heterodimer interface might also 
contribute to the unique features of the NMDARs (Nakanishi et al., 1992, Dingledine 
et al., 1999). Our results show that although the GluN2A- and GluN2B-LBDs share a 
high sequence identity of ~82% the mutations analyzed in this study had partly 
differing effects on the respective receptor function. We reckon that the interface 
interactions are connected to other parts of the receptor which we cannot point at 
because of our poor understanding of the conformational changes involved. For 
instance, the GluN2A LBD was only crystallized in the agonist-bound conformation, 
to date we have no information about the respective apo-state. Nevertheless, the 
mutual information bioinformatics approach highlighted residues of functional 
significance and thus has the potential to identify the residues that account for the 
differences observed between the GluN2A- and GluN2B-receptor combinations. 
 
Conclusions - In conclusion, the data presented here show that the LBD 
interface interactions of NMDAR-subunits are involved in receptor function in a non-
specific way and various other molecular bases must underlie the unique NMDA-
receptor functions. Also we identified a specific functional implication of the GluN1-
NTD on receptor function as its presence, but not the GluN2-NTD, recovers the 
reduction in IMax observed with the GluN1-E781A mutation. 
We also used the mutual information approach to identify residues that are 
evolutionary correlated and we are convinced that this approach will help to 
understand the receptor function on a molecular level. 
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ABSTRACT 
N-methyl-D-aspartate (NMDA) receptors composed of glycine binding GluN1 
and GluN3A subunits are referred to as excitatory glycine receptors. The 
binding of glycine to the GluN1/GluN3A receptor induces channel opening but 
with a very low efficacy. Preventing glycine binding to the GluN1 subunit 
results in a strong potentiation of the glycine-induced currents. Thus, it is 
thought that glycine binding to the GluN3A subunit induces channel opening 
whereas glycine binding to the GluN1 subunit forces the receptor into 
desensitization and thus channel closure. In another study, it was shown that 
polar residues in the interface of GluN1/GluN2A receptors prevent channel 
opening by raising the activation energy that is needed to induce 
conformational changes that are required for channel opening. Here we 
mutated polar residues in the GluN1 LBD interface to alanine to increase the 
low efficacy of GluN1/GluN3A receptors. Failing that, we tested N-terminal 
domain (NTD)-lacking NMDAR subunits and also used homology modeling to 
analyze NTD interactions and interactions in the linker connecting the NTD to 
the LBD (NTD–LBD linker). Our results demonstrate that the GluN3A-NTD is 
responsible for the low efficacy of GluN1/GluN3A receptors and mutations in 
the homophilic GluN3A-NTD interface as well as in the GluN3A-NTD-LBD linker 
region specifically increase glycine-gated currents without altering apparent 
glycine affinity. Thus, we generated a highly efficient GluN1/GluN3A receptor 
and uncovered the GluN3A-NTD to resemble the role of an autoinhibitory 
domain (AID), which is the first time that such a domain is described for a 
ligand-gated ion channel. 
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INTRODUCTION 
The N-methyl-D-aspartate (NMDA) subtype of ionotropic glutamate receptors 
(iGluRs) is a tetrameric protein composed of homologous GluN1 and GluN2 or GluN3 
subunits, which require the binding of glycine and/or glutamate for efficient channel 
gating (Kuryatov et al., 1994, Sucher et al., 1995, Laube et al., 1997, Dingledine et 
al., 1999, Chatterton et al., 2002, Madry et al., 2007a, Awobuluyi et al., 2007, 
Smothers and Woodward, 2007). All iGluR subunits share a modular structure 
composed of: an extracellular N-terminal domain (NTD), a ligand-binding domain 
(LBD), a transmembrane domain (TMD) and an intracellular C-terminal domain 
(CTD) (reviewed in Madden, 2002). Crystallization studies revealed that the LBD 
dimers of iGluRs are organized in a ‘back-to-back’ fashion (Armstrong et al., 2000, 
Furukawa et al., 2005, Armstrong et al., 2006). Agonist binding to the respective 
subunits leads to a venus-flytrap like closure of the S1 and S2 subdomains of the 
LBD which results in ion channel opening (Armstrong et al., 2000, Furukawa et al., 
2003, Inanobe et al., 2005, Ahmed et al., 2009). Functional and crystallization 
experiments show that during this process the stability of three distinct interaction 
sites (I-III) of the iGluR LBD dimer interface have an impact on the degree of receptor 
desensitization (Stern-Bach et al., 1998, Sun et al., 2002, Furukawa et al., 2005, 
Armstrong et al., 2006, Mayer, 2006). According to these findings, strong LBD dimer 
interface interactions would stabilize the activated conformation and prevent the 
receptor from desensitizing. Vice versa, weak interactions would result in brief 
channel opening and a rapid transition to the desensitized state and thus closure of 
the channel. Based on the current view of iGluR function, it is assumed that the low 
efficacy of GluN1/GluN3A receptors depends on weak LBD dimer interface 
interactions which cause the receptor to desensitize quickly after activation (Madry et 
al., 2007a, Awobuluyi et al., 2007). Furthermore, it was found that the GluN1 
antagonist MDL-29951 as well as GluN1 ligand binding site mutations increase 
glycine-induced currents (Madry et al., 2007a). Thus, it is concluded that glycine 
binding to the GluN3A subunit is sufficient for channel opening whereas glycine 
binding to the GluN1 subunit presumably causes receptor desensitization. In a recent 
study by Borschel et al. cysteine mutations were introduced in the GluN1-GluN2A 
LBD dimer interface and single channel experiments were performed (Borschel et al., 
2011). Upon modeling of the kinetic properties it became evident that it is not the 
desensitization that causes reduced receptor efficacy but a reduced activation. 
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Apparently, activation of the receptor requires rearrangements of the LBD dimer 
interface, which in turn means that this interface must be flexible. It is concluded that 
polar residues in the LBD dimer interface reduce flexibility and in consequence 
activation requires more energy. These results stand in stark contrast to previous 
views on receptor function because they suggest that removal of polar interactions in 
the GluN1-GluN3A LBD dimer interface might increase the efficacy of these 
receptors. Therefore we decided to substitute polar residues in the GluN1 LBD that 
make contacts with the GluN3A LBD, namely GluN1-N521A, -K531A, -Y535A and –
E781A. The location of these residues in the LBD was described in Chapter 3 and in 
Furukawa et al. (2005). 
However, we do not exclude the possibility that in addiction to the LBDs, the 
NTDs might play an essential role in determining GluN1/GluN3A receptor efficacy. 
NTDs have been implicated in receptor oligomerization, trafficking and also 
modulation of receptor function (Fayyazuddin et al., 2000, Papadakis et al., 2004, 
Qiu et al., 2005, Hu et al., 2005, Madry et al., 2007a, Yuan et al., 2009, Gielen et al., 
2009, Hansen et al., 2010, Farina et al., 2011). With regard to receptor function, 
especially GluN2 NTDs have been shown to determine the channel open probability 
(P0) (Yuan et al., 2009, Gielen et al., 2009). Studies that sought to alter subunit-
specific receptor function by substituting NTDs between the different GluN2 subunits 
showed that conferral of specific function required the substitution of the NTD-LBD 
linker, in addition to the NTD (Yuan et al., 2009, Gielen et al., 2009). Therefore, we 
decided to also include the NTDs and the NTD-LBD linker in our analyses. In that 
respect we built a homology model for the full-length GluN1/GluN3A receptor based 
on the crystal structures of the full-length, homomeric GluA2-subtype AMPA-receptor 
by Sobolevsky et al. (2009), the GluN1-Glun2A LBD heterodimer by Furukawa et al. 
(2005) and the GluN2B NTD by Karakas et al. (2009). Subsequently we 
characterized partially NTD-lacking GluN1/GluN3A receptors as well as amino acid 
substitutions in the GluN3A-NTD and –NTD-LBD linker functionally by measuring 
whole-cell currents from Xenopus oocytes and biochemically using affinity purification 
and SDS-PAGE. 
We show that the GluN3A-NTD is the structural determinant of the low efficacy of 
GluN1/GluN3A receptors and furthermore we describe mutations in the homophilic 
GluN3-NTD interface and especially the GluN3A-NTD-LBD linker that largely 
increase glycine-induced currents. By means of homology modeling and site-directed 
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mutagenesis we were able to generate a highly efficient ‘excitatory’ GluN1/GluN3A 
Glycine-receptor. 
 
EXPERIMENTAL PROCEDURES 
DNA constructs, oocyte expression and electrophysiology - The GluN1-1a, 
GluN1∆, GluN3A and GluN3A∆ expression constructs have been described previously 
(Madry et al., 2007a, Madry et al., 2008). Amino acid substitutions were generated 
via site-directed mutagenesis (QuikChange XL Site-Directed Mutagenesis Kit, 
Stratagene) and confirmed by DNA sequencing (Eurofins MWG Operon). All 
constructs were linearized and transcribed into cRNA (mCAP mRNA Capping Kit, 
Ambion) as described (Madry et al., 2010). For electrophysiological analysis, 
Xenopus laevis oocytes were injected with 40 ng of the respective wt or NTD-deleted 
GluN1 and GluN3 cRNAs at a ratio of 1:3. Oocytes were isolated manually or 
enzymatically and maintained as described previously (Laube et al., 1997). 3-4 days 
after injection, two-electrode voltage-clamp recording (TEVC) of whole-cell currents 
was performed according to (Laube et al., 1997). For the functional characterization 
of wt and mutated receptor complexes we determined apparent glycine and Zn2+ 
affinities, as well as maximal inducible currents by glycine and Zn2+ as well as GluN1 
antagonist (MDL-29951) mediated potentiation of GluN1/GluN3A receptors as 
described in Madry et al. (2007a). 
 
Metabolic [35S]methionine labeling, purification and SDS-PAGE of NMDA 
receptor complexes - After cRNA injection, oocytes were labeled overnight by 
incubation in [35S]methionine (>40 TBq/mM, Amersham Biosciences) at ~100 MBq/ml 
(0.2 MBq per oocyte) and thereafter chased for additional two days as described 
(10). Receptor complexes were purified from dodecylmaltoside extracts of the labeled 
oocytes via a His6-tag added to the GluN1 and GluN1∆NTD C-terminus by Ni2+-NTA 
agarose (Qiagen) chromatography as described previously (Madry et al., 2007b). 
[35S]-Methionine-labeled protein samples were solubilized in SDS sample buffer 
containing 20 mM dithiothreitol and electrophoresed in parallel with molecular mass 
markers (SeeBlue® Plus2 Pre-Stained Standard, Invitrogen) on 8% tricine-SDS-
polyacrylamide gels. Gels were blotted, fixed, dried, and exposed to BioMax MR films 
(Kodak, Stuttgart, Germany) at –80 °C.  
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Surface labeling with Cy5-NHS-ester - Three days after the injection of cRNAs, 
the injected and non-injected control oocytes were surface-labeled with 65 µM of 
Cy5-NHS-ester dye (Amersham Biosciences) and solubilized for affinity purification 
as described above. Gels containing Cy5-labeled protein samples were scanned with 
a gel imager (Typhoon 9400, Amersham Biosciences) as described (Madry et al., 
2007a). 
 
Glycosylation assay - To discriminate between mature and immature receptor 
complexes, 10 µl of the affinity-purified receptor were incubated in reducing sample 
buffer (20 mM DTT, 1% (w/v) SDS) containing 1% (w/v) octylglucoside with 5 U 
endoglycosidase H (Endo H) or peptide: N-Glycosidase F (PNGase F; NEB, 
Frankfurt, Germany) at 37°C for 1 h. Afterwards protein samples were analyzed by 
SDS-PAGE as described above. 
 
Molecular modeling of the tetrameric GluN1/GluN3A receptor structure - 
Sequence alignment of the NMDA receptor subunits was taken from Sobolevsky et 
al. (2009) and supplemented with the sequences of the GluN2B-D and GluN3B 
subunits. The homology model of the GluN1/GluN3A receptor is based on the crystal 
structures of the GluN3A LBD (Yaol et al., 2008, PDB ID: 2RC7), GluN2B NTD 
(Karakas et al., 2009, PDB ID: 3JPW), GluN1-GluN2A-LBD-dimer (Furukawa et al., 
2005, PDB ID: 2A5T) and the GluA2 receptor (Sobolevsky et al., 2009, PDB ID: 
3KG2). The models for the protomers were generated using the Modeller program 
9v7 (Fiser and Sali, 2003) and energy minimized using Chimera build 2577 
(Pettersen et al., 2004). Arranging the protomers according to the GluA2 tetrameric 
structure was accomplished using lsqman 9.7.9 (Kleywegt, 1996). Protein fold 
prediction for the GluN3A-NTD-LBD linker was conducted using Scratch Protein 
Prediction Server (University of California, Scratch Protein Prediction Server; 
http://solpro.proteomics.ics.uci.edu/) and Wurst Server (University of Hamburg; 
http://neuropa.zbh.uni-hamburg.de/wurst/index.php). Molecular dynamics simulations 
were computed using Gromacs 4.0.5 (Hess et al., 2008). Pymol 1.3 (Schrödinger 
Inc., New York, NY, USA) was used for illustration. 
For statistical data analysis Graphpad Prism v.5.0a (GraphPad Software Inc., San 
Diego, CA, USA) has been used. 
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For all analyses, values are given as means ± SEM. Statistical significance was 
determined at p<0.01 (*) and p<0.001 (**) levels using Student's T-test or one-way 
ANOVA and the Dunnett Post-Hoc-Test. 
 
RESULTS 
Analysis of putative GluN1-GluN3A LBD interface interactions - We used 
the crystal structures of the GluN1-GluN2A LBD dimer and the GluN3A LBD in order 
to make a model for the GluN1-GluN3A LBD heterodimer (Fig. 1A, 1B). Using this 
model we analyzed the three interaction sites that were described by Furukawa et al 
(Fig. 1B) (Furukawa et al., 2005). Our aim was to identify polar LBD interface 
interactions that might account for the low efficacy of GluN1/GluN3A receptors. 
The interaction site I involves the D-Helix of the GluN1 and the J-Helix of the 
GluN2A/3A subunit. Residue N521 in GluN1 forms a polar interaction with the 
GluN3A-E889 residue (Fig. 1C). This interaction site has been previously implicated 
in desensitization and assembly of AMPA- and NMDA-receptors (Stern-Bach et al., 
1998, Furukawa et al., 2005). We chose to mutate the GluN1-N521 residue to an 
alanine in order to remove this polar interaction. 
Fig. 1. Modeling of GluN1-GluN3A LBD heterodimer interface interactions. (A) Side 
view of the GluN1-GluN(2A/3A) LBD heterodimer in the back-to-back conformation in 
complex with glycine and glutamate, respectively. The GluN1 subunit is colored in green 
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whereas GluN2A is cyan and GluN3A is red. D- and J-Helices of the GluN1 and GluN3A 
subunits are highlighted for better orientation. (B) Top view of the GluN1-GluN(2A/3A) LBD 
heterodimer, the interface is separated into three distinct interaction sites (site I-III) depicted 
in the rectangles. This separation is according to Furukawa et al., 2005. (C-E) Magnification 
of the three interaction sites (I-III). Dashed lines indicate polar interactions. The residues 
participating in intersubunit contacts are shown as sticks and are colored in white (GluN1), 
cyan (GluN2A) and green (GluN3A). 
 
The site II interactions include a conserved hydrogen-bonded interaction of K531 
in the GluN1 with the backbone carbonyl oxygen of the phenylalanine residue F644 
in GluN3A (Fig. 1D). Notably, multiple sequence alignment shows that this interaction 
is conserved between all AMPA- and NMDA-receptor subunits. In our previous study 
with GluN1/GluN2 heteromers the GluN1-K531A mutation led to a significant 
increase in agonist-induced currents. Therefore, we decided to incorporate this 
mutation in GluN1/GluN3A receptors. In a study by Furukawa et al. (2005), the 
GluN1-Y535 residue at site II was found to modulate deactivation properties of 
GluN1/GluN2A receptors, therefore we also analyzed a mutation at this position, 
namely GluN1-Y535A in the context of NTD-lacking GluN1∆/GluN2∆ receptors. In 
combination with GluN2A∆ we saw a decrease in receptor currents whereas in 
combination with the GluN2B∆ subunit no significant change in the IMax was found 
(see Chapter II). Therefore, we were interested if this mutation might have an effect 
on macroscopic currents from GluN1/GluN3A receptors. 
Next we analyzed the site III interactions that involve the J-Helix of GluN1 and 
the D-Helix of GluN2A/3A. As depicted in Fig. 1E the E781 residue in the GluN1 
subunit makes a hydrogen-bonded interaction with the backbone nitrogen of E516 in 
the GluN2A or T636 in GluN3A. Additionally E781 in GluN1 is able to interact with the 
side chains of GluN2A-E516 or GluN3A-T636 (Fig. 1E). As stated in Chapter II this 
residue GluN1-E781 is conserved in the majority of all iGluR subunits except for the 
GluN2 and GluN3 subunits. 
Our analysis of the heterodimer contacts in the LBD interface does not show 
huge differences between the GluN1-GluN2A and GluN1-GluN3A LBD heterodimer 
interface. Despite this, according to Borschel et al. (2011) removal of polar residues 
from the LBD dimer interface should increase the efficacy of GluN1/GluN3A 
receptors presumably by lowering the activation energy that is needed for channel 
opening. Therefore, we introduced amino acid mutations in the full-length GluN1 LBD 
at the three respective interaction sites (site I N521A; site II K531A and Y535A; site 
III E781A) and characterized them by using TEVC. 
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Functional characterization of GluN1-GluN3A LBD interface mutations - We 
conducted TEVC experiments on Xenopus oocytes (Fig. 2A) that were injected with 
cRNA and maintained for 3-4 days. From the currents measured we analyzed 
apparent glycine and Zn2+ affinities, GluN1 antagonist (MDL) mediated potentiation, 
and IMax where possible (Fig. 2B, 3A-C). The GluN1-Y535A and –E781A mutations 
resulted in very small agonist-induced currents and thus measuring apparent 
affinities was not possible. It is known that glycine binds to the GluN1 and the 
GluN3A subunit but previously it was also found that Zn2+ is able to activate 
GluN1/GluN3A receptors to a similar extent as glycine, yet the binding site for Zn2+ 
has not been identified (Madry et al., 2008). However, we decided to include Zn2+-
activated currents in our analyses. 
 
 
 
Fig. 2. Agonist-induced traces of wt and mutant GluN1/GluN3A NMDA receptors. (A) 
Agonist-induced responses of wt and mutant GluN1/GluN3A receptors to glycine. The 
currents for the receptors carrying the GluN1-Y535A and –E781A mutation were much 
smaller than the wt and are therefore magnified below, respectively. The bars indicate 
application of 1mM glycine  
 
The site II GluN1-K531A mutation significantly decreased glycine and Zn2+ EC50 
values (Fig. 2B, 3A). Compared to the wt glycine EC50 (4.46±0.58 µM) the EC50 for 
the GluN1-K531A/GluN3A receptor is ~5-fold reduced (24.02±4.03 µM, p<0.001). 
The same mutation decreased the Zn2+ EC50 by 3.7-fold, suggesting an increase in 
apparent affinity (wt: 371±21 µM vs. 100±11 µM, p<0.001). The fact that both 
apparent affinities are affected indicates a crucial role of this residue in the activation 
process of the receptor. In contrast, the site I GluN1-N521A residue only had an 
effect on the apparent Zn2+ affinity (Fig. 2B, 3A)(wt EC50: 371±21 µM vs. 77±8.4 µM, 
p<0.001). It is noteworthy that the mutations caused a reduction in the apparent 
glycine affinity but an increase in the apparent Zn2+ affinity. This contradiction most 
probably lies in the molecular mechanism of the activation or the location of the 
putative binding site for Zn2+. 
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Table 1. Pharmacological and functional properties of wt and mutant GluN1/GluN3A 
receptors. 
Values represent mean±SEM, n.d. – not detectable 
 
Interestingly, none of the GluN1 mutants had a significant effect on the MDL-
mediated potentiation (Fig. 2B, 3B left). This finding contradicts our current view of 
the molecular mechanism of the potentiation. We believe that MDL binding to the 
GluN1 subunit contributes to the stability of the LBD heterodimer interface (Madry et 
al., 2007a). In that respect we expected a significant reduction in MDL-mediated 
potentiation with one of the GluN1 mutants. In this respect the exact mechanism of 
the potentiation is apparently not well understood. 
 
Gly Zn2+
x-fold nA nA
GluN1 / GluN3A 4.46 ± 0.58 371 ± 21 18.3 ± 1.9 134 ± 17 724 ± 91
GluN1-N521A / GluN3A     2.61 ± 0.63     77 ± 8.4** 20.2 ± 2.2 51 ± 15** 133 ± 31**
GluN1-K531A / GluN3A  24.02 ± 4.03**  100 ± 11** 19.6 ± 1.3 103 ± 16 112 ± 38**
GluN1-Y535A / GluN3A n.d. n.d. 30.0 ± 5.8 16 ± 5.2** n.d.
GluN1-E781A / GluN3A n.d. n.d.  8.7 ± 1.4 24 ± 5.8** n.d.
* P < 0.01
** P < 0.001
n = 4-16
Subunit Composition MDL potentiation
EC50
!M
 Gly IMax  Zn2+ IMax
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Fig. 3. Functional properties of wt and mutated GluN1/GluN3A receptors. (A) Scatter 
plot with mean and SEM of the apparent glycine affinity (left) and Zn2+ (right). (B) Scatter plot 
with mean and SEM of the GluN1 antagonist (MDL) mediated potentiation of glycine-induced 
currents. (C) Scatter plot with mean and SEM of the maximal inducible current (IMax) for 
glycine (left) and Zn2+ (right). 
(*) p<0.01, (**) p<0.001 
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Next we analyzed maximal-inducible currents by glycine and by Zn2+ (Fig. 3C). 
Except for the GluN1-K531A mutation, all other mutations (GluN1-N521A, -Y535A 
and –E781A) lowered the IMax of glycine-induced currents significantly (Fig. 3C 
left)(wt: 134±17 nA, GluN1-N521A/GluN3A: 51±15 nA, GluN1-Y535A/GluN3A: 
16±5.2 nA, GluN1-E781A/GluN3A: 24±5.8 nA, p<0.001). Consistent with the results 
from glycine-induced currents the GluN1-N521A mutation decreased the Zn2+ IMax 
significantly (Fig. 3C)(wt: 724±91 nA vs. 133±31 nA, p<0.001). The GluN1-K531A 
mutation did not have a significant effect on maximal glycine-induced currents but it 
significantly decreased the IMax in combination with Zn2+ (Fig. 3C right)(wt: 724±91 nA 
vs. 112±38 nA). We were surprised to see that the GluN1-Y535A and -E781A 
mutations completely abolished Zn2+-activated currents (Fig. 3C right). Two possible 
explanations for this are that the Zn2+ binding site lies in the LBD dimer interface and 
is affected by the two mutations or the conformational changes upon Zn2+-activation 
largely rely on the interactions of GluN1-Y535A and -E78A. 
In conclusion, the site I mutation GluN1-N521A affected many parameters of 
receptor function, either these functions share a common structural basis that 
converges at GluN1-N521 or the GluN1-N521A mutation generally disrupts receptor 
function. The GluN1-K531A mutation affected mainly Zn2+-activation, therefore this 
residue is quite specifically involved in the pharmacology of Zn2+ at GluN1/GluN3A 
receptors. The exact binding site and molecular mechanism of Zn2+-activation is 
unknown, however, site II in the LBD heterodimer interface seems to play an 
important role in this respect. Surprisingly, we observed that GluN1-Y535A and -
E781A largely interfere with the receptor function in GluN1/GluN3A receptors. This 
was not expected and also not seen with GluN1/GluN2 receptors (data not shown). 
Our aim was to increase the efficacy of GluN1/GluN3A receptors, but apparently 
mutations in the LBD heterodimer interface reduce the efficacy of this receptor type. 
 
Analysis of partially NTD-deleted GluN1/GluN3A receptors reveal a 
prominent role for the GluN3A-NTDs in receptor efficacy (Note, the following 
experiments were conducted by Dr. Ivana Mesic) - Next, we expressed NTD-
deleted subunits together with their full-length counterparts and analyzed the glycine-
induced GluN1/GluN3A receptor currents. The IMax of GluN1/GluN3A∆ receptors were 
significantly higher (0.9±0.21 µA)(Table 1) compared to GluN1∆/GluN3A (0.15±0.03 
µA; p<0.01)(Table1) and wt GluN1/GluN3A receptors (0.15±0.02 µA, p<0.001) (Table 
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1). Thus, we found that the GluN3A-NTD seems to be critically involved in 
determining the low efficacy of GluN1/GluN3A receptors. Subsequently we also 
assessed the MDL-mediated potentiation and here we observed that GluN1∆/GluN3A 
receptors are still strongly potentiated by MDL (~19-fold, Table 1), whereas in 
GluN1/GluN3A∆ receptors the MDL-potentiation is almost abolished (~2-fold, Table 
1). In summary, our data show that the GluN3A-NTDs markedly determine the 
efficacy of GluN1/GluN3A receptors, whereas the GluN1-NTDs are only marginally 
involved. 
 
Modeling of the full-length GluN1/GluN3A receptor and analysis of NTD 
interactions - The previous experiments show that the GluN3A-NTD is the structural 
feature that determines the low efficacy of GluN1/GluN3A receptors. Therefore we 
aimed to identify residues in the GluN3A-NTD that are involved in the control of the 
receptor efficacy. Residues that are important for receptor function are commonly 
conserved among the distinct subunits but for the unique properties of the GluN3A 
subunit we expect this subunit to have distinct residues at homologous positions 
compared to their GluN2 counterparts. Due to the low sequence identity of the NTDs 
among the iGluR family members, it is not possible to identify residues involved in 
unique functions by amino acid sequence alignment alone. 
Previously it was suggested that the NTDs of the GluN2 subunits are arranged as 
local homodimers by Sobolevsky et al. (2009) and thus we assume that the overall 
arrangement of the NTDs does not differ in the NMDAR family. Thus, we assume that 
the GluN3 NTDs are also arranged as local homodimers (Fig. 4A, blue subunits box 
#1). We built a homology model for the full-length GluN1/GluN3A receptor based on 
the full-length, homomeric GluA2-subtype AMPAR crystal structure by Sobolevsky et 
al. (2009). But we also used the GluN1-GluN2A LBD dimer crystal structure 
(Furukawa et al., 2005) and the GluN2B-NTD crystal structure (Karakas et al., 2009) 
as templates (see Experimental Procedures). Analyzing the homodimeric GluN3A-
NTD interface we identified a (homophilic) interface consisting of the two α7-helices, 
one from each GluN3A NTD, interacting with the opposing loop between ß13 and 
ß14 of the other GluN3A NTD (Fig. 4A, box #1 and Fig. 4B). 
  82 
 
Fig. 4. GluN1/GluN3A model and partial amino acid sequence alignment of NMDA 
receptor subunits. (A) Model of the GluN1/GluN3A tetrameric complex (GluN1 red, GluN3A 
blue), box #1 depicts the homophilic GluN3A-NTD interface, the box #2 depicts the GluN3A 
NTD-LBD linker. (B) The homophilic interface consists of the α7-helix (purple) of one subunit 
interacting with the loop ß13/ß14 (purple) of the other GluN3A subunit. (C) Potential stacking 
interaction between GluN3A-H470 with -F345 in the NTD-interface. (D) Overview of the 
GluN3A-NTD interface and the amino acid substitutions together with the respective partial 
sequence alignments on the right. (E) Model of the secondary structure of a part of the 
GluN3A NTD-LBD linker with the amino acids that were mutated together with their 
respective partial sequence alignments to the right. 
Model color code: GluN1 red, GluN3A blue (purple), the alignment is Clustal color coded. 
 
The GluN3A-M332 residue is, according to the sequence alignment and 
homology model, part of the α7-helix. The homologous residues in the GluA2 and 
GluN2A-D subunits carry positive charges, which is an indication for a pivotal role of 
a positive charge at this position. The methionine residue at this position is interesting 
because of its nonpolar and neutral character. The mutation to the neutral but 
sterically shorter alanine should answer the question whether it is a steric effect of 
the methionine at this position that might be important for the unique features of the 
GluN3A NTD (Fig. 4D, upper alignment). 
To further characterize the GluN3A NTD-NTD homophilic interface we generated 
the GluN3A-H470A mutation in the loop region between ß13 and ß14, which is, 
according to our model, the second region that forms the NTD-NTD interface by 
interacting with the respective α7-helix of the other GluN3A NTD. The GluN2A-D and 
GluN3B subunits carry positive charges at this position (Fig. 4D, lower alignment). 
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For GluN1/GluN3A we suggest that GluN3A-H470 is stacking with GluN3A-F345 and 
thereby stabilizing the interface (Fig. 4C). Therefore, we suggest that residues at this 
position either stabilize the loop itself or engage in interactions with the α7-helix. 
In addition to the GluN3A NTD-NTD homophilic interface we selected mutations in 
the linker region between the GluN3A NTD and LBD (Fig. 4A, box #2). We focused 
on the negatively charged residue GluN3A-E498, as the GluN2A-D subunits possess 
residues with positive charges at this position (Fig. 4E, upper alignment). The 
homologous residues in GluN2 subunits play an active part in determining receptor 
kinetics, as it was shown by Gielen et al. (2009) and Yuan et al. (2009). We suggest, 
relying on the homology model, that these effects are exerted by their interaction with 
residues in the ß14 strand (e.g. R480 for GluN3A) of the NTD. Therefore, we decided 
to substitute the glutamate with a neutral alanine (GluN3A-E498A). 
The next mutation we selected was GluN3A-H509D because; compared to the 
negatively charged residues in the GluN2A-B subunits, the GluN3A subunit has a 
histidine with an aromatic side chain (Fig. 4E, lower alignment). Although our model 
does not reveal a possible interfacial interaction with this residue, we chose to imitate 
the negative charge by mutating the histidine into aspartate. 
In order to further assess this point and gain insight in the structure of the 
GluN3A-NTD-LBD linker region, we used protein folding prediction servers. This 
approach consistently showed an α-helix as well as a loop region in the GluN3A-
NTD-LBD linker (Fig. 4E). To test the stability of the α-helix we constructed the 
GluN3A-NTD-LBD linker using the Chimera Software package and subsequently 
conducted MD simulations for 1 ns using Gromacs. During the simulation period the 
predicted α-helix remained stable. Taking together these indications, we put forward 
a model of the NTD-LBD linker that holds at least one α-helix. This α-helix is 
supposedly capable of making specific interactions, presumably with ß14 of the NTD, 
and this interaction largely determines kinetic properties of the NMDA receptors in 
general. In the case of GluN1/GluN3A receptors these interactions might account for 
the low efficacy of glycine-mediated receptor currents. 
 
Functional and biochemical assessment of GluN3A-NTD mutations on 
receptor efficacy (Note, the following experiments were conducted by Dr. Ivana 
Mesic) - According to our results from the analysis of the GluN1/GluN3A homology 
model, we introduced the following single amino acid substitutions: GluN3A-M332A 
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and -H470A within the putative GluN3A-NTD homophilic interface, as well as 
GluN3A-E498A and -H509D in the GluN3A-NTD-LBD linker region (GluN3A 493-
512). Expression of the GluN3A-M332A and GluN3A-H470A subunits with the wt 
GluN1 subunit resulted in glycine-gated currents that were up to 3- and 4-fold larger 
than the wt GluN1/GluN3A receptor (p<0.01 and p<0.001, respectively; Fig. 5A and 
Table 1). Analysing the GluN3A-NTD-LBD linker mutants GluN3A-E498A and 
GluN3A-H509D we obtained significantly higher glycine-mediated currents than those 
recorded from wt receptors (11- and 3-fold, respectively; p<0.001; Fig. 5A and Table 
1). Interestingly, the GluN1/GluN3A-E498A receptors exhibited similar maximal 
inducible currents as we found for GluN1/GluN3A∆ receptors (Table 1). 
To exclude that the mutations cause an altered receptor expression or surface 
insertion, we affinity-purified wt and mutated GluN1/GluN3AHis receptors from 
[35S]methionine and Cy5-labeled oocytes. SDS-PAGE from the wt and the mutated 
GluN1/GluN3A receptor proteins revealed no differences, either in the amount of total 
protein levels or in the cell-surface expression (Fig. 5B and 5C, respectively). We 
also analyzed whether the apparent glycine affinities of the GluN3A-mutated 
receptors differed from those seen with the wt GluN1/GluN3A receptor but no 
significant changes in the apparent glycine-affinity were detected (Table 1). 
Subsequently we assessed the MDL-mediated potentiation of the glycine-gated 
currents in the mutant GluN1/GluN3A receptors. With GluN1/GluN3A-H470A 
receptors we observed a reduced (8-fold) MDL-potentiation compared to the wt (>20-
fold, p<0.01) (Fig. 5E and Table 1). The GluN3A-NTD-LBD linker mutant GluN3A-
E498A resulted in a drastic decrease in MDL-potentiation compared to the wt 
(GluN1/GluN3A-E498A: 3-fold, p<0.001) (Fig. 5E and Table 1). Thus, mutations 
within the putative homophilic GluN3A-NTD interface and the GluN3A-NTD-LBD 
linker selectively increase the efficacy of GluN1/GluN3A receptors without affecting 
the apparent glycine-affinity or cell-surface expression. 
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Fig. 5. Effects of GluN3A-NTD interface and GluN3A-NTD-LBD linker mutations on the 
functional and biochemical properties of GluN1/GluN3A receptors. (A) Mutant 
GluN1/GluN3A-M332A, GluN1/GluN3A-H470A, GluN1/GluN3A-E498A and GluN1/GluN3A-
H509D receptors exhibit increased receptor currents upon application of 1 mM glycine 
compared to the wt GluN1/GluN3A receptor. (B) Radiogram of the SDS-PAGE of 
metabolically labeled and affinity-purified GluN1/GluN3A wt as well as mutant 
GluN1/GluN3A-M332A, GluN1/GluN3A-H470A, GluN1/GluN3A-E498A and GluN1/GluN3A-
H509D receptor complexes expressed in Xenopus oocytes. The control (ctrl) indicates 
  86 
proteins from non-injected oocytes. (C) Comparison of the intensities of affinity-purified Cy5 
surface-labeled wt GluN1/GluN3A (lanes 1-3) as well as GluN1/GluN3A-M332A (lanes 4-6), 
GluN1/GluN3A-H470A (lanes 7-9), GluN1/GluN3A-E498A (lanes 10-12) and GluN1/GluN3A-
H509D receptors (lanes 13-15) by SDS-PAGE revealed comparable surface-expression 
levels. Treatment with EndoH and PNGaseF is shown below the respective lanes indicating 
surface location of wt- and mutant GluN1/GluN3A receptors. The control (ctrl) denotes 
proteins from non-injected oocytes. (D) Glycine-dose response curves of GluN1/GluN3A-
M332A (!), GluN1/GluN3A-H470A ("), GluN1/GluN3-E498A () and GluN/GluN3A-H509D 
receptors (!). (E) Quantitative analysis of the extent of MDL-potentiation of glycine-mediated 
currents from wt, as well as GluN3A-NTD interface and GluN3A-NTD-LBD linker mutant 
receptors. Note the highly significant decrease of MDL-potentiation in GluN1/GluN3A-H470A 
and GluN1/GluN3A-E498A receptors (p < 0.001). 
(*) p<0.05, (**) p<0.01, (***) p<0.001 
These experiments were conducted by Dr. Ivana Mesic. 
 
!A !M x-fold
GluN1/GluN3A 0.15 ± 0.02 6.5 ± 1.2 22 ± 2.6
GluN1!/GluN3A 0.15 ± 0.03 19 ± 3.2 18.8 ± 4.0
GluN1/GluN3A! 0.9 ± 0.21** 23 ± 0.95 1.9 ± 0.5**
GluN1!/GluN3A! 1.9 ± 0.23** 33 ± 2.4 2.0 ± 0.2**
GluN1/GluN3A-M332A 0.41 ± 0.1* 13.6 ± 2.4 14.4 ± 2.2
GluN1/GluN3A-H470A 0.54 ± 0.07** 6.5 ± 0.9 7.5 ± 1.0*
GluN1/GluN3A-E498A 1.64 ± 0.29** 9.4 ± 1.8 3.2 ± 0.8**
GluN1/GluN3A-H509D 0.48 ± 0.11** 11.1 ± 2.7 10.5 ± 3.3
* P < 0.01
** P < 0.001
n = 3-16
Subunit Composition MDL potentiation Gly IMax Gly EC50
 
Table 2. Pharmacology from wt, mutated and NTD-deleted GluN1/GluN3A NMDA 
receptors after expression in Xenopus laevis oocytes. 
Values represent means ± SEM 
These experiments were conducted by Dr. Ivana Mesic. 
 
Therefore, we suggest that GluN3A-H470 (GluN3A NTD-interface) and especially 
GluN3A-E498A (GluN3A-NTD-LBD linker) contribute to the low efficacy of 
GluN1/GluN3A receptors. 
 
DISCUSSION 
The glycine-gated GluN1/GluN3 receptors are unique among the NMDAR family 
because of their low-efficacy. To date it was known that the GluN1 ligand-binding site 
antagonist MDL-29951 and mutations within the GluN1 ligand-binding site increase 
glycine-induced currents (Madry et al., 2007a). However, the exact molecular 
mechanism of this apparent relief from auto-inhibition remained elusive. In the 
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present study, we generated a high-efficacy GluN1/GluN3A receptor by building and 
analyzing a homology model and introducing amino acid substitutions in the 
homophilic GluN3A-NTD interface and in the GluN3A-NTD-LBD linker region 
connecting the GluN3A-NTD to the subjacent GluN3A-LBD. 
Our results establish a dominant negative role of the GluN3-NTDs for receptor 
function and thus we conclude that the GluN3-NTD resembles an auto-inhibitory 
domain of GluN1/GluN3 receptors.  
 
The GluN3-NTD accounts for the low efficacy of GluN1/GluN3 receptors - 
Despite numerous studies on the role of the LBD dimer interface in the function of 
iGluRs it is not very clear if results from non-NMDARs also apply to NMDARs. For 
non-NMDARs it is commonly accepted that the stability of LBD dimer interactions 
largely determine the degree of receptor desensitization (Stern-Bach et al., 1998, 
Sun et al., 2002, Armstrong et al., 2006). Because of the close homology between 
non-NMDARs and NMDARs it was believed that the same mechanism for receptor 
desensitization applies to NMDARs (Furukawa et al., 2005). However, Borschel et 
al., (2011) reported from single-channel studies that it is not the degree of 
desensitization but the activation that is altered by LBD heterodimer mutations in 
NMDARs. Specifically, for receptor activation the LBD heterodimer interface 
undergoes conformational changes that are facilitated by non-polar residues, as 
polar residues raise the energy barrier that is needed for activation. Based on this 
precedent we analyzed amino acid substitutions in the GluN1-GluN3A LBD 
heterodimer at three distinct interaction sites (I-III) and aimed to increase the efficacy 
of GluN1/GluN3A receptors. Our findings indicate that the LBD heterodimer contacts 
are involved in general in receptor function, as we also found for GluN1Δ/GluN2Δ 
receptors (see Chapter 2). None of the LBD heterodimer mutations enhanced 
responses to glycine, and in fact these mutations significantly decreased IMax values 
for activation by glycine and Zn2+. The GluN1-Y535A and -E781A mutations did not 
respond to Zn2+ and thus we reasoned that Zn2+ either binds or acts via the LBD 
heterodimer interface. Furthermore, our homology model-based analysis and 
mutation studies revealed the GluN3A-NTDs as the auto-inhibitory domain that 
dictates the low-efficacy. This finding, although surprising, is in accordance with 
results that underline the role of the GluN2-NTDs in NMDA-receptor function. 
Precisely, previous studies suggest that the GluN2-NTDs determine the apparent 
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glycine-affinity, deactivation time course, channel open probability and 
desensitization kinetics of GluN1/GluN2 receptors (Madry et al., 2007b, Yuan et al., 
2009, Gielen et al., 2009). It was suggested that the bilobed GluN2-NTDs oscillate 
between distinct conformational states and these conformational changes are 
thought to be responsible for the aforementioned modulatory actions (Paoletti et al., 
2007, Madry et al., 2007b, Yuan et al., 2009, Gielen et al., 2009). Furthermore, it was 
concluded that the frequency with which the GluN2-NTDs oscillate account for the 
differences between the distinct GluN2 subunits (i.e. GluN2A-D). In a similar vein, it is 
conceivable that the GluN3A-NTD oscillates between conformers and thus causing 
the low-efficacy of GluN1/GluN3A receptors. Our results demonstrate a pivotal role of 
the GluN3A-NTD-NTD interface and the GluN3A-NTD-LBD linker, which might be 
based on their involvement in GluN3A-NTD oscillations. 
 
Importance of the NTD-LBD linker region and the putative NTD-NTD 
interface in determining NMDAR efficacy - As aforementioned, it is well known that 
the GluN2-NTDs modulate the kinetic properties of conventional NMDARs (Madry et 
al., 2007b, Yuan et al., 2009, Gielen et al., 2009). When substituting the NTDs 
between GluN2A-D subunits in order to transfer their specific properties, i.e. 
desensitization kinetics and P0, it was necessary to also replace the linker regions in 
order to achieve the full effect (Yuan et al., 2009, Gielen et al., 2009). However, the 
exact mechanism that couples the modulatory action of the GluN2-NTDs and the 
NTD-LBD linker to the channel is yet unknown.  
Similar to the findings with GluN2 NTD-LBD linkers (Yuan et al., 2009, Gielen et 
al., 2009), we observed that the GluN3A NTD-LBD linker participates in determining 
channel properties of GluN1/GluN3A receptors, since amino acid substitutions in this 
region largely enhanced the receptor efficacy. Despite the recent crystallization of the 
tetrameric GluA2cryst complex (Sobolevsky et al., 2009), we still lack information 
about the structure and conformation of the NTD-LBD linker of any of the iGluR 
members (Sobolevsky et al., 2009). In this crystal structure one of the four NTD-LBD 
linkers has a α-helical structure whereas the remaining three linkers are unwound. 
Thus, also in our GluN1/GluN3A homology model the NTD-LBD linkers are unwound. 
However, the presence of one α-helix in one of the NTD-LBD linkers in the GluA2cryst 
complex (Sobolevsky et al., 2009) provoked us to analyze this linker in more detail. 
Based on the aforementioned crystal structure and our secondary structure 
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prediction, as well as, molecular dynamics simulation we suggest that the NTD-LBD 
linker adopts a α-helical secondary structure and we further suggest that this 
structure is essential for NTD-mediated modulation of the receptor properties.  
Besides the GluN3A NTD-LBD linker we have shown that mutations within the 
putative homophilic GluN3A NTD-interface also enhance GluN1/GluN3A receptor 
efficacy. The importance of this substructure in determining receptor efficacy 
becomes apparent when examining the heterotrimeric GluN1/GluN3A/GluN3B 
receptors. In contrast to the low-efficacy GluN1/GluN3A and GluN1/GluN3B 
receptors, these heterotrimeric receptors, that lack a homophilic GluN3-NTD 
interface, display large glycine-gated currents (Smothers and Woodward, 2007). 
According to our homology model of the GluN1/GluN3A receptor the GluN3 NTD-
interface consists of two symmetrical contacts. Namely, the α7-helix of one GluN3-
NTD interacts with the loop region between ß13 and ß14 of the opposing GluN3-NTD 
and vice versa. Our sequence analysis of the GluN3A and GluN3B NTD-interface 
shows a pair wise identity of 6.7% within the α7-helix and 41.7% in the loop ß13/ß14. 
The low identity in the α7-helix is due to a putatively shorter α7-helix in the GluN3B 
NTD. In our experiments disruption of the NTD-NTD-interface in GluN1/GluN3A 
receptors increased the receptor efficacy. Hence, we suggest that this asymmetric 
NTD-NTD-interface accounts for the high-efficacy of GluN1/GluN3A/GluN3B 
receptors. The homophilic GluN3-NTD interface is required for the inhibitory effect of 
the GluN3-NTDs and we suggest that the GluN3-NTD-LBD linker is involved in 
transmitting this inhibitory effect from the NTDs to the subjacent LBDs. How this 
inhibitory signal is then transmitted to the TMDs is currently not known. We reasoned 
that the LBD heterodimer interface is involved but in our experiments we did not find 
indications to verify this hypothesis. Further examination of the structure and 
properties of the NTD-LBD, as well as, LBD-TMD interactions will be required to fully 
understand the molecular mechanism of GluN3-NTD mediated low efficacy. 
 
Auto-inhibition is a general mechanism to control protein function - Auto-
inhibitory domains have already been described in various signaling proteins like 
AMP-activated protein kinase (AMPK), endosomal sorting complexes required for 
transport-III (ESCRT-III) or Crk-II type adaptor proteins (Chen et al., 2009, Bajorek et 
al., 2009, Cho et al., 2011). Crystallization and in silico analyses suggest that an 
auto-inhibitory domain (AID) either reduces the mobility of other subdomains until a 
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ligand binds (e.g. AMPK) or the AID occludes the binding site for ligands in a 
thermodynamic manner (e.g. Crk-II) or the AID prevents protomers to assemble to 
higher-order oligomers (e.g. ESCRT-III)(Chen et al., 2009, Bajorek et al., 2009, Cho 
et al., 2011). The equilibrium between auto-inhibited and activated conformations of 
signaling proteins is believed to play a key role in preventing uncontrolled activation 
to cellular stimuli (Yao et al., 2008, Li et al., 2008). Thus, the interdomain interfaces 
responsible for auto-inhibition must be stable enough to prevent constitutive 
activation but also labile to allow for prompt response to external or internal triggers. 
To our knowledge this is the first time that an AID has been described for a 
ligand-gated ion channel. Under physiological conditions conventional NMDARs are 
blocked by extracellular Mg2+ and upon depolarization this Mg2+-block is abolished, 
rendering conventional NMDARs so-called ‘co-incidence detectors’ (Madden, 2002). 
In contrast, GluN1/GluN3 receptors are not blocked by extracellular Mg2+ and thus 
they are constitutively inducible (Chatterton et al., 2002) but due to their low-
efficacies this might not have detrimental consequences. However, the role of the 
GluN3-NTDs as AIDs might play a similar role as the Mg2+-block in GluN2-containing 
receptors, i.e. fine tuning of receptor activation. Despite these similarities, the 
molecular mechanisms of AIDs seem to vary. We conclude that auto-inhibition is a 
common tool to control protein function but the underlying mechanism is not 
conserved. 
Apart from endogenous GluN1 binding site antagonists (e.g. kynurenic acid) that 
might potentiate glycine-induced currents, also other molecules might exist that bind 
to the GluN3-NTD like it was described for Zn2+ and the GluN2A-NTD (Choi and 
Lipton, 1999, Fayyazuddin et al., 2000, Low et al., 2000, Paoletti et al., 1997, Paoletti 
et al., 2000). The functional consequence of the binding of a ligand to the GluN3A-
NTD is currently not foreseeable. A relief from auto-inhibition is as reasonable as a 
reinforced inhibition. 
 
Conclusions - The present study establishes a prominent role of the GluN3-NTD 
as an auto-inhibitory domain (AID) in GluN1/GluN3A receptor function. In contrast to 
the GluN1-NTD, deletion of the GluN3A-NTD resulted in a strong increase in channel 
efficacy. Apart from deleting the GluN3A-NTD, it is possible to increase efficacy by 
introducing mutations in the homophilic GluN3A-NTD interface or the GluN3A NTD-
LBD linker region. Taken together, these results underline the differential roles of 
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NTDs in determining NMDA receptor efficacy and we also identified critical 
intersubunit and interdomain residues that account for the auto-inhibitory effect of the 
GluN3A-NTDs. 
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CHAPTER 5 
INTERSUBUNIT CONTACTS IN THE TRANSMEMBRANE DOMAIN INVOLVING 
TM4 DETERMINE RECEPTOR FUNCTION BUT NOT ASSEMBLY OF NMDA 
RECEPTORS 
 
Ceyhun Tamer, Adriana Längle and Bodo Laube 
Department of Molecular and Cellular Neurophysiology, TU-Darmstadt, Schnittspahnstrasse 3, 64287 
Darmstadt, Germany 
 
 
 N-Methyl-D-Aspartic acid (NMDA) receptors are tetrameric complexes that 
belong to the family of ionotropic glutamate receptors (iGluRs). NMDA 
receptors are composed of two glycine binding GluN1 and glutamate binding 
GluN2 and/or glycine binding GluN3 subunits. The subunits consist of two 
large extracellular domains that are homologous to bacterial, periplasmic 
amino acid binding proteins. Furthermore, the transmembrane domain (TMD) 
of iGluRs is homologous to potassium channels (K+ channels). Despite this, 
iGluRs require one membrane spanning segment (TM4) more than K+ channels 
for proper receptor function. However, the exact role of this TM4 segment is 
not well understood but crystallization of the GluA2-subtype AMPA receptor 
complex allows further structural analysis. Based on experimental findings in 
our lab (by Dipl. Biol. Adriana Längle) the TM4 is implicated in receptor 
function but not the assembly, trafficking or stoichiometry of NMDARs 
composed of GluN1 and GluN3A subunits. Here, we analyzed a model of the 
GluN1/GluN2A TMD and introduced single amino acid substitutions in the 
GluN1-TM4 and GluN2A-TM3. We identified two mutations that render 
GluN1/GluN2A receptors non-functional. One glycine residue (GluN1-G828) 
being part of a GxxxG motif and one glutamate residue (GluN1-E835) that forms 
a polar connection to the GluN2A-TM3. Additionally we performed a 
bioinformatics approach to identify residues that are evolutionary dependent 
on either GluN1-G828 or -E835. We found correlations to residues mainly 
located in the TM1 and TM4 facing the TMD intersubunit contact between 
GluN1 and GluN2A. Thereby we conclude, GluN1-G828 and -E835 are involved 
in maintaining the stability of the TMDs but are not directly involved in gating 
or ion permeation. 
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Introduction 
Ionotropic glutamate receptors (iGluRs) are ligand-gated ion channels that are 
present at excitatory synapses in the central nervous system and mediate fast 
information transfer (Dingledine et al., 1999). These tetrameric complexes can be 
activated by subtype specific ligands, such as (RS)-2-amino-3-(3-hydroxy-5-methyl-4-
isoxazolyl)propionic acid (AMPA), kainate and N-methyl-D-aspartic acid (NMDA) thus 
being classified as AMPA receptors (subunits GluA1-4), kainate receptors (subunits 
GluK1-4) and NMDA receptors (subunits GluN1, GluN2A-D and GluN3A-B). Each 
subunit has a modular structure with two large extracellular domains, i.e. N-terminal 
domain (NTD) and ligand-binding domain (LBD) that show sequence homology to 
bacterial, periplasmic amino acid binding proteins, i.e. Leucine-Isoleucine-Valine-
binding protein (LIVBP) and Lysine-Arginine-Ornithine-binding protein (LAOBP) 
respectively (Masuko et al., 1999, Paoletti et al., 2000, Madden, 2002, Paoletti and 
Neyton, 2007). The transmembrane domain (TMD) is formed by three 
transmembrane segments (TM1, TM3 and TM4) and one M2 re-entrant loop. The C-
terminal domain (CTD) is located intracellular and has been implicated to interact 
with scaffolding proteins (Dingledine et al., 1999). 
The overall tetrameric structure of the TMDs and the presence of a re-entrant 
loop closely resembles the composition of an inverted K+ channel (KcsA) except for 
the TM4 that is absent in KcsA channels (Wollmuth et al., 2004). The crystallization 
of the tetrameric GluA2-subtype of AMPA receptors by Sobolevsky et al. (2009) 
further confirmed this observation. Although the TMD of the AMPA receptors shares 
only ~20% sequence identity with the KcsA channel, the structures of TM1, M2 and 
TM3 of the AMPA receptor superimpose very well on the structure of the KcsA 
channel (Doyle et al., 1998) yielding a RMSD (root mean squared deviation) of 2.2Å 
(Sobolevsky et al., 2009). Due to the close homology between NMDARs and 
AMPARs it is suggested that the NMDAR TMDs are arranged in a similar fashion 
(Sobolevsky et al., 2009). However, the lack of a fourth membrane domain in the 
KcsA channel suggests that the TM4 in iGluRs was an evolutionary addition and as 
such the role of the TM4 is a matter of debate (Wollmuth et al., 2004). The TM4 is not 
a dispensable domain, Schorge and Colquhoun (2003) analyzed TM4 truncated 
constructs and found that TM4-lacking subunits are not functional, however, co-
expression of the respective TM4 fragment recovers receptor function. The reason 
why TM4 is required for channel function is unknown. It has been suggested that the 
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TM4 contributes to the channel pore and mutations in it affect ion channel gating 
(Beck et al., 1999, Ren et al. 2003). Despite this finding, the AMPA receptor crystal 
structure shows that the TM4 does not directly contribute to the ion channel, it is 
located close to TM1 and TM3 of the neighboring subunit and thus engages in 
intersubunit contacts (Sobolevsky et al., 2009). In a study by Horak et al. (2008) it 
was reported that endoplasmic reticulum (ER) retention signals in the TM1 and TM3 
of GluN1 and GluN2B subunits are present and TM4 truncation results in the 
intracellular accumulation of the subunits. Furthermore, it is shown that TM4 is 
required to mask the ER retention signals and thus facilitate surface trafficking of the 
receptors. It is though that ER retention is a quality assurance system and as such it 
prevents misfolded proteins to reach cell-surface. Misfolded proteins are retained in 
the ER and are subsequently degraded. 
A study by Haeger et al. (2010) analyzed TMD interactions in another family of 
ligand-gated ion channels, the Cys-loop receptors. Cys-loop receptors are 
pentameric complexes in contrast to iGluRs, which are tetramers. Haeger et al (2010) 
studied the inhibitory glycine receptors (GlyRs) and serotonine receptors (5HT3 
receptors) that are members of this class. Each subunit consists of an extracellular 
ligand-binding domain (ECD), four transmembrane helices (TM1-TM4) and an 
extracellular C-terminal domain. The TMDs of Cys-loop receptors are not 
homologous to the TMDs of iGluRs. However, Haeger et al. (2010) found that the 
truncation of TM4 impairs the subunit stoichiometry and thus, subunits assemble 
uncontrolled into higher oligomeric states. The co-expression of the TM4 recovers 
proper subunit stoichiometry and receptor function and it is further shown that an 
aromatic network of residues determines the pentameric assembly (Haeger et al., 
2010). 
Experimental findings in our lab indicate that the TM4 is not required for the 
assembly, stoichiometry or cell surface trafficking of GluN1/GluN3A receptors. 
Therefore, we suggest that the TM4 might not only be essential for masking ER 
retention signals but plays an important role in the overall stability of the TMD. Based 
on these results and our model of the GluN1-GluN2A TMD we aimed at identifying 
residues in the TMD intersubunit interface of GluN1/GluN2A receptors that determine 
the stability and function of the receptor complex. For this, we introduced single 
amino acid substitutions in the TM4 of GluN1 and TM3 of GluN2A and characterized 
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the resulting receptors by means of recording whole cell currents from cRNA injected 
Xenopus oocytes using two-electrode voltage-clamp. 
 
EXPERIMENTAL PROCEDURES 
cDNA constructs, heterologous expression and electrophysiology - The 
cDNA constructs of GluN1-1a (rat), C-terminal hexahistidyl-tagged GluN1-1a (rat) 
and GluN2A (mouse) have been described previously (Madry et al., 2007b). Single 
point mutations were introduced via site-directed mutagenesis (QuikChange XL Site-
Directed Mutagenesis Kit, Stratagene) and confirmed by DNA sequencing (Eurofins 
MWG Operon). All constructs were linearized and transcribed into cRNA (mCAP 
mRNA Capping Kit, Ambion) as described (Madry et al., 2010). For biochemical 
analyzes and electrophysiological recordings, 25 ng of cRNA/oocyte was injected. 
Xenopus laevis oocytes were isolated and maintained as described (Laube et al., 
1997). Two-electrode voltage-clamp recording of glutamate- and glycine-induced 
whole cell currents was performed according to Laube et al., 1997. 
 
Metabolic [35S]-methionine labelling, purification and SDS-PAGE - To detect 
intracellular expressed receptor complexes the oocytes were labelled after cRNA 
injection, by incubation in [35S]-methionine solution overnight (>40 TBq/mM, 
Amersham Biosciences) at ~100 MBq/ml (0.2 MBq per oocyte) (Schuler et al., 2008). 
The receptor complexes were purified from dodecylmaltoside extracts of the labelled 
oocytes via a hexahistidyl tag by nickel nitriloacetic acid (Ni2+-NTA) agarose (Qiagen) 
chromatography as described in Madry et al., 2007b. [35S]-methionine-labelled 
protein samples were solubilized in SDS sample buffer containing 20 mM 
dithiothreitol (DTT) and electrophoresed together with molecular mass markers 
(SeeBlue® Plus2 Pre-Stained Standard, Invitrogen) on 8% tricine- SDS-
polyacrylamide gels. After blotting, fixation and drying of the gel, it was exposed to 
BioMax MR films (Kodak, Stuttgart, Germany) at –80 °C.  
 
Surface labelling with cell impermeable Cy5 dye - Four days after the injection 
of cRNAs, the injected and non-injected control oocytes were surface labelled with 65 
µM of Cy5-NHS-ester dye (Amersham Biosciences) and solubilized for affinity 
purification as described above. Gels containing Cy5-labelled protein samples were 
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scanned with a gel imager (Storm 840, Molecular dynamics) as described in Madry et 
al., 2007a. 
 
Glycosylation Assay - To distinguish between intracellular and cell-surface 
receptor complexes, 10µl of the affinity-purified receptors were incubated in reducing 
sample buffer (20 mM DTT, 1% (w/v) SDS) containing 1% (w/v) octylglucoside with 
5U endoglycosidase H (Endo H) or peptide-N-Glycosidase F (PNGase F; NEB, 
Frankfurt, Germany) at 37°C for 1 h. Afterwards protein samples were analyzed by 
SDS-PAGE as described above. 
 
Mutual Information analysis - Sequence alignment of the iGluR-receptor 
subunits was taken from (Sobolevsky et al., 2009) and supplemented with the 
sequences of GluA1-4, GluK1-4, GluN1, GluN2A-D and GluN3A-B from different 
species which gave a total of 249 sequences that were downloaded from NCBI. The 
alignments were computed using Geneious Software (v.4.8.3, Biomatters Ltd. 
Auckland, New Zealand) and then the alignment was optimized by hand and trimmed 
to the TM1, TM3 and TM4 domains only. In the MI analysis interdependencies 
between pairs of positions in a multiple sequence alignment are calculated. If it is 
possible to infer the amino acid at a certain position by knowing the amino acid at 
another position, these two positions will have a high MI value, thus they are 
interdependent. If it is not possible to infer the amino acid at another position, such a 
pair will have a low MI value and thus they are not interdependent. The MI is 
calculated according to the following equation: !" !;! = ! !,! log! ! !,!! ! ! !!!  
p(x) and p(y) represent the frequencies of each amino acid type at position X or Y, 
respectively. The probability to observe the combination of these two amino acids is 
given by p(x,y). Apart from the 20 standard amino acids, x and y can have a gap “-“ 
or “X” for non-standard amino acids as their values. The MI calculation results in a N 
x N matrix with N being the sequence length of the multiple sequence alignment. 
Thus the symmetrical MI matrix holds !(!!!)!  values, one for each pair of positions in 
the alignment. The calculation was performed using the statistical software package 
R (v.2.10, R Development Core Team 2011) and the BioPhysConnectoR library 
(Hoffgaard et al., 2010). Based on the sequence alignment the MI matrix was 
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computed and standardized to a null model with 10,000 randomization steps (White 
et al., 2007, Weil et al., 2009). The null model consists of the same alignment but the 
amino acids in each column are shuffled vertically in their position as to remove the 
sequence correlation. In each randomization step a new null model MI matrix is 
computed. The expectation value from the null model mij is the average of the 10,000 
(i,j) entries and together with the corresponding variances the Z-scores can be 
calculated. For this, the null model was subtracted from the MI matrix and the 
resulting matrix was divided by the standard deviation (square root of the variance). 
The entries in the resulting matrix represent Z-scores, which are normalized onto the 
standard deviation. Thus each Z-score has the standard deviation as its unit e.g. a 
value of 10 means that the Z-Score is 10 standard deviations away from the 
expectation value mij. Because of its symmetry the diagonal and the lower triangle of 
the Z-score matrix were set to 0. For subsequent data analyses Microsoft Excel 
(v.2011) and for visualization purposes PyMOL v.1.3 (Schrödinger Inc., New York, 
NY, USA) were used. 
 
For statistical data analysis Graphpad Prism v.5.0a (GraphPad Software Inc., San 
Diego, CA, USA) has been used. 
For all analyses, values are given as means ± SEM if not stated otherwise. 
Statistical significance was tested with one-way ANOVA and the Dunnett Post-Hoc-
Test. For all p-values applies (*) p<0.01, (**) p<0.001 if not stated otherwise. 
 
RESULTS 
In this study we aimed at identifying residues in the intersubunit interface in 
the TMDs of GluN1/GluN2A receptors that are critical for receptor function and thus 
gain more insight into the role of the fourth membrane domain (TM4). 
 
TM4 truncation does not interfere with receptor assembly, cell-surface 
expression or subunit stoichiometry (Note, the following experiments were 
conducted by Dipl Biol. Adriana Längle) - Studies by Schorge and Colquhoun 
(2003) and Horak et al. (2008), conducted on GluN1/GluN2 NMDARs, pointed out 
that the TM4 is required for proper receptor function and assembly. However, co-
expression of the TM4 fragment recovers receptor function. Furthermore an ER 
retention signal in the TM3 domains was identified and the TM4 domain is involved in 
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masking this ER retention (Horak et al., 2008). Thus, TM4 truncation impairs cell-
surface trafficking of NMDAR complexes. These experiments were conducted on 
classical GluN1/GluN2 NMDARs. To further investigate the role of the TM4 domain 
Dipl. Biol. Adriana Längle conducted experiments on GluN1/GluN3A NMDARs. She 
generated a TM4-truncated GluN1 construct (GluN1ΔM4) and the respective TM4 
fragment (GluN1-M4). Functional and biochemical analyses were carried out on 
cRNA injected Xenopus oocytes. It was found that co-expression of GluN1ΔM4 and 
GluN3A subunits leads to the formation of GluN1ΔM4/GluN3A receptors. These 
receptors are not only expressed intracellular but also reach the cell surface, shown 
by  [35S]methionine- or Cy5-labelling and SDS-PAGE (Längle et al., in preparation). 
Analysis of the band intensities also revealed unaltered subunit stoichiometry and 
thus it is concluded that the GluN1-TM4 does not interfere with receptor assembly, 
cell-surface trafficking or subunit stoichiometry. However, functional analysis using 
two-electrode voltage-clamp showed no detectable responses upon agonist 
application (Längle et al., in preparation). Therefore it is further concluded that the 
TM4, although not required for proper receptor assembly and trafficking, is essential 
for receptor function. 
These results define a different role of the TM4 in GluN1/GluN2 and 
GluN1/GluN3A receptors. In Glun1/GluN2 receptors the GluN1-TM4 is required for 
surface trafficking (Horakt et al., 2008), whereas in GluN1/GluN3A receptors it is not 
(Längle et al., in preparation). In order to disclose the functional role of the TM4 in 
more detail we chose to introduce single amino acid substitutions rather than deleting 
the whole TM4. 
 
Homology model based analysis of TM4 intersubunit contacts - Here, we 
analyzed our homology model of the tetrameric GluN1-GluN2A TMD. This homology 
model is based on the tetrameric GluA2-subtype AMPA receptor crystal structure by 
Sobolevsky et al. (2009, PDB ID: 3KG2) and has already been published in Endele et 
al. (2010). Each subunit consists of three membrane-spanning domains, i.e. TM1, 
TM3 and TM4, whereas the M2 domain is a re-entrant loop and was not included in 
our analyses. The TM3 helices form the inner core of the ion channel (Fig. 1A), 
whereas TM1 and TM4 helices are not directly located in the ion permeation 
pathway. Interestingly, the TM1, TM3 and M2 domains of each subunit are in close 
proximity to each other whereas the TM4 engages mainly in intersubunit interactions 
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with the neighboring TM1 and TM3 domains (Fig. 1A-B). The TM4 adopts a remote 
position with respect to its subunit and thus resembles a hook that seems to tie up 
the neighboring subunit. Therefore, we were interested in the functional role of the 
intersubunit interface between the TM4 and the neighboring TM1 and TM3 (Fig. 1B). 
Based on the homology model and the multiple sequence alignment of NMDAR 
subunits we chose to introduce four amino acid substitutions in the GluN1-TM4, 
namely GluN1-F817A, -I824A, -G827V and –E834A. According to the homology 
model the residues GluN1-F817 and –I824 are facing towards the TM1 of the 
neighboring subunit, as well the position of GluN1-817 is strictly conserved in the 
other NMDAR subunits, whereas GluN-I824 is not (Fig. 1B-C). By mutating these two 
residues we intended to asses the functional implication of this TM4 and TM1 
intersubunit interface. Furthermore, the GluN1-G827 and –E834 residues are 
directed towards the TM3 of the neighboring subunit according to our homology 
model. According to sequence information (Fig. 1C) GluN1-G827 might be a part of a 
GxxxG motif, a motif that has been shown to critically determine TMD interactions 
(Unterreitmeier et al., 2007, Langosch et al., 2009). In contrast to the residues 
mentioned before the GluN1-E834 residue is hydrophilic. Due to its charged 
character and observations from the homology model we reasoned that this 
glutamate might form a hydrogen bond with residues GluN2A-T625 or –T626. The 
respective Cα-atom distance is 11.4 and 10.9 Å, this is a little too far for hydrogen 
bonds to form, however, in vivo this distance might be shorter and the high level of 
conservation of this position indicates a pivotal role. The apparent interacting 
residues in the TM3 are only partially conserved. The homologous residues to 
GluN2A-T625 are only conserved within GluN2A-D subunits, whereas the 
homologous position of GluN2A-T626 shows a higher degree of conservation, i.e. 
only the GluN1 subunit differs as it carries a serine at this position (Fig. 1C). By 
mutating the GluN1-G827 and –E834 residues we intended to gain insight into the 
functional implication of the TM4 and TM3 intersubunit interface. 
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Fig. 1. Homology model based analysis of GluN1-GluN2A TMD interactions. (A) Top 
view of the 4-fold symmetrical GluN1-GluN2A TMD. The GluN1 subunit is colored in green 
whereas GluN2A is cyan. (B) Magnification of GluN1-GluN2A TMD intersubunit interface. 
GluN1-TM4 and GluN2A-TM3 are highlighted, amino acids that were selected for site-
directed mutagenesis are depicted as sticks. (C) Multiple sequence alignment of rat NMDAR 
subunits. Degree of conservation for each position is shown above the alignment, red 
horizontal bars indicate TM1, TM3 and TM4 respectively. 
 
Apart from the GluN1-TM4 we decided to mutate two residues in the GluN2A-
TM3, which, according to our model, are oriented towards the space between the 
GluN1-TM4 and TM1 and TM3 of GluN2A. We reasoned that these two residues, 
GluN2A-F637 and -641, might play a critical role in forming an aromatic network 
between the TMDs. According to the sequence alignment, GluN2A-F637 and the 
homologous residues in the other NMDAR subunits are very well conserved (Fig. 
1C). GluN2A-F641 and the homologous residues are only conserved within the 
GluN2 subunits (Fig. 1C). Both residues were mutated to alanine residues, i.e. 
GluN2A-F637A and –F641A. 
Utilizing our homology model of the GluN1-GluN2A TMD and multiple 
sequence alignment we identified residues that form the TMD intersubunit interface 
involving the TM4 of GluN1 and TM1 as well as TM3 of GluN2A, thereby assessing 
the functional implication of the TM4. 
  105 
 
Single amino acid substitutions in the TM4 render the NMDA receptor 
non-functional (Note, the following experiments were conducted by Dipl Biol. 
Adriana Längle) – In the GluN1 and GluN2A subunits a total of 6 residues were 
mutated by sited-directed mutagenesis and whole-cell current responses were 
recorded from Xenopus oocytes. The mutations were selected based on the GluN1-
GluN2A TMD homology model and sequence alignment, namely these were GluN1-
F817A, -I824A, -G827V, -E834A and GluN2A-F637A as well as –F641A. From these 
GluN1/GluN2A mutant receptor combinations four exhibited robust current responses 
upon co-application of glycine and glutamate. The GluN1-TM4 mutation G827V 
resulted in a drastic decrease in the maximal inducible current (IMax)(p<0.001), 
whereas the GluN1-E834A/GluN2A mutant receptors failed to exhibit agonist-induced 
currents (Fig. 2). The multiple sequence alignment indicates that GluN1-G827 is part 
of a GxxxG-motif, which was found to be important for TMD interactions and stability 
(Unterreitmeier et al., 2007, Langosch et al., 2009). The significant reduction in IMax 
supports the importance of this residue and indicates that indeed a TMD intersubunit 
ineraction is stabilized by this GxxxG-motif. Even more significant than the GluN1-
G827V mutation is the –E834A mutation, as GluN1/GluN2A receptors carrying this 
mutation did not elicit any measurable currents. The lack of response shows that this 
highly conserved residue plays an important role in the TMD intersubunit interface. 
According to our hypothesis, this residue makes a polar connection to the TM3 of the 
neighboring subunit. As the TM3 domains form the inner core of the ion channel, a 
functional implication of GluN1-E834 was expected. However, if this effect is caused 
by a functional effect or a lack of cell-surface expressed receptors in not clear at the 
moment. 
In contrast to these findings, the GluN2A-F641A mutation caused a significant 
increase in IMax when co-expressed with the GluN1 subunit (Fig. 2)(p<0.001). This 
finding was surprising as we expected that impairment of the aromatic network 
between the TMDs would destabilize the receptor. Therefore, we expected to see a 
decrease in the IMax. The increase in IMax might indicate an increase of the receptor 
efficacy, which might be due to eased rearrangements in the TMD that lead to the 
opening of the ion channel. 
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Fig. 2. Maximal inducible currents of mutated GluN1/GluN2A receptors. IMax values were 
determined in the presence of 100 µM glycine and glutamate. 
Data represent means ± SEM, (*) p<0.01, (**) p<0.001 
Note: Dipl. Biol. Adriana Längle conducted experiments. 
 
Additionally, the IMax, apparent affinities (EC50) for glycine and glutamate were 
determined (Table 1). For the mutations that led to non-functional or almost non-
functional receptors it was not possible to make dose-response measurements. The 
other mutant receptor combinations did not alter either glycine or glutamate EC50 
values significantly (Table 1). These results indicate that the mutations decrease or 
increase receptor currents specifically by increasing/decreasing receptor efficacy. 
However, we cannot exclude the possibility that the mutations also affect receptor 
assembly and/or cell-surface trafficking. 
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Table 1. Pharmacology of wt and mutated GluN1/GluN2A receptors. Glycine and 
glutamate EC50 values as well as IMax values were determined in the presence of 100 µM 
glycine and/or glutamate. 
Data represent means ± SEM, nf, non-functional 
Note: Dipl. Biol. Adriana Längle conducted experiments. 
 
 
The data presented here show that the mutations in GluN1-TM4 and GluN2A-
TM3 either increase or decrease maximal inducible currents but without significantly 
affecting apparent glycine or glutamate affinities. Note that the mutations in the 
GluN1-TM4 and GluN2A-TM3 interface, i.e. GluN1-G828V and –E834A, drastically 
decreased the IMax or led to non-functional receptors, whereas mutations in the 
GluN1-TM4 and GluN2A-TM1 interface, i.e. GluN1-F817A and –I824A, resulted in 
currents and apparent affinities comparable to those of wild-type (wt) GluN1/GluN2A 
receptors. 
 
Using MI analysis for putative functional implications of GluN1-G828V 
and -E835A – The data presented here establish a prominent role of residues in the 
GluN1-TM4 and GluN2A-TM3 interface. Whether these residues are involved in 
receptor function or in receptor assembly or trafficking is unclear. In order to address 
this question we utilized a bioinformatics approach that is commonly used for the 
identification of evolutionary interdependent positions in a protein, the so-called 
mutual information (MI). Using large multiple sequence alignments it is possible to 
address the question if two positions in the alignment are paired in a way that they 
Gly Glu
μA
GluN1 / GluN2A 0.6 ± 0.1 1.7 ± 0.3 2.5 ± 0.2
GluN1-F817A / GluN2A 1.5 ± 0.4 1.7 ± 0.2 2.2 ± 0.3
GluN1-I824A / GluN2A 0.8 ± 0.4 1.7 ± 0.3 3.8 ± 0.9
GluN1-G827V / GluN2A - -     0.05 ± 0.01**
GluN1-E834A / GluN2A - -      nf **
GluN1 / GluN2A-F637A 3.6 ± 2.0 0.7 ± 0.2 2.8 ± 0.1
GluN1 / GluN2A-F641A 0.4 ± 0.1 2.3 ± 0.6     5.0 ± 0.3**
* P < 0.01
** P < 0.001
n = 6-7
 Gly IMaxEC50
μM
Subunit Composition
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tend to mutate dependently. We already applied this approach successfully in 
Chapter 2. This approach does not directly reveal putative functions of the residues. 
Despite this, we reasoned that if two positions are evolutionary connected they might 
also serve a similar function in the protein. Our hypothesis is that positions that are 
important for receptor assembly will be evolutionary connected and thus receive a 
high Z-score in the MI analysis. Vice versa, positions implicated in receptor function 
will also have a high Z-score in the MI analysis. On the other hand positions that play 
a role in receptor assembly and those that are crucial for receptor function should 
receive a lesser Z-score. Based on this hypothesis we were expecting to see 
significant correlations of either GluN1-G827 or GluN1-E834 with positions in the 
TM3 that are proximal to the ion permeation pathway, if these residues are involved 
in receptor function rather than assembly or trafficking. Conversely, if these residues 
are not directly involved in receptor function but the overall stability of the TMD, we 
would expect to see significant correlations with residues that putatively stabilize 
TMD interactions. To test this hypothesis, we selected a position in the highly 
conserved SYTANLAAF motif in the TM3 of NMDARs. This motif is essential for 
receptor function and mutations in this motif lead to non-functional receptors (Blanke 
and VanDongen, 2007). The GluN1-N650 residue is part of the SYTANLAAF motif 
and we utilized the MI analysis to find positions that are correlated with this position 
(Fig. 4). According to our hypothesis we would expect to find mainly correlations to 
positions within TM3 and especially in the SYTANLAAF motif (Table 2). First, we 
analyzed the Z-score distribution of the MI analysis in order to assess the reliability of 
the Z-scores. We found a Gaussian-like distribution with its center at Z-score values 
of 25-30 (Fig. 3). Below a Z-score of 10 an increase the number of data points is 
visible and we suppose that this increase is generated by a false, i.e. random, signal. 
Therefore we suggest to focus on Z-scores greater than 5. 
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Fig. 3. Histogram of Z-score distribution of MI analysis for TMDs of iGluR subunits. 
The histogram shows a bimodal distribution of Z-scores. One Gaussian-like distribution with 
its center at Z-score values of 25-30. The increase of data points at Z-scores 0-5 is 
presumably caused by random correlations. 
 
Next, we searched for MI correlations for GluN1-N650 with Z-scores greater than 5. 
We found 10 correlations, which are shown in Table 2. 
 
Table 2. Results of MI analysis for GluN1-N650 in TM3. GluN1-N650 is part of the highly 
conserved SYTANLAAF motif, which is crucial for receptor function. Shown are GluN1 
residues that are present at the respective position. MI analysis is based on multiple 
sequence alignment of TM1, TM3 and TM4 of 249 iGluR subunits. 
 
As expected we found 9 out of 10 correlations within TM3 and 5 correlated 
positions are within the SYTANLAAF motif and one correlation was found with the 
GluN1-TM4 residue F810 (Table 2 and Fig. 4). Although not a proof, we take this as 
an indication for the validity of our hypothesis. 
GluN1&TM1 Z&score GluN1&TM3 Z&score GluN1&TM4 Z&score
1 S585 13.32 F810 7.74
2 A649 12.41
3 W636 10.78
4 L651 10.77
5 A653 10.51
6 F639 10.34
7 T648 9.90
8 Y647 9.69
9 M634 7.77
GluN1&N6504correlations
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Fig. 4. Homology model of GluN1-GluN2A TMD and MI correlations of GluN1-N650. Top 
view of the 4-fold symmetrical GluN1-GluN2A TMD. The GluN1 subunit is colored in green 
whereas GluN2A is cyan. The residue highlighted in magenta is GluN1-N650, an important 
residue in the SYTANLAAF motif. The other residues depicted as sticks are, according to MI 
analysis, evolutionary correlated to GluN1-N650. 
 
Next, we applied the MI analysis to the aforementioned GluN1-G827 and GluN1-
E834 positions. The MI analysis showed correlations mainly in the TM1 and TM4 
domains. As the GluN1-TM4 makes contact to the neighboring subunits’ TM1 and 
TM3 we reasoned that GluN1-G827 and GluN1-E834 are correlated with GluN2A-
TM1 and GluN2A-TM3 (Table 3, Fig. 5). 
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Table 3. Results of MI analysis for GluN1-G827 and GluN1-E834. Identification of 
positions that are interdependent with GluN1-G827 and GluN-E834. All of the correlations 
were found either in the TM1 or TM4. MI analysis is based on multiple sequence alignment of 
TM1, TM3 and TM4 of 249 iGluR subunits. 
 
The correlated positions were only distributed between the GluN1-TM4 and 
GluN2A-TM1 (Table 3). We observed that preferentially correlations to hydrophobic 
residues were found. The correlated positions are also distributed along the full 
length of the TMDs (Fig. 5) indicating that GluN1-G827 and GluN1-E834 are involved 
in a hydrophobic, not necessarily aromatic, network that stabilizes TMD interactions. 
We take these observations as an indication that the GluN1-G827 and GluN1-E834 
residues are generally involved in stabilizing TMD interactions, which seems to be 
also important for receptor function as mutations at these positions largely reduced 
agonist-induced receptor currents. 
GluN2A'TM1 Z'score GluN2A'TM3 Z'score GluN1'TM4 Z'score
1 S556 43.94 F810 47.28
2 M560 43.47 A821 42.04
3 F576 40.18 G822 39.66
4 V575 38.53 F832 38.41
5 V825 38.25
6 A836 36.17
GluN2A'TM1 Z'score GluN2A'TM3 Z'score GluN1'TM4 Z'score
1 V575 8.22 F817 12.3
2 E577 5.51 M813 6.72
3 M561 5.42 I834 6.48
4 V559 5.35 I824 6.34
5 L566 5.3 G815 5.65
GluN1'G8275correlations
GluN1'E8345correlations
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Fig. 5. Homology model based visualization of MI correlations for GluN1-G827 and 
GluN1-E834. The GluN1 subunit is shown in green and GluN2A is shown in cyan. (A,B) 
Side/Top view of a GluN1-GluN2A TMD dimer. Highlighted in magenta is GluN1-G827 and 
positions that were found to be interdependent are depicted as sticks. (C,D) Side/Top view of 
a GluN1-GluN2A TMD dimer. Highlighted in magenta is GluN1-E834 and positions that were 
found to be interdependent are depicted as sticks. 
 
From our MI analysis we conclude that it is possible to draw functional 
implications for positions that were found to be correlated with each other. Thus, 
positions with a crucial role in receptor function will most probably tend to have high 
Z-scores with positions that are also critically involved in receptor function. We 
hypothesize that the same is true for positions that are important for receptor 
assembly. The analysis of the GluN1-G827 and GluN1-E834 positions indicates that 
these positions determine receptor function by stabilizing TMD interactions. 
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DISCUSSION 
In this study we aimed at identifying residues in the intersubunit interface in 
NMDAR TMDs and thus assess the role of the fourth membrane domain TM4. Our 
results revealed that the TM4 is not essential in GluN1/GluN3A receptors for receptor 
expression, assembly, subunit stoichiometry or cell-surface trafficking. These results 
stand in contrast to findings for GluN1/GluN2B receptors where the TM4 was found 
to be necessary to mask an ER retention signal for the receptors to reach the cell-
surface (Horak et al., 2008). Based on this observation we reasoned that the TM4 is 
implicated in receptor function. Additionally, Ren et al. (2003) found that a methionine 
residue (M823) in GluN2A affects functional receptor properties, such as 
desensitization and channel open probability. Here, we used a homology model of 
the GluN1-GluN2A TMD to select amino acids in the intersubunit interface between 
GluN1-TM4 and GluN2A-TM1, as well as GluN1-TM4 and GluN2A-TM3. These 
residues were mutated and electrophysiological characterized. We also utilized MI 
analysis to draw conclusions about putative functional implications of these residues. 
We found that a glycine residue (G827) in a not conserved GxxxG motif in the GluN1-
TM4 and the GluN1-E834 residue are critically involved in stabilizing the intersubunit 
interactions, which seem to be significant for receptor function. 
 
The TM4 is an evolutionary addition responsible for the overall stability of 
the tetrameric iGluR complex – The crystal structure of the KcsA-type K+ channel 
shows that two transmembrane helices are sufficient to ensure ion channel function 
(Doyle et al., 1998). The crystal structure of the GluA2-type AMPA receptor revealed 
that despite a relatively low sequence identity of ~20% between the TMDs of 
AMPARs and the KcsA channel, their structures superimpose pretty well (Sobolevsky 
et al., 2009). However, all iGluR subunits have a fourth membrane-spanning domain, 
the TM4. Therefore, the TM4 seems to be indispensable for iGluR function. In a 
previous study by Horak et al. (2008) it was found that the TM4 masks ER retention 
signals in GluN1/GluN2B receptors. Our results display a pivotal role of the TM4 in 
stabilizing TMD intersubunit interactions that are required for receptor function. 
Combining these findings with the results from Horak et al. (2008) we suggest that 
masking the ER retention signals is not the essential role of the TM4 but the 
stabilization of the TMD. We suggest that ER retention developed subsequently as a 
quality control to prevent non-functional receptors to reach cell-surface. Thus, we 
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suggest that masking of ER retention signals is a consequence of the significant role 
of the TM4 in iGluR function. To answer the question why the TM4 is required for the 
stability of the ion channel we reasoned that size might matter. A KcsA subunit 
consists of 166 amino acids, hence, the tetrameric complex has 664 amino acids. 
The GluN1 (rat) and GluN2A (rat) subunits consist of 938 and 1504 amino acids, 
respectively. Therefore, the tetrameric complex has 4884 amino acids, this is 7.35-
times the size of the KcsA channel. We propose that, due to the heavily increased 
size of iGluRs in general compared to the KcsA channel, a fourth membrane domain 
was necessary to stabilize the complex. 
In contrast, the TM4 in another class of ligand-gated ion channels, the Cys-loop 
receptors, was found to determine the pentameric subunit stoichiometry (Haeger et 
al., 2010). Truncation of the TM4 causes the subunits to oligomerize in a non-defined 
manner. But co-expression of the TM4 fragment recovers the pentameric assembly. 
The overall organization of the TMD of Cys-loop receptors differs significantly from 
the KcsA or iGluR TMD. The transmembrane helices of Cys-loop receptors sit 
straight next to each other, contrary the transmembrane helices in KcsA and iGluR 
subunits are leaning and twisted (Doyle et al., 1998, Sobolevsky et al., 2009, Haeger 
et al., 2010). Thus, it seems that the role of the TM4 depends on the receptor class, 
hence, no underlying general mechanism exists. 
 
MI analysis has the potential to provide functional implications for 
correlated positions in proteins – The MI analysis is a bioinformatics approach that 
has originated from telecommunication but was adapted for the identification of 
positions in proteins that are interdependent in a way that mutations at these 
positions affect each other. Thus, the MI analysis is a tool to search for positions that 
mutated in a concerted manner. We utilized the MI analysis to draw conclusions 
about functional implications of correlated positions and tested this hypothesis by 
applying the MI analysis to a position in the well-conserved SYTANLAAF motif, which 
is known to directly determine receptor function. The correlations that were found 
were mainly located in the SYTANLAAF motif itself and in close vicinity of this motif. 
This is a good indication that positions that are mainly implicated in receptor function 
will have a high Z-score with positions that are also implicated in receptor function. 
The MI analysis of positions in the TM4 found correlations within the TM4 and with 
TM1 but no positions within the SYTANLAAF motif for example. Hence, we conclude 
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that the TM4 is not directly involved in determining functional properties. Although 
these findings are preliminary, we believe that the MI analysis might prove to be a 
useful utility to predict roles of certain positions and residues in protein complexes. 
However, this hypothesis should be tested with various proteins and needs to be 
verified by experiments. 
 
Conclusions – We conclude that the fourth membrane-domain (TM4) is an 
evolutionary addition to the iGluR subunits to stabilize the TMD and ensure proper 
channel function. We suggest that this auxiliary stabilizing element was necessary 
because of the increased size of iGluR subunits compared to KcsA channel subunits. 
Also we tested the MI analysis for the prediction of identifying functional or other roles 
of residues in the protein complex. Our results indicate that it is indeed possible to 
distinguish between positions that determine functional properties and positions that 
lead to the overall stabilization of the TMD. 
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CHAPTER 6 
GENERAL DISCUSSION 
 
 
Molecular mechanism of partial agonism 
Crystal structures and nuclear magnetic resonance (NMR) structures are often 
the only reliable source for structural information on peptides and proteins. We used 
crystal structures of iGluR LBDs to probe for the molecular mechanism of partial 
agonists. Crystal structures of GluN1 LBDs with agonists, partial agonists and 
antagonists suggested that agonists as well as partial agonists could induce a full 
closure of the clamshell-like LBD structure (Furukawa et al., 2003, Inanobe et al., 
2005). However, antagonists stabilize the LBD in an open-conformation (Furukawa et 
al., 2003). We reasoned that although partial agonists could induce a full closure of 
the LBDs, the energetic more favorable state would be a partially closed-
conformation. Therefore we used crystal structures and homology models of iGluR 
LBDs with different degrees of clamshell closure and conducted molecular docking 
experiments. This approach worked well for the GluN1 subunit, using the GluN1 
crystal structures it was possible to predict the action of a ligand with 90% accuracy, 
when using GluN1 homology models the accuracy dropped to 50%. Despite this, 
docking experiments with GluA2 LBD crystal structures as well as with GluN2A and 
GluN3A LBD homology models did not give reliable results as most of the ligands 
docked into the closed-conformation. One possible explanation is that homology 
models are not suitable for docking experiments. Our results indicate that homology 
models can be used for docking experiments but one should not expect highly 
accurate results, though it is possible to identify basic principles or tendencies. 
Results from GluN1 LBD homology models indicate that the size of the ligand is 
important for its action but it was not possible to predict ligand actions as accurately 
as with the GluN1 LBD crystal structures. From our docking analyses we conclude 
that for the GluN1 subunit the size of the ligand mainly determines its action, thus 
agonists are small in size whereas partial agonists are generally larger in size. 
However, this does not seem to be valid for GluA2, Glun2A and GluN3A subunits. In 
these subunits the ligand binding pocket is larger compared to the ligand binding 
pocket in the GluN1 subunit. Thus, these subunits have to have another molecular 
mechanism to distinguish between agonists and partial agonists. We conducted 
these experiments under the assumption that the molecular mechanism of partial 
agonism is located within the LBD, however, we cannot exclude the possibility that 
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other parts of the receptor play an important role in this respect, which would mean 
that it is not possible to uncover the basic principle of partial agonism on isolated 
LBDs. We conclude: 
I) The size of the ligand mainly determines its action (i.e. agonist, partial 
agonist, antagonist) in GluN1 but not GluA2, GluN2A or GluN3A 
subunits. 
 
The LBD heterodimer interface is generally involved in receptor function 
We conducted experiments using a reduced GluN1/GluN2 receptor model (i.e. 
NTD-lacking GluN1/GluN2 receptors) as the NTDs were shown to largely affect 
functional properties of NMDARs and thus the NTDs might also lead to a 
misinterpretation of the results. We introduced amino acid substitutions into the LBD 
heterodimer interface to disclose functional implications of this interface. The 
interface has been subdivided into three distinct sites (sites I-III) and mutations were 
introduced at all three sites. Using TEVC we characterized NTD-lacking 
GluN1/GluN2A and GluN1/GluN2B mutant receptors by determining apparent agonist 
affinities, extent of desensitization and maximal inducible currents. Our results 
indicate that the LBD heterodimer interface is generally involved in receptor function 
as we observed diverse and unspecific effects of the mutations. We were not able to 
assign specific functional roles to the distinct sites. However, one mutation at site III 
of the LBD heterodimer interface largely decreased maximal inducible currents in the 
receptor combinations analyzed. This effect could not be observed when full-length 
GluN1 subunits carrying the same mutation were expressed together with either full-
length or NTD-lacking GluN2 subunits. It is not unclear in which way the GluN1-NTD 
but not the GluN2-NTD rescues receptor function or if the effect is based on reduced 
receptor expression, assembly or cell-surface trafficking. This question might be 
addressed by means of affinity purification of hexahistidyl-tagged subunits and 
subsequent SDS-PAGE or Blue Native PAGE. If the effect was truly based on e.g. 
assembly deficiency, this would indicate that the LBD heterodimer interface is 
involved in receptor assembly rather than receptor function. We conclude: 
II) The LBD heterodimer interface in NMDARs is generally involved in 
receptor function but might also be significant for receptor assembly. 
Identification of an autoinhibitory domain in NMDARs 
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GluN1/GluN3A receptors are glycine-gated NMDARs with very low efficacy. In 
previous studies it was found that GluN1 antagonists or mutations within the GluN1 
ligand-binding pocket potentiate glycine-induced currents ~25-fold (Madry et al., 
2007a). These findings indicate that this receptor combination is constitutively 
inhibited. We constructed a model of the full-length GluN1/GluN3A receptor based on 
the GluA2-type AMPA receptor crystal structure by Sobolevsky et al. (2009) and we 
introduced amino acid mutations in the GluN1-GluN3A LBD heterodimer interface 
because we reasoned that interactions in this interface might account for the 
observed low efficacy. However, none of the LBD heterodimer mutations increased 
glycine-induced receptor currents. Thus, we focused on the NTDs and findings by Dr. 
Ivana Mesic from our lab showed that truncation of the GluN3A-NTD largely increase 
glycine-induced receptor currents. Hence, we analyzed homodimeric GluN3A-NTD-
NTD interactions in our homology model, as it was shown for the GluA2-NTDs by 
Sobolevsky et al. (2009), and we selected residues in this NTD-NTD interface for 
amino acid substitutions. Previous studies also mentioned that the NTD-LBD linker in 
GluN1/GluN2 receptors is involved in receptor function (Yuan et al., 2009, Gielen et 
al., 2009). Therefore, we also selected residues in the GluN3A-NTD-LBD linker for 
amino acid substitutions. Further, we used secondary structure prediction algorithms 
implemented in online servers and also molecular dynamics simulation, which 
indicate that the NTD-LBD linker might adopt a α-helical conformation. The functional 
characterization of the aforementioned mutations showed that mutations in the 
GluN3A-NTD-NTD interface as well as in the GluN3A-NTD-LBD linker increase 
GluN1/GluN3A receptor efficacy. However, the greatest increase was observed for a 
GluN3A-NTD-LBD linker mutation. Because of its strategical position we reckon that 
the NTD-LBD linker and its secondary structure directly convey the modulatory action 
of the NTDs to the LBDs. In the case of GluN3A this modulatory action is inhibitory, 
thus representing an autoinhibitory domain (AID). We conclude: 
III) The GluN3A-NTD represents an AID and the NTD-LBD linker adopts a 
α-helical secondary structure, which is pivotal for conveying modulatory 
signals from the NTD to the LBD. 
 
The TM4 is an evolutionary addition to ensure ion channel function 
Earlier reports have indicated that the TMDs of iGluRs are homologous to the 
KcsA-type potassium channel (Doyle et al., 1998, Wollmuth et al., 2004, Sobolevsky 
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et al., 2009). But a major difference between these two structures, i.e. KcsA channel 
and iGluR TMDs, is that the iGluR TMDs have a fourth membrane domain (TM4), 
which is not present in the KcsA channel (Wollmuth et al., 2004, Sobolevsky et al., 
2009). We were interested in the functional implications of this additional membrane 
domain. Previously it was found, that the TM4 is required to mask ER retention 
signals present in the TM3s of GluN1 and GluN2B (Horak et al., 2008). Also it was 
found that coexpression of TM4-lacking subunits together with the TM4 fragment 
recovers receptor function as shown with GluN1/GluN2A receptors (Schorge and 
Colquhoun, 2003). Experimental data from Dip.Biol. Adriana Längle showed that the 
TM4 in GluN1/GluN3A receptors is not required for assembly, subunit stoichiometry 
or trafficking. Thus, we intended to specifically analyze TM4 interactions with the TM1 
and TM3 of the neighboring subunit. Using a homology model of the tetrameric TMD 
of GluN1/GluN2A receptors, site-directed mutagenesis, TEVC and MI analysis we 
found that the TM4 is implicated in stabilizing the TMDs, which is required for proper 
ion channel function. We hypothesize that the TM4 was added to the TMD because 
of the ~7.35-fold increase in amino acid count for GluN1/GluN2A receptors compared 
to the KcsA channel. We conclude: 
IV) The TM4 is an evolutionary addition to add stability to the TMDs and 
thus ensure ion channel function. 
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SUMMARY 
 
 
Ionotropic glutamate receptors (iGluRs) are tetrameric ligand-gated ion channels that 
convey the majority of excitatory neurotransmission in the mammalian central 
nervous system. Members of the iGluR family are AMPA and kainate receptors as 
well as NMDA receptors. NMDA receptors are unique among the iGluRs due to the 
obligate heteromeric assembly and their particular roles for learning and memory 
formation but on the other hand NMDA receptor mediated excitotoxicity causes cell 
death in various pathophysiological conditions and neurodegenerative disorders. 
Conventional NMDA receptors are composed of two glycine binding Glun1 subunits 
and two glutamate binding GluN2 subunits. These receptors are also referred to as 
‘coincidence detectors’ as for the activation a predepolarization of the postsynaptic 
membrane and ligand binding is required. Receptors composed of two glycine 
binding GluN1 and two glycine binding GluN3 subunits are referred to as ‘excitatory 
glycine receptors’. Each iGluR subunit has a modular structure and it is hypothesized 
that each module/domain originates from a prokaryotic ancestral protein. The 
extracellular N-terminal domains (NTDs) are thought to form local heterodimers 
between GluN1 and GluN2 or GluN3 NTDs, additionally the GluN2- or GluN3-NTDs 
form a homodimeric contact. The ligand-binding domains (LBDs) of GluN1 and 
GluN2 or GluN3 subunits are arranged in a ‘back-to-back’ conformation forming the 
LBD heterodimer interface, which is subdivided into three distinct sites (sites I-III). 
This heterodimer interface has been previously implicated in receptor desensitization, 
weak interface interactions increase receptor desensitization. Upon ligand-binding, 
the S1 and S2 subdomains of the LBDs close in a ‘venus-flytrap’ like fashion. The 
transmembrane domains (TMDs) of iGluRs show homology to prokaryotic K+ 
channels but iGluR TMDs have one transmembrane domain (TM4) more than the 
prokaryotic ion channel. 
The aim of the work presented here was to analyze intra- and intersubunit 
interface interactions in the NTDs, LBDs and TMDs to determine their functional 
implications. To achieve this, in vitro and in silico methods were combined. 
Molecular docking experiments and homology modelling were used to gain 
insight into the molecular mechanism of agonism, partial agonism and antagonism. 
The results indicate that for GluN1 subunits it is the size of the ligand that determines 
its action, i.e. agonists are small, partial agonists are slightly larger and antagonists 
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are large molecules. However, this could not be validated for GluA2-type AMPA 
receptor subunits, GluN2A or GluN3A subunits. Thus, the mechanism for partial 
agonism seems to be not conserved but subunit specific. 
In order to gain insight into the role of the GluN1-GluN2 LBD heterodimer 
interface we analyzed the GluN1-GluN2A LBD crystal structure as well used the 
mutual information (MI) analysis to select amino acids for site-directed mutagenesis. 
The respective mutants were functionally characterized by two-electrode voltage-
clamp on Xenopus oocytes. The results did not show specific effects of the 
mutations, hence it is not possible to imply one interaction site to one function. We 
conclude that the interface as a network of interactions is generally involved in 
receptor function. However, one mutation in site III largely decreased agonist-
induced currents from NTD-lacking GluN1/GluN2 receptors. Whether this effect is 
caused by reduced subunit expression, receptor assembly or trafficking needs to be 
disclosed in further experiments. 
Homology model based analysis and subsequent site-directed mutagenesis and 
functional characterization of GluN1/GluN3A receptors led to the identification of 
specific residues in the GluN3A-NTD that selectively increased the receptor efficacy. 
Thus, the GluN3A-NTD resembles the role of an autoinhibitory domain (AID), to our 
knowledge no AID has been described so far for ligand-gated ion channels. 
In a last set of experiments we assessed interactions between the GluN1 TM4 
and the TM1 and TM3 of the neighboring GluN2A subunit. Amino acid substitutions 
were selected based on our GluN1-GluN2A TMD model and functional 
characterization by TECV revealed two residues that almost completely abolished 
receptor function. We further used the MI analysis to probe for positions that are 
evolutionary interdependent and from the position of these correlations we inferred 
that the TM4 is mainly involved in stabilizing the TMD and thus ensuring proper ion 
channel function. 
  
  125 
ZUSAMMENFASSUNG 
 
 
Ionotrope Glutamatrezeptoren (iGluRs) sind tetramere liganden-gesteuerte 
Ionenkanäle, die im Zentralnervensystem von Säugern für den Großteil der 
exzitatorischen Signalweiterleitung verantwortlich sind. Zur iGluR Familie gehören die 
AMPA-, Kainat- und NMDA-Rezeptoren. Den NMDA-Rezeptoren wird eine 
besondere Rolle zugeschrieben, da sie obligate heteromere Komplexe bilden und 
eine besondere Rolle für das Lernen und die Gedächtnisbildung spielen. 
Andererseits sind sie auch an pathophysiologischen Vorgängen und 
neurodegenerativen Erkrankungen beteiligt, da NMDA-Rezeptor vermittelte 
Exzitotoxizität zum Zelltod führt. Konventionelle NMDA-Rezeptoren bestehen aus 
zwei Glyzin-bindenden GluN1-Untereinheiten (UEs) und zwei Glutamat-bindenen 
GluN2-UEs. Dieser Rezeptortyp wird auch als “Koinzidenz-Detektor” bezeichnet, da 
zusätzlich zur Ligandierung eine Vordepolarisation der postsynaptischen Membran 
notwendig ist. Rezeptoren, die aus zwei Glyzin-bindenden GluN1-UEs und zwei 
Glyzin-bindenden GluN3-UEs bestehen, werden als “exzitatorische Glyzin-
Rezeptoren” bezeichnet. Jede iGluR-UE hat einen modularen Aufbau und es wird 
vermutet, dass jedes Modul bzw. jede Domäne von einem prokaryotischen 
Vorläuferprotein abstammt. Die extrazellulären N-terminalen Domänen (NTDs) bilden 
lokale Heterodimere zwischen GluN1- und GluN2- oder GluN3- NTDs, zusätzlich 
bilden die GluN2- oder GluN3-NTDs untereinander homodimere Kontakte. Die 
Ligandenbindedomänen (LBDs) der GluN1- und GluN2- oder GluN3-UEs sind in 
einer “Rücken-an-Rücken” Konformation angeordnet. Die Kontaktfläche zwischen 
den beiden LBDs wird in drei Kontaktstellen unterteilt (Kontaktstellen I-III). Diese 
Kontaktfläche wurde zuvor mit der Rezeptordesensitisierung in Verbindung gebracht, 
schwache Interaktionen an der Kontaktfläche würden demnach die Desensitisierung 
verstärken. Die Ligandenbindung führt dazu, dass die beiden Subdomänen der LBD, 
S1 und S2, sich in einem “Venus-Fliegenfallen” artigen Mechanismus schließen. Die 
Transmembranregionen (TMDs) der iGluRs zeigen Homologien zu prokaryotischen 
Kalium-Kanälen, aber sie unterscheiden sich vorallem darin, dass die TMDs von 
iGluRs eine vierte Membrandomäne (TM4) besitzen, die im Kalium-Kanal nicht 
vorhanden ist. 
Das Ziel der vorliegenden Arbeit war es Kontaktflächen innerhalb einer 
Untereinheit und zwischen Untereinheiten in den NTDs, LBDs und TMDs zu 
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untersuchen, um die jeweilige Rolle für die Rezeptorfunktion besser zu verstehen. 
Hierfür wurden in vitro und in silico Methoden miteinander kombiniert. 
Docking-Experimente mit Kristallstrukturen und Homologiemodellen wurden 
durchgeführt, um den Mechanismus des Agonismus, partiellen Agonismus und 
Antagonismus an NMDA-Rezeptoren besser zu verstehen. Die Ergebnisse zeigten, 
dass bei der GluN1-UE vorallem die Größe des Liganden seine Aktivität bestimmt. 
Demnach sind Agonisten immer kleine Moleküle, partielle Agonisten sind größer als 
Agonisten und Antagonisten sind große Moleküle. Dieses konnte aber nicht für die 
GluA2-UE der AMPARs oder für GluN2A- und GluN3A-UEs der NMDARs gezeigt 
werden. Wir schließen daraus, dass der zugrundeliegende Mechanismus für den 
partiellen Agonismus untereinheitenspezifisch ist. 
Für die Untersuchung der Kontaktfläche zwischen den GluN1-GluN2 LBDs wurde 
die Kristallstruktur näher betrachtet und mit Hilfe der Transinformations-Analyse (TI) 
Aminosäuren für Substitutionsexperimente ausgesucht. Die daraus resultierenden 
mutierten Rezeptorkomplexe wurden funktionell mit der Zwei-Elektroden 
Spannungsklemme (TEVC) an Xenopus Oozyten charakterisiert. Die Ergebnisse 
ließen nicht auf spezielle Funktionen der drei Kontaktstellen schließen. Es erscheint 
wahrscheinlicher, dass die Kontaktfläche allgemein in der Rezeptorfunktion 
eingebunden ist. Eine Mutation jedoch an der Kontaktstelle III zeigte bei NTD-
trunkierten GluN1/GluN2 Rezeptoren eine Erniedrigung des Agonisten-induzierten 
Stromes. Ob diese Mutation die Expression, Assemblierung oder 
Zelloberflächenexpression stört ist nicht bekannt und muss in zukünftigen 
Experimenten näher untersucht werden. 
Homologiemodell-basierte Analyse gefolgt von Aminosäuresubstitution und 
funktioneller Charakterisierung von mutierten GluN1/GluN3A Rezeptoren, 
ermöglichte die Identifizierung von Aminosäureresten in der GluN3A-NTD, die 
spezifisch für die niedrige Effizienz von Glun1/GluN3A Rezeptoren verantwortlich 
sind. Daher kann der GluN3A-NTD die Rolle einer autoinhibitorischen Domäne (AID) 
zugeschrieben werden. Nach unseren Kenntnissen ist bisher noch keine AID für 
liganden-gesteuerte Ionenkanäle bekannt. 
Letztlich wurden die Interaktionen zwischen der GluN1-TM4 und der TM1 und 
TM3 der GluN2A-UE untersucht. Aminosäurereste wurden aufgrund unseres 
Homologiemodells für Aminosäuresubstitutionsexperimente ausgewählt und 
funktionell mit der TEVC untersucht. Hierbei wurden zwei Positionen in der GluN1-
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TM4 identifiziert, deren Mutation zu nicht funktionellen Rezeptoren führte. Diese 
Positionen wurden weiter mit Hilfe der TI untersucht um evolutionär-abhängige 
Positionen in der TMD zu identifizieren. Anhand der Position dieser gefundenen 
Korrelationen lässt sich schlußfolgern, dass die TM4 wichtig für die Stabilität der 
TMD ist und nur durch diese Stabilisierung kann eine normale Funktion des 
Ionenkanals sichergestellt werden. 
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